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The	   immune	   system	   responds	   to	   an	   enormous	   variety	   of	   pathogens	   as	   well	   as	   to	  
malignant	   cells.	   Since	   healthy	   (ssues	   may	   also	   be	   damaged	   during	   immune	  
responses,	  mul(ple	  mechanisms	  have	  evolved	  to	  shape	  and	  limit	  immune	  responses,	  
in	  order	   to	  protect	   the	   integrity	  of	   the	   respec(ve	  (ssue.	   	  Understanding	   the	  basic	  
mechanisms	   of	   immune	   regula(on	   will	   help	   to	   successfully	   reprogram	   immune	  
reac(vity	   in	   immune-­‐mediated	   diseases.	   T	   cell	   responses	   can	   be	   regulated	   by	  
mul(ple	  factors	  including	  intrinsic	  and	  extrinsic	  modulators.	  !
In	  the	  ﬁrst	  part	  of	  this	  thesis	  we	  aimed	  to	  understand	  how	  the	  Nck	  adaptor	  proteins,	  
as	  intrinsic	  modulators,	  control	  T	  cell	  eﬀector	  func(on.	  Nck	  adaptor	  proteins	  stabilize	  
proximal	   signaling	   complexes	   of	   T	   cell	   receptors	   (TCR)	   in	   the	   cytoplasm,	   thereby	  
enhancing	   TCR	   signaling.	   We	   found	   that	   T	   cell-­‐speciﬁc	   dele(on	   of	   Nck	   proteins	  
(Nck.T-­‐/-­‐)	   lead	  to	   impaired	  germinal	  center	   forma(on,	  which	   is	   the	  central	  event	  for	  
produc(ve	  T	  cell-­‐dependent	  an(body	  produc(on.	  The	  number	  of	  follicular	  helper	  T	  
(T`)	  cells,	  which	  are	  essen(al	   for	  germinal	  center	   forma(on,	  was	  decreased	   in	   the	  
spleen	   of	   Nck.T-­‐/-­‐	   mice	   in	   comparison	   to	   wild	   type	   controls.	   The	   produc(on	   of	  
cytokines,	  such	  as	  IL-­‐4,	  IL-­‐10,	  and	  IL-­‐21,	  by	  T`	  cells	  was	  reduced.	  The	  dysfunc(on	  of	  
T`	   cells	   was	   associated	   with	   decreased	   Akt	   phosphoryla(on	   and	   intensiﬁed	  
apoptosis	   of	   T`	   cells.	   Consequently,	   T	   cell-­‐dependent	   an(body	   responses	   were	  
reduced	  in	  regard	  to	  quan(ty	  as	  well	  as	  quality	  by	  aﬃnity	  matura(on.	  Furthermore,	  
using	  experimental	  autoimmune	  encephalomyeli(s	  as	  an	  autoimmune	  model	   lower	  
disease	  scores,	  delayed	  dynamics	  and	  faster	  recovery	  were	  observed	  in	  Nck.T-­‐/-­‐	  mice	  
in	  comparison	  to	  wild	  type	  animals.	  Together,	  our	  ﬁndings	  show	  an	  essen(al	  role	  for	  
the	  Nck	  adapter	  proteins	  in	  the	  genera(on	  of	  potent	  eﬀector	  T	  cells.	  Thus,	  defects	  in	  
Nck	  protein	   func(on	  may	  have	  a	   so	   far	  un-­‐recognized	   role	   in	  human	  diseases	  with	  
defec(ve	  T	  cell	  responses.	  	  !
The	   second	   part	   focused	   on	   the	   role	   of	   the	   secreted	   protein	   Dickkopf-­‐3	   (DKK3)	   in	  
modula(ng	   T	   cell	   responses	   against	   transplanted	   tumors.	  Mesenchymal	   stem	   cells	  
(MSCs)	  are	  known	  to	  limit	  T	  cell	  responses	  in	  vivo.	  We	  found	  that	  DKK3	  is	  produced	  
by	  MSCs	   and	   contributed	   to	  MSC-­‐mediated	   immune-­‐suppression.	  Wild	   type	  MSCs	  
inhibited	   an(-­‐tumor	   responses	   whereas	   DKK3	   deﬁcient	   MSCs	   did	   not	   aﬀect	   the	  
rejec(on	  process.	  Impaired	  chemokine	  produc(on	  by	  DKK3-­‐/-­‐	  MSCs	  could	  be	  related	  
to	  enhanced	  inﬁltra(on	  of	  CD8+	  T	  cells	  within	  the	  DKK3-­‐/-­‐	  MSC-­‐inoculated	  tumors.	  In	  
addi(on,	   loss	   of	   DKK3	   in	   MSCs	   resulted	   in	   increased	   expression	   of	   MHC	   class	   II	  
an(gens	  that	  may	  render	  MSCs	  more	  immunogenic	  rather	  than	  immune-­‐suppressive.	  
The	   higher	   expression	   of	   MHC	   II	   in	   DKK3-­‐/-­‐	   MSCs	   was	   associated	   with	   decreased	  
mTOR	  ac(vity	  and	  thereby	  enhanced	  autophagy.	  We	  hypothesize	  that	  DKK3	  may	  act	   
iii
as	   a	  posi(ve	  modulator	  of	   the	  non-­‐canonical	  Wnt/PCP	  pathway.	   Presently,	  DKK3	   is	  
being	  suggested	  as	  a	  poten(al	  an(-­‐tumoral	  agent	  in	  human	  cancers	  based	  on	  reports	  
that	  DKK3	  is	  a	  tumor-­‐suppressor.	  Our	  studies	  showing	  an	  immune-­‐suppressive	  eﬀect	  
of	  DKK3	  in	  the	  tumor	  mass	  may	  counteract	  these	  op(mis(c	  expecta(ons	  and	  call	  for	  
further	   detailed	   studies	   on	   the	   role	   of	   DKK3	   in	   tumor	   development	   and	   in	   the	  
respec(ve	  immune	  responses	  before	  star(ng	  clinical	  trials.	  	  !
Together,	  our	  studies	  contribute	  to	  a	  be/er	  understanding	  of	  mechanisms,	  which	  are	  



























Das	   Immunsystem	  schützt	  uns	  gegen	  alle	  möglichen	  Krankheitserreger	  sowie	  gegen	  
maligne	   Zellen.	   Da	   während	   einer	   Immunantwort	   auch	   gesundes	   Gewebe	   zerstört	  
werden	   kann,	   haben	   sich	   Mechanismen	   entwickelt,	   um	   Immunantworten	   zu	  
begrenzen	   und	   um	   somit	   die	   Integrität	   des	   entsprechenden	  Gewebes	   zu	   schützen.	  
Ein	  besseres	  Verständnis	  der	  grundlegenden	  Mechanismen	  der	  Immunregula(on	  ist	  
notwendig,	   um	   immunologische	   Reak(vität	   bei	   entsprechenden	   Krankheiten	  
therapeu(sch	   neu	   zu	   programmieren.	   T-­‐Zellantworten	   können	   durch	   verschiedene	  
Faktoren	   reguliert	   werden,	   die	   intrinsische	   und	   extrinsische	   Modulatoren	  
einschließen.	  !
Der	  erste	  Teil	  dieser	  Arbeit	  ha/e	  das	  Ziel,	  zu	  verstehen,	  wie	  die	  Nck	  Adapterproteine,	  
als	  T-­‐Zell-­‐intrinsische	  Modulatoren,	  T-­‐Zell-­‐Eﬀektor-­‐Funk(on	  kontrollieren	  können.	  Nck	  
Adapterproteine	   stabilisieren	   den	   proximalen	   Signalkomplex	   des	   T-­‐Zell-­‐Rezeptors	  
(TCR)	   im	   Zytoplasma	  und	   verstärken	   dadurch	   das	   TCR-­‐Signal.	  Wir	   haben	   gefunden,	  
dass	  T-­‐Zell-­‐speziﬁsche	  Dele(on	  von	  Nck	  Proteinen	  (Nck.T-­‐/-­‐)	  zu	  einer	  Beeinträch(gung	  
der	  Keimzentrum-­‐Bildung	  führt,	  die	  das	  zentrale	  Ereignis	  bei	  einer	  produk(ven	  T-­‐Zell-­‐
abhängigen	  An(körper-­‐Bildung	  ist.	  Die	  Anzahl	  follikulärer	  Helfer	  T-­‐Zellen	  (T`),	  die	  für	  
die	   Keimzentrum-­‐Bildung	   wich(g	   sind,	   war	   in	   der	   Milz	   von	   Nck.T-­‐/-­‐	   Tieren	   im	  
Vergleich	   zu	  Wild-­‐Typ	  Kontrollen	   verringert.	  Die	  Produk(on	  der	   Zytokine	   IL-­‐4,	   IL-­‐10	  
und	   IL-­‐21	  durch	  T`	  Zellen	  war	   reduziert.	  Diese	  Dysfunk(on	  von	  T`	  Zellen	  war	  mit	  
einer	   verminderten	   Akt	   Phosphorylierung	   und	   einer	   verstärkten	   Apoptose	   dieser	  
Zellen	   verbunden.	   Folglich	   waren	   die	   Menge	   und	   die	   Qualität	   T-­‐Zell-­‐abhängiger	  
An(körper	   reduziert.	   Weiterhin	   haben	   wir	   in	   einem	   Autoimmunmodel,	   der	  
Experimentellen	   Autoimmunen	   Enzephalomyeli(s,	   verringerte	   Krankheitswerte,	  
einen	   verzögerten	   Verlauf	   und	   eine	   schnellere	   Erholung	   bei	   Nck.T-­‐/-­‐	   Mäusen	   im	  
Vergleich	   zu	  Wild-­‐typ	  Tieren	  beobachtet.	  Unsere	  Befunde	  weisen	  auf	  eine	  wich(ge	  
Rolle	  der	  Nck	  Adapterproteine	  in	  der	  Generierung	  von	  potenten	  Eﬀektor-­‐T-­‐Zellen	  hin.	  
Möglicherweise	  haben	  die	  Nck	  Proteine	  eine	  bisher	  noch	  nicht	  erkannte	  Bedeutung	  
bei	  Erkrankungen	  mit	  defekter	  T-­‐Zell-­‐Reak(vität.	  	  !
Der	   zweite	   Teil	   der	   Arbeit	   konzentriert	   sich	   auf	   die	   Rolle	   des	   sezernierten	   Proteins	  
Dickkopf	   3	   (DKK3)	   in	   der	   Modula(on	   von	   T-­‐Zellantworten	   gegen	   transplan(erte	  
Tumoren.	  Es	  ist	  bekannt,	  dass	  mesenchymale	  Stammzellen	  (MSC)	  T-­‐Zellantworten	  in	  
vivo	   begrenzen	   können.	  Wir	   haben	   gefunden,	   dass	  DKK3	   von	  MSC	   produziert	  wird	  
und	   zu	   ihrer	   immunsuppressiven	   Wirkung	   beiträgt.	   Wild-­‐Typ	   MSC	   inhibierten	   die	  
Immunantwort	   gegen	   Tumore,	   während	   DKK3-­‐/-­‐	   MSC	   die	   Tumorabstoßung	   nicht	  
beeinﬂussten.	   Eine	   verminderte	   Produk(on	   von	   Chemokinen	   durch	   DKK3-­‐/-­‐	   MSC	  
konnte	  mit	  einer	  verstärkten	  Inﬁltra(on	  von	  CD8+	  T-­‐Zellen	  in	  die	  DKK3-­‐/-­‐	  MSC-­‐  
v
inokulierten	  Tumoren	  korreliert	  werden.	  Zusätzlich	  zeigten	  DKK3-­‐/-­‐	  MSC	  eine	  erhöhte	  
MHC-­‐Klasse	   II	   Expression,	   die	   zu	   einer	   besseren	  An(genpräsenta(on	   und	   damit	   zu	  
einer	   eﬃzienteren	   T-­‐Zellantwort	   führen	   könnte.	   Die	   höhere	   Expression	   von	  MHC	   II	  
An(genen	   war	   mit	   einer	   verringerten	   mTOR	   Ak(vität	   und	   dadurch	   mit	   einer	  
verbesserten	   Autophagozytose	   in	   DKK3-­‐/-­‐	   MSC	   verbunden.	   Wir	   nehmen	   an,	   dass	  
DKK3	  posi(v	  auf	  den	  nicht-­‐kanonischen	  Wnt	  Signalweg	  wirkt.	  Derzeit	  wird	  DKK3	  als	  
ein	   mögliches	   Krebsmi/el	   disku(ert,	   da	   DKK3	   als	   Tumor-­‐Suppressor	   beschrieben	  
wurde.	   Unsere	   Ergebnisse	   zeigen	   eine	   immune-­‐suppressive	   Wirkung	   von	   DKK3	   in	  
Tumoren	   und	   unterstützen	   daher	   diese	   op(mis(schen	   Einschätzungen	   nicht.	  
Vielmehr	   sind	   detaillierte	   Studien	   zur	  Wirkung	   von	   DKK3	   in	   der	   Tumorentwicklung	  
und	   bei	   den	   entsprechenden	   Immunantworten	   gegen	   diese	   Tumoren	   notwendig,	  
bevor	  klinische	  Studien	  begonnen	  werden.	  	  !
Unsere	   Studien	   tragen	   zu	   einem	   besseren	   Verständnis	   der	   Regula(on	   von	   T-­‐























AICD Ac(va(on-­‐induced	  Cell	  Death
AIRE Autoimmune	  Regulator
APC An(gen	  Presen(ng	  Cell
Atg Autophagy-­‐related	  Gene
BCR B	  Cell	  Receptor
Breg Regulatory	  B	  Cell
BSA Bovine	  Serum	  Albumin
CD Cluster	  of	  Diﬀeren(a(on
CFA Complete	  Freund’s	  Adjuvant
CMA Chaperon-­‐mediated	  Autophagy
CNS Central	  Nervous	  System
CREB Cyclic	  AMP-­‐responsive	  Element-­‐binding	  Protein
CVID Common	  Variable	  Immunodeﬁciency	  
DAMP Damage-­‐associated	  Molecular	  Pa/ern
DKK Dickkopf
DN Double	  Nega(ve
EAE Experimental	  Autoimmune	  Encephalomyeli(s
EGFP Enhanced	  Green	  Fluorescence	  Protein
ELISA Enzyme-­‐linked	  Immunosorbent	  Assay
ERK Extracellular	  Signal-­‐regulated	  Kinase
FACS Fluorescence-­‐ac(vated	  Cell	  Sor(ng
FBS	   Fetal	  Bovine	  Serum
GALT Gut-­‐associated	  Lymphoid	  Tissue	  
GC Germinal	  Center
HRP Horseradish	  Peroxidase
HSC Heat	  Shock	  Cognate	  Protein
i.p. Intraperitoneal
ICOS Inducible	  T	  Cell	  Co-­‐s(mulator
iDC Immature	  Dendri(c	  Cell
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ILC Innate	  Lymphoid	  Cell
iTreg Inducible	  Regulatory	  T	  Cell
JNK c-­‐Jun-­‐NH2-­‐Kinase




LAMP Lysosome-­‐associated	  Membrane	  Protein
LSEC Liver	  Sinusoidal	  Endothelium	  Cell
MDSC Myeloid-­‐derived	  Suppressor	  Cell
MFI Mean	  Fluorescence	  Intensity
MHC Major	  Histocompa(bility	  Complex
MIIC MHC	  Class	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MMP Metalloproteinase
MOG Myelin	  Oligodendrocyte	  Glycoprotein
mOVA Membrane-­‐bound	  Ovalbumin
MS Mul(ple	  Sclerosis
MSC Mesenchymal	  Stem	  Cell
mTOR Mammalian	  Target	  of	  Rapamycin
mTORC1 mTOR	  Complex	  1
NK Nature	  Killer
NKT Nature	  Killer	  T	  
NLR Nod-­‐like	  Receptor
NO Nitric	  Oxygen
nTreg Natural	  Regulatory	  T	  Cell
PAK p21-­‐Ac(vated	  Kinase
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PID Primary	  Immunodeﬁciency	  Disease
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  12-­‐Myristate	  13-­‐Acetate
PRR Pa/ern	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  Receptor
REIC Reduced	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ROR Receptor	  Tyrosine	  Kinase-­‐like	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TCR T	  Cell	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T` Follicular	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  Factor	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TNFα Tumor	  Necrosis	  Factor	  α
TNP Trinitrophenol
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                            Introduction
1.	  Introduc/on	  !
1.0.0.0.	  Immune	  System	  !
To	  reach	  homeostasis,	  evolu(on	  built	  up	  several	  systems	  within	  an	  organism,	  such	  as	  
the	   neural	   system,	   the	   endocrine	   system,	   and	   the	   immune	   system.	   These	   systems	  
react	  to	  external	  stress	  or	  internal	  dysregual(on	  and	  help	  the	  organism	  to	  overcome	  
such	   challenges.	   Reciprocal	   regula(ons	   are	   found	   between	   diﬀerent	   systems.	   For	  
example,	  the	  central	  nervous	  system	  (CNS)	  can	  regulate	  the	  immune	  system	  through	  
hormones	  and	  direct	  neural	  signaling.	  On	  the	  other	  hand,	  the	  immune	  system	  aﬀects	  
neurological	  func(ons	  through	  various	  cytokines	  [1].	  	  !
The	   immune	   system	   is	   responsible	   for	   both	   external	   and	   internal	   threats.	   It	   ﬁghts	  
against	  invading	  pathogens	  from	  outside	  and	  also	  monitors	  malignant	  cells	  inside	  of	  
the	   body.	   Based	   on	   response	   dynamics,	   immunological	   memory	   forma(on,	   and	  
an(gen	  recogni(on,	  the	  immune	  system	  can	  be	  divided	  in	  two	  rough	  categories:	  the	  
innate	  immunity	  and	  the	  adap(ve	  immunity	  [2].	  Innate	  immunity	  serves	  as	  cardinals	  
to	   sense	   dangers	   and	   alert	   the	   whole	   immune	   system.	   An(gen	   presen(ng	   cells	  
(APCs)	  from	  innate	  cells	  such	  as	  dendri(c	  cells	  [3]	  and	  macrophages	  [4]	  will	  present	  
an(gens	   to	   T	   cells	   in	   the	   adap(ve	   compartment.	   In	   addi(on,	   APCs	   direct	   T	   cell	  
homing	  to	   inﬂammatory	  sites	  through	  chemokines	  and	  produce	  cytokines	   like	   IL-­‐12	  
and	  TNFα to	  help	  T	  cell	  ac(va(on	  [3].	  Reciprocally,	  T	  cell-­‐derived	  cytokines	  aﬀect	  the	  
diﬀeren(a(on	  and	  ac(vi(es	  of	  APCs	  [3].	  The	  boundary	  can	  somehow	  be	  blurred	  by	  
cells	   like	   innate	   lymphoid	  cells	   (ILCs)	   [5-­‐7]	  and	  nature	  killer	  T	   (NKT)	  cells	   [8],	  which	  
possess	  characteris(cs	  from	  both	  sides	  and	  by	  which	  innate	  and	  adap(ve	  immunity	  
may	  also	  be	  bridged	  and	  collaborate.	  	  !
1.1.0.0.	  Innate	  Immunity	  !
Once	  the	  immune	  system	  is	  triggered	  by	  danger	  signals	  [9],	  an	  immune	  response	  is	  
ini(ated	  (Fig.	  1.1).	  Danger	  signals	  may	  be	  derived	  from	  external	  invading	  pathogens	  
(pathogen-­‐associated	   molecular	   pa/erns,	   PAMPs)	   or	   internal	   damaged	   cells	  
(damage-­‐associated	  molecular	   pa/erns,	   DAMPs)	   [9,	   10].	   PAMPs,	   like	   sugar	   chains,	  
DNA,	  or	  RNA	  will	  be	   recognized	  by	   soluble	   factors	  or	  pa/ern	   recogni(on	   receptors	  
(PRRs)	  [10,	  11]	  of	  innate	  immune	  cells.	  Toll-­‐like	  receptors	  (TLRs)	  [12]	  are	  for	  example	  
the	  most	  well-­‐deﬁned	  PRRs.	  PRRs	  of	  innate	  cells	  can	  also	  detect	  DAMPs	  derived	  from	  
cytosolic	  or	  nulear	  components	  of	  necro(c	  cells	  [13].	  Innate	  immunity	  serves	  the	  ﬁrst	  
wave	  of	   recogni(on,	  pathogen	  elimina(on,	   and	   clearance	  of	  undesirable	  wastes	  or	  
debris.	   In	   addi(on,	   it	   ini(ates	   the	   adap(ve	   immunity	   a{erwards	   through	   an(gen	  
presenta(on,	  chemotaxis,	  and	  cytokine	  secre(on.	  	  !!
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Figure	  1.1	   Ini/aton	  of	   innate	   immunity	  by	  
the	   paGern	   recogni/on	   receptors	   (PRRs).	  
Molecules	   from	   invading	   pathogens,	  
damaged	   (ssues,	   or	   toxic	   par(cles	   can	   be	  
recognized	  by	  pa/ern	  recogni(on	  receptors	  
(PRRs)	  either	  on	  the	  cell	  surface	  or	  inside	  of	  
the	   cell.	   The	   signals	   relayed	   then	   may	  
induce	   the	  produc(on	  of	  pro-­‐inﬂammatory	  
cytokines	   and	   chemokines	   as	   well	   as	  
phagocy(c	   and	   an(gen	   presenta(ng	  
ac(vi(es	  by	   the	   s(mulated	   innate	   immune	  
cells.	   The	   cytokines	   and	   chemokines	  
mediate	  the	  diﬀeren(a(on	  and	  migra(on	  of	  
both	   innate	   and	   adap(ve	   immune	   cells	  
while	   the	   an(gen	   presenta(on	   bridges	   the	  
innate	   and	   adap(ve	   compartments	  
together	   and	   promote	   further	   immune	  
responses.	   The	   ﬁgure	   is	   derived	   from	  
Ashley,	   et	   al.,	   Annu.	   Rev.	   Ecol.	   Evol.	   Syst.	  







Soluble	  factors,	  such	  as	  complement	  proteins	  [14],	  natural	  an(bodies	  [15],	  or	  Type-­‐I	  
interferons	   [16],	   are	   essen(al	   for	   innate	   responses.	   For	   example,	   complement	  
proteins	  can	  form	  a/acking	  complexes	  directly	  on	  the	  surface	  of	  bacteria	  and	  destroy	  
targets	  by	  damaging	  the	  cell	  wall.	  The	  complexes	  are	  also	  involved	  in	  building	  up	  pro-­‐
inﬂammatory	   signals	   for	   further	   response	   cascades	   [14].	   While	   the	   complement	  
proteins	   work	   directly	   on	   the	   target	   pathogens,	   the	   interferons	   func(on	   through	  
indirect	   routes.	   Type-­‐I	   interferons	   trigger	   the	   intracellular	   an(-­‐viral	  machinary	   and	  
therefore	  help	  cells	  seong	  up	  barriers	  to	  defend	  themselves	  [16].	  	  !
Cellular	   compartments	   including	   both	   hematopoie(c	   immune	   cells	   and	  (ssue	   cells	  
contribute	   to	   innate	   immunity.	   Other	   than	   immune	   cells,	   various	   (ssue	   cell	   types,	  
including	   epithelium	   cells,	   ﬁbroblasts,	   and	   mesenchymal	   stem	   cells	   (MSCs),	   can	  
present	  an(gens	  [17,	  18],	  produce	  cytokines	  [19]	  and	  regulate	  the	  homing	  of	  T	  cells	  
[18].	  	  !!!!
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!
1.2.0.0.	  Adap/ve	  Immunity	  !
Speciﬁc	  an(gen	  recogni(on	  and	  memory	   forma(on	  are	   the	  most	  cri(cal	  proper(es	  
which	   dis(nguish	   adap(ve	   immunity	   from	   innate	   immunity.	   Through	  mechanisms,	  
like	   clonal	   expansion,	   soma(c	   hypermuta(on,	   and	   epitope	   edi(ng,	   the	   adap(ve	  
immune	  system	  can	  select	  and	  reﬁne	  its	  speciﬁcity	  and	  eﬃciency.	  Though	  delayed	  at	  
the	   ﬁrst	   moment	   when	   encountering	   new	   threats,	   adap(ve	   immunity	   serves	   as	   a	  
more	  powerful	  and	  speciﬁc	  defending	  system	  for	  the	  organism.	  The	  major	  humoral	  
components	   for	   adap(ve	   immunity	   are	   an(gen-­‐speciﬁc	   an(bodies,	   which	   are	  
produced	  by	  B	  cells.	  The	  cellular	  parts	  are	  composed	  by	  T	  cells	  and	  B	  cells.	  
	  	  
1.2.1.0.	  T	  Cells	  !
The	   ‘T’ for	   T	   cells	   is	   derived	   from	   the	   ﬁrst	   le/er	   of	   thymus,	   in	   which	   the	   T	   cells	  
mature.	  T	  cells	  express	  T	  cell	   receptors	   (TCRs)	  on	  their	  surface	  to	  recognize	  speciﬁc	  
pep(des	   [20]	   presented	   by	   major	   histocompa(bility	   complex	   (MHCs)	   on	   an(gen-­‐
presen(ng	   cells	   (APCs).	   By	   diﬀerent	   combina(ons	   of	   pep(de	   chains	   expressed	   to	  
form	  heterodimeric	  TCR,	  T	  cells	  can	  be	  iden(ﬁed	  as	  αβT	  or	  γδT	  cells	  [21].	  Based	  on	  
other	   surface	  markers,	   αβT	   cells	  may	   be	   further	   divided	   into	   CD4+,	   CD8+,	   and	  NKT	  
cells	   [22,	  23].	   In	  general,	  CD4+	  T	   cells	  are	  “helpers” which	  guide	   the	  diﬀeren(a(on	  
and	  func(ons	  of	  other	  immune	  cells.	  Speciﬁc	  regulatory	  popula(ons,	  the	  regulatory	  
T	  cells	  (Treg)	  [24,	  25],	  serve	  as	  immunological	  brakes	  to	  cease	  immune	  responses.	  On	  
the	   other	   hand,	   most	   CD8+	   T	   cells	   are	   canonical	   eﬀectors	   which	   carry	   out	   the	  
cytotoxic	  responses	  to	  kill	  target	  cells.	  However,	  like	  in	  the	  case	  of	  CD4+	  T	  cells,	  some	  
CD8+	  T	  cells	  are	  suppressors	  for	   immune	  responses	  and	  possess	  regulatory	  capacity	  
[25].	  NKT	  cells	  are	  T	  cells	  recognizing	  an(gens	  loaded	  on	  CD1d	  rather	  than	  MHCs	  on	  
APCs	   [8].	   They	   are	   not	   only	   capable	   to	   kill	   the	   target	   cells	   but	   also	   have	   been	  
described	   to	  help	  B	   cells	  or	  become	   regulatory	  during	   immune	   responses	   [26,	   27].	  
Through	  out	   the	   life	   span	  of	  one	  T	   cell,	   combina(ons	  of	   signals	  and	  quality	  of	  one	  
single	   signal	   can	   control	   the	   fate	  of	   T	   cells.	  Among	  all	   the	  diverse	   signals	   including	  
cytokines	   and	   co-­‐s(mulatory	   molecules,	   TCR	   signaling	   is	   the	   central	   event.	   The	  
signaling	   strength	   as	   well	   as	   signaling	   dura(on	   of	   TCR	   make	   indispensable	  
contribu(on	   to	   survival,	   development,	   diﬀeren(a(on,	   eﬀector	   func(ons,	   and	  
memory	  forma(on	  of	  T	  cells	  [28-­‐34].	  TCR	  signaling	  can	  be	  tuned	  by	  both	  external	  and	  
internal	   factors.	   The	   aﬃnity	   of	   an(gens,	   the	   conforma(on	   of	  MHC	  molecules,	   the	  
interac(on	  dura(on	  and	  the	  (ming	  during	  immune	  responses	  are	  all	  external	  factors	  
contribu(ng	   to	   TCR	   signaling.	   On	   the	   other	   hand,	   the	   co-­‐receptors,	   cytoplasmic	  
adaptor	  proteins,	  and	  other	  signaling	  molecules	  are	  internal	  factors	  to	  modulate	  the	  
TCR	  signaling.	  !!!
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1.2.1.1.	  TCR	  Signaling	  Strength	  in	  T	  Cell	  Lineage	  and	  Fate	  !
T	   cell	   precursors	  develope	   from	  hematopoie(c	   stem	  cells	   in	   the	  bone	  marrow	  and	  
then	  migrate	  to	  the	  thymus	  for	  further	  matura(on	  [21].	  In	  the	  thymus,	  T	  cells	  have	  to	  
survive	   posi(ve	   and	   nega(ve	   selec(on	   to	   become	   mature	   and	   emigrate	   to	   the	  
periphery	   [30].	   The	   survival	   in	   the	   two	   selec(on	   processes	   depends	   on	   signaling	  
strength	   of	   TCR.	   T	   cells	   bearing	   TCRs	   with	   extremely	   low	   aﬃnity	   and	   therefore	  
transducing	   very	   weak	   signals	   can	   not	   ini(ate	   suﬃcient	   survival	   signals	   to	   pass	  
posi(ve	  selec(on.	  On	  the	  other	  hand,	  the	  T	  cells	  which	  survive	  posi(ve	  selec(on	  but	  
express	  TCRs	  with	  extremely	  high	  aﬃnity	  and	  produce	  very	  strong	  TCR	  signaling	  are	  




Moreover,	  the	  signaling	  strength	  of	  TCR	  can	  determine	  not	  only	  the	  survival	  but	  also	  
the	   fate	   between	   αβ/γδ T	   cell	   lineages	   in	   this	   stage	   (Fig.	   1.3).	   In	   early	   stage	   of	  
development	   (the	   CD4-­‐CD8-­‐	   double	   nega(ve	   stage	   “DN”),	   T	   cells	   express	   γδ TCR	  
isoforms.	  Lower	  signaling	  strength	  from	  γδ TCR	  favours	  T	  cells	  to	  express	  αβ isoforms	  
instead.	  However,	  stronger	  signaling	  promote	  T	  cells	  to	  maintain	  themselves	  in	  the	  γδ 
lineage	   [28,	   36,	   37].	   Overall,	   TCR	   signaling	   is	   the	   central	   event	   to	   decide	   the	  
developmental	  fate	  of	  T	  cells	  in	  the	  thymus.	  !!!!
 5
Figure	   1.2	   TCR	   signaling	   strength	   determines	   fate	   of	   T	   cells	   in	   thymic	   selec/on.	  While	  
extremely	  strong	  TCR	  signals	  lead	  to	  apoptosis	  in	  nega(ve	  selec(on,	  insuﬃcient	  TCR	  signaling	  
causes	  cell	  death	  or	   ignorance	   in	  posi(ve	  selec(on.	  Only	  T	  cells	  with	  TCR	  signals	   in	  op(mal	  
range	  can	  survive	  and	  mature.	  Model	  (a)	  is	  rela(vely	  simple	  and	  considers	  only	  whether	  the	  
TCR	   signal	   strength	   reaches	   thresholds	   deﬁned	   in	   posi(ve	   or	   nega(ve	   selec(on.	   Once	   the	  
threshold	   is	   reached,	   the	   fates	   of	   T	   cells	   are	   decided.	   To	  be	  noted,	   if	   the	   apoptosis	   fails	   to	  
eliminate	  doomed	  cells,	  the	  escaped	  cells	  will	  be	  kept	  alive.	  Model	  (b)	  takes	  the	  dura(on	  of	  
signals	  into	  considera(on.	  Only	  when	  the	  op(mal	  signals	  are	  sustained	  the	  T	  cells	  can	  survive.	  
Overall,	  strength	  and	  dura(on	  of	  TCR	  signaling	  are	  essen(al	  for	  thymic	  selec(on.	  The	  chart	  is	  
derived	  from	  Moran	  and	  Hogquist,	  Immunology	  2012,	  135,	  261–267




Signaling	   strength	   of	   TCR	   also	   decides	  whether	   T	   cells	   can	   be	   ac(vated	   and	   go	   on	  
further	  diﬀeren(a(on	  as	  well	  as	  eﬀector	  func(on.	  Inappropriate	  TCR	  signaling,	  either	  
too	   high	   or	   too	   low,	   will	   lead	   to	   cell	   death	   or	   unresponsiveness.	   Only	   when	  
appropriate	  TCR	  signaling	  occurs	  T	  cells	  can	  be	  ac(vated	  [38,	  39].	  A{er	   ini(al	  T	  cell	  
ac(va(on,	   the	   signaling	   strength	   of	   TCR	   is	   coordinated	  with	   other	   signals,	   such	   as	  
cytokines,	   to	   drive	   T	   cells	   into	   diverse	   diﬀeren(a(on	   [29].	   During	   diﬀeren(a(on	   T	  
cells	  acquire	  specialized	  func(ons,	  cytokine	  proﬁles,	  and	  chemotaxis	  proper(es	  along	  
with	  expression	  of	   speciﬁc	  master	   transcrip(onal	   factors.	  For	  example,	  CD4+	  T	  cells	  
can	   diﬀeren(ate	   into	   lineages	   such	   as	   Th1,	   Th2,	   Th17,	   T`	   (follicular	   helper	   T),	   or	  
Treg.	  Newly	  deﬁned	  popula(ons	  like	  Th9	  or	  ThGM-­‐CSF	  keep	  emerging	  on	  the	  list	  [40].	  
Previous	   studies	  have	   shown	   that	   stronger	   TCR	   signaling	  promotes	   Th1	   [41]	   or	   T`	  
[42,	  43]	   (also	  Th2	  when	   the	  TCR	   signal	   is	  extremely	  high	   [44])	  diﬀeren(a(on	  while	  
lower	  strength	  favours	  Th2	  [45]	  or	  Th17	  [46]	  (Fig.	  1.4).	  On	  the	  molecular	  basis,	  TCR	  
signaling	   strength	   decides	   the	   phosphoryla(on	   of	   signaling	   molecules	   which	   can	  
essen(ally	  contribute	  to	  the	  produc(on	  of	  respec(ve	  cytokines	  [47-­‐49].	  	  !
	    	  !!
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Figure	   1.3	   TCR	   signaling	   strength	  
favors	  αβ/γδ T	  cell	   fates.	  γδ TCR	   is	  
expressed	   earlier	   than	   the	   TCRβ 
chain	   during	   the	   development.	  
Strong	   signals	   from	   γδ TCR	   will	  
maintain	   the	   development	   of	   γδ T	  
cells.	  Rela(vely	  weak	  γδ TCR	  signals	  
favors	   the	   commitment	   of	   αβ 
lineage.	   The	   ﬁgure	   is	   derived	   from	  
Hayes	   and	   Love,	   Immunological	  
Reviews	  2006,	  Vol.	  209:	  170–175.	  
Figure	   1.4	   TCR	   signaling	   strength	   favors	  
Th1/Th2	   diﬀeren/a/on.	   An(gen	   dosages,	  
TCR	   aﬃnity,	   co-­‐receptors,	   co-­‐s(mulatory	  
molecules,	   and	   intracellular	   signaling	  
complexes	   contribute	   to	   spectrum	   of	   TCR	  
signaling	   strength.	   Extremely	   high	   or	   low	  
strength	  favors	  Th2	  diﬀeren(a(on	  while	  the	  
medium	   range	   confers	   Th1-­‐promo(ng	  
capacity.	   The	   ﬁgure	   is	   derived	   from	  
Nakayama	   and	   Yamashita,	   Seminars	   in	  
Immunology	  2010,	  22:303–309
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1.2.1.2.	  Nck	  Adaptor	  Proteins	  for	  Tuning	  of	  TCR	  Signaling	  Strength	  
 
Nck	  proteins	  are	  adaptor	  proteins,	  which	  exhibit	  no	  enzyma(c	  ac(vi(es	  but	  possess	  
protein-­‐interac(ng	  domains	  to	  bring	  enzymes	  and	  substrates	  together	  [50].	  Nck1	  and	  
Nck2	  are	  highly	  homologous,	  widely	  expressed	  adaptor	  proteins,	  which	  contain	  three	  
Src	   homology	   (SH)3	   domains	   and	   a	   single	   SH2	   domain	   [51]	   (Fig.	   1.5).	   In	  many	   cell	  
types,	   the	   Nck	   proteins	   link	   phosphotyrosine	   signals	   to	   ac(n	   cytoskeleton	  
reorganiza(on	   through	   the	  Wisko/-­‐Aldrich	   syndrome	   protein	   (WASP)	   and	   the	   p21	  
ac(vated	   kinase	   (PAK)	   [51]	   (Fig.	   1.5).	   Nck	   adaptor	   proteins	   are	   also	   key	   players	   to	  
enhance	   and	   tune	   TCR	   signaling	   strength	   [52,	   53].	   The	   involvement	   of	   Nck	   in	   TCR	  
signalling	   [38]	  has	  been	  suggested	  on	   the	  basis	  of	   its	  binding	   to	  CD3ε [54,	  55]	  and	  
SLP-­‐76	  [56]	   (Fig.	  1.5).	  Using	  a	  condi(onal	  knock-­‐out	  approach,	   it	  was	  demonstrated	  
that	   in	   vivo	   Nck	   dele(on	   induced	   a	   severe	   impairment	   in	   thymic	   selec(on	   of	   low	  
avidity	  T	  cells	  [52].	  In	  peripheral	  lymphoid	  organs,	  Nck	  dele(on	  resulted	  in	  profound	  
T	  cell	  lymphopenia	  and	  hypo-­‐reac(vity	  to	  TCR-­‐mediated	  s(mula(on.	  Nck-­‐deﬁcient	  T	  
cells	  expressing	  TCRs	  with	  low	  avidity	  for	  self-­‐an(gens	  were	  strongly	  reduced,	  while	  T	  
cell	   prolifera(on	  was	   defec(ve	   upon	  weak	   an(genic	   s(mula(on.	   Downstream	   TCR	  
signaling	  events	  such	  as	  phosphoryla(on	  of	  ERK	  and	  the	  calcium	  inﬂux	  are	  found	  to	  
be	  diminished	  [53].	  Thus,	  Nck	  adaptors	  reduce	  the	  threshold	  of	  TCR	  responsiveness	  





1.2.2.0.	  B	  Cells	  !
B	  cells	  are	  named	  a{er	  an	  avian-­‐speciﬁc	   lymphoid	  organ,	   ‘bursa’,	  where	   they	  were	  
ﬁrst	  classiﬁed.	  B	  cells	  originate	  from	  HSCs	  and	  then	  mature	  in	  the	  bone	  marrow	  [57,	  
58].	   They	   express	   B	   cell	   receptors	   (BCRs)	   on	   their	   surface	   to	   recognize	   an(gens	  
directly	  [58].	  B	  cells	  can	  be	  classiﬁed	  into	  B1	  [15]	  and	  B2	  cells,	  with	  low	  expression	  of	  
CD45R(B220)	  for	  B1	  and	  high	  expression	  for	  B2	  cells.	  B1	  cells	  can	  be	  further	  deﬁned	  
by	  CD5-­‐posi(ve	  B1a	  and	  CD5-­‐nega(ve	  B1b	  cells	  [15].	  They	  are	  mainly	  resident	  cells	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Figure	  1.5	  Nck	  protein	  structure	  and	  interac/ng	  partners.	  Nck	  proteins	  are	  composed	  with	  3	  SH3	  
domains	  and	  1	  C-­‐terminal	  SH2	  domain.	  Two	  highly	  conserved	  homologues	  are	  found	  in	  the	  murine	  
system.	  Various	  interac(ng	  partners	  are	  shown.
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within	   body	   cavi(es	   such	   as	   the	   peritoneal	   cavity	   [59].	   By	   contrast,	   B2	   cells	   can	  
circulate	   or	   reside	   in	   spleen,	   lymph	   nodes	   or	   bone	   marrow.	   A{er	   ac(va(on	   by	  
signaling	   of	   BCRs,	   B	   cells	   home	   to	   secondary	   lymphoid	   organs	   to	   proliferate,	  
diﬀeren(ate,	   and	   form	   germinal	   centers	   (GCs)	   [60,	   61].	  Most	   B	   cells,	   especially	   B2	  
cells	   respond	   in	  adap(ve	   immunity	   to	  produce	  an(bodies.	  B1	  cells	  can	  take	  part	   in	  
innate	   immunity	   by	   producing	   natural	   an(bodies	   [15]	   to	   recognize	   invading	  
pathogens	  and	  also	  autoan(gens	  [62]	  at	  the	  very	  beginning	  of	  immune	  responses.	  To	  
improve	   the	   aﬃnity	   and	  quality	   of	   an(bodies,	   B	   cells	  may	  undergo	  an(body	   class-­‐
switching	  and	  soma(c	  hypermuta(on.	  These	  processes	  will	   lead	  to	  so	  called	  aﬃnity	  
matura(on.	   Aﬃnity	   matura(on	   occurs	   within	   the	   GCs	   [61].	   To	   ini(ate	   aﬃnity	  
matura(on,	   B	   cells	   require	   help	   from	   T	   cells	   with	   cell-­‐cell	   contact	   [43,	   63].	   In	  
addi(on,	  cytokines	  such	  as	  IL-­‐4,	  IL-­‐10,	  and	  IL-­‐21	  produced	  by	  T	  cells	  are	  essen(al	  for	  
the	  survival	  and	  aﬃnity	  matura(on	  of	  B	  cells	  [43,	  63].	  Similar	  to	  T	  cells,	  BCR	  signaling	  
strength	   is	   also	   cri(cal	   for	   the	  diﬀeren(a(on	  and	  eﬀector	   func(ons	  of	  B	   cells	   [58].	  
Nck	   adaptor	  proteins,	  which	  are	  expressed	  also	   in	  B	   cells	   and	  enhance	  BCR	  down-­‐
stream	  signaling,	  were	  found	  to	  be	  important	  for	  eﬃcient	  an(body	  produc(on	  [64].	  	  !
1.2.3.0	  Follicular	  Helper	  T	  Cells	  (TX)	  !
Within	  the	  germinal	  centers,	  B	  cells	  require	  help	  from	  T	  cells	  [63,	  65-­‐67],	  mainly	  from	  
follicular	  helper	  T	   (T`)	   cells	   [43,	  63,	  68]	   (Fig.	   1.6),	   to	  proliferate,	  diﬀeren(ate,	   and	  
produce	  high	  aﬃnity	  an(bodies	  through	  class-­‐switching	  and	  soma(c	  hypermuta(on.	  
The	  name	  ‘follicular’ is	  derived	  from	  B	  cell	  follicles	  in	  secondary	  lymphoid	  organs.	  T`	  
cells	  can	  be	  deﬁned	  by	  the	  expression	  of	  CD4,	  CXCR5,	  and	  other	  markers,	   like	  GL-­‐7,	  
ICOS,	  and	  PD-­‐1	  [43,	  69,	  70]	  (Fig.	  1.6).	  Speciﬁc	  cytokines	  such	  as	  IL-­‐4,	  IL-­‐10,	  IL-­‐21	  can	  
be	  produced	  by	  T`.	  Bcl-­‐6	  is	  reported	  to	  be	  the	  master	  transcrip(onal	  factor	  for	  T`	  
[71-­‐73]	  which	  may	  be	   supported	  by	   low	  expression	  of	  other	   transcrip(onal	   factors	  
[74].	   Several	   models	   are	   proposed	   for	   the	   origin	   of	   T`	   cells	   [43].	   Some	   ﬁndings	  
suggest	  that	  the	  T`	  cells	  are	  only	  the	  B	  cell	  follicle-­‐resident	  counterparts	  of	  other	  T	  




Figure	   1.6	   TX	   cells	   provide	   help	   to	   B	   cells	   in	   B	   cell	  
follicles.	  Follicular	  helper	  T	  cells	  provide	  help	  to	  B	  cells	  
within	   the	   B	   follicles	   through	   cell-­‐cell	   contact	   and	  
soluble	   factors.	  The	  ﬁgure	   is	  derived	   from	  King,	  et.	  al.,	  
Annu.	  Rev.	  Immunol.	  2008,	  26:741–66	  and	  CroYy,	  Annu.	  
Rev.	  Immunol.	  2011,	  29:621–63.
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1.3.0.0.	  Regula/on	  of	  Immune	  Responses:	  Immune	  Tolerance	  
 
During	  lymphocytes	  development,	  TCRs	  or	  BCRs	  are	  generated	  by	  recombina(on	  of	  a	  
limited	   repertoire	   of	   gene	   segments	   in	   soma(c	   immune	   cells.	   The	   recombina(on	  
assembles	   randomly	   selected	   V(variable),	   D(diversity),	   and	   J(joining)	   segments	   by	  
RAG	  (recombina(on	  ac(va(ng	  genes)	  recombinases	  [75]	  to	  form	  immune	  receptors.	  
This	   process,	   named	   V(D)J	   recombina(on	   [76],	   is	   conserved	   among	   vertebrates	  
through	  the	  evolu(on	  [77].	  The	  randomized	  recombina(on,	  together	  with	  individual	  
varia(ons	   in	   one	   single	   gene	   locus,	   muta(ons,	   and	   also	   secondary	   recombina(on	  
[78],	   created	   tremendous	   variety	   of	   receptors	   for	   an(gen-­‐speciﬁc	   recogni(on	   [76].	  
However,	   the	   randomly	   created	   speciﬁci(es	   inevitably	   generate	   autoreac(ve	  
receptors	  [79,	  80]	  which	  recognize	  self	  an(gens.	  	  !
Once	  immune	  responses	  against	  foreign	  an(gens	  are	  ini(ated,	  there	  must	  be	  ceased	  
in	   order	   to	   repair	   the	   damaged	   (ssues	   and	   restore	   homeostasis.	   If	   the	   immune	  
responses	  cannot	  be	  regulated,	  as	  observed	  in	  dengue	  virus	  infec(on	  [81]	  and	  sepsis	  
[82],	  catastrophic	  cytokine	  storm	  and	  mul(ple	  organ	  failure	  may	  be	  induced	  [9].	  For	  
example,	  during	  the	  1918	  Spanish	  ﬂu	  [83,	  84]	  or	  SARS	  [85]	  outbreak	  in	  2003,	  massive	  
death	   was	   not	   only	   caused	   by	   the	   viral	   virulence	   but	   also	   by	   excessive	   immune	  
responses.	  Many	  vic(ms	  were	  immune	  competent	  adults	  or	  youth	  and	  were	  killed	  by	  
overwhelming	   cytokine	   storm	   and	   respiratory	   failure	   caused	   by	   lung-­‐inﬁltra(ng	  
immune	   cells	   [83,	   85].	   Furthermore,	   immune	   responses	   in	   diﬀerent	   areas	   show	  
qualita(ve	   and	   quan(ta(ve	   diﬀerences.	   Destruc(ve	   immune	   responses	   have	   to	   be	  
prevented	   in	   (ssues	   with	   a	   limited	   capacity	   of	   regenera(on,	   such	   as	   the	   central	  
nervous	  system	  [86],	  eyes	  [86],	  liver	  [87],	  tes(s	  [88],	  placenta	  [89],	  and	  hair	  follicles	  
[90].	   The	   concept	   of	   so-­‐called	   immune	   privilege	   [91-­‐95]	  was	   ini(ally	   based	   on	   the	  
observa(on	  that	  skin	  allogra{s	  were	  rejected	  when	  placed	  on	  the	  skin	  of	  a	  recipient	  
but	  were	  accepted	   in	  the	  anterial	  chamber	  of	  the	  eye	  [89].	   It	  has	  been	  shown	  that	  
immune	  privilege	  can	  be	  established	  by	  both	  ac(ve	  and	  passive	  processes	  [91,	  92].
!
During	   pregnancy,	   paternal	   an(gens	   from	   the	   fetus	   can	   also	   be	   taken	   as	   foreign	  
an(gens.	   Dysregulated	   immunological	   tolerance	   during	   pregnancy	   can	   lead	   to	  
immune	  responses	  against	  fetus	  and	  subsequent	  abor(on	  [96-­‐98].	  !
Several	   mechanisms	   exist	   to	   tolerize	   immune	   responses	   against	   food	   an(gens	   to	  
avoid	  food	  allergy	  [99].	  If	  these	  mechanisms	  fail,	  allergic	  diarrhea,	  malnutri(on,	  and	  
even	  lethal	  allergic	  responses	  could	  be	  induced	  [100].	  Desensi(za(on	  and	  tolerance	  
induc(on	   [101]	   are	   important	   clinical	   applica(on	   of	   immunue	   tolerance	   [102]	   to	  
treat	  the	  food	  allergy.	  	  !
To	   avoid	   undesirable	   immune	   responses,	   either	   autoreac(ve	   or	   excessive,	   the	  
immune	   system	   is	   equipped	  with	  mechanisms	  deﬁned	  as	   immune	   tolerance	   [103].	  
Tolerance	   represents	   a	   ‘physiological	   state	   in	   which	   the	   immune	   system	   does	   not	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react	  destruc(vely	  against	  the	  organism	  that	  harbours	   it’,	  which	   is	  quoted	  from	  the	  
deﬁni(on	  by	  Ronald	  H.	  Schwartz	  in	  1993	  [104].	  It	  can	  be	  achieved	  according	  to	  two	  
principles.	  One	  is	  to	  delete,	  allegedly	  to	  ‘purge’,	  autoreac(ve	  cells	  from	  the	  immune	  
repertoire.	  The	  most	  well	  known	  mechanism	  to	  carry	  out	  this	  part	  is	  clonal	  dele(on.	  
The	  other	  principle	  is	  to	  compromise,	  allegedly	  to	  ‘tune’,	  autoreac(vity	  or	  excessive	  
immune	   responses	   by	   receptor	   edi(ng,	   clonal	   anergy,	   or	   by	   regula(on	   [105,	   106].	  
Immune	  tolerance	  can	  be	  further	  categorized	  into	  central	  or	  peripheral	  tolerance	  as	  
discussed	  below.	  	  	  !
1.3.1.0.	  Central	  Tolerance	  
 
Central	   tolerance	   is	  used	  as	   term	  to	   summarize	  processes	   that	   induce	  autoreac(ve	  
lymphocytes	  tolerance	  in	  primary	  lymphoid	  organs	  such	  as	  the	  thymus	  and	  the	  bone	  
marrow	   [80,	   107,	   108].	   Taking	   T	   cells	   as	   examples,	   thymic	   epithelial	   cells	   (TECs)	  
express	  self-­‐an(gens	  in	  a	  randomized	  manner	  [107]	  by	  promiscuous	  gene	  expression	  
[109],	  which	   is	  regulated	  by	  AIRE	  [110].	  Most	  autoreac(ve	  T	  cells	  are	  eliminated	  or	  
become	  hyporesponsive.	  Only	  cells	  surviving	  the	  nega(ve	  selec(on	  can	  mature	  and	  
emigrate	   from	   the	   thymus	   to	   the	   periphery.	   In	   addi(on,	   natural	   regulatory	   T	   cells	  
(nTregs)	  develop	  in	  the	  thymus	  and	  are	  exported	  to	  the	  periphery	  to	  control	  immune	  
responses	  [106].	  	  !
nTregs	   are	   phenotypically	   iden(ﬁed	   as	   CD4+CD25+Foxp3+	  T	   cells	   [25].	   Foxp3	   is	   the	  
master	  transcrip(onal	  factor	  of	  the	  nTreg	  lineage	  [111]	  although	  it	  can	  be	  transiently	  
expressed	  by	  newly	   ac(vated	  eﬀector	   T	   cells	   [112,	   113].	   Scurfy	  mice,	   in	  which	   the	  
Foxp3	   gene	   is	   deleted,	   develop	   sever	   autoimmune	   diseases	   [114-­‐116]	   while	   in	  
humans	  the	  corresponding	  dysfunc(on	  of	   the	  human	  Foxp3	  gene	   leads	  to	  the	   IPEX	  
syndrome	   (immunodysregula(on,	   polyendocrinopathy,	   enteropathy,	   X-linked	  
syndrome)	   [117-­‐119].	   Strong	   TCR	   signaling	   strength	   favours	   the	   development	   of	  
nTreg	  [120,	  121]	  (Fig.	  1.7).	  The	  expression	  of	  Foxp3	  [122]	  as	  well	  as	  cytokines	  like	  IL-­‐2	  
[123]	  and	  TGFβ [124]	  are	  essen(al	  to	  support	  the	  development	  of	  nTreg.	  Enhanced	  
NFκB	  ac(vi(es	  also	  favour	  the	  expression	  of	  Foxp3	  and	  therefore	  the	  development	  of	  
nTreg	  [125].	  As	  strong	  TCR	  signaling	  risks	  clonal	  dele(on	  of	  the	  developing	  T	  cells	  by	  
nega(ve	  selec(on,	  a	  two	  step	  model	  is	  proposed	  to	  link	  the	  requirements	  of	  strong	  
TCR	   and	   pro-­‐survival	   ac(vi(es	   of	   cytokines	   like	   IL-­‐2	   [126,	   127].	   Thus,	   strong	   TCR	  
signaling	  up-­‐regulates	  the	  expression	  of	  CD25,	  the	  high-­‐aﬃnity	  receptor	  of	  IL-­‐2,	  and	  
therefore	   increases	   the	   pro-­‐survival	   signals	   to	   counteract	  with	   the	   driving	   force	   of	  
nega(ve	  selec(on	  [126].	  	  !
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Figure	  1.7	  Op/mal	  TCR	  signaling	  strength	  drives	  
developing	  T	  cells	  toward	  the	  fate	  of	  regulatory	  
T	   cells.	   The	   weight	   of	   arrows	   stands	   for	   the	  
probability	   of	   diﬀerent	   developmental	   fates.	  
Basically,	   strong	   TCR	   signaling	   risks	   clonal	  
dele(on	   of	   the	   developing	   T	   cells	   and	   low	   TCR	  
s ignal ing	   favours	   the	   development	   of	  
conven(onal	   T	   cells.	   Foxp3+	   nTregs	   require	  
op(mal	   range	   of	   TCR	   signaling,	   which	   is	  
rela(vely	   narrow,	   and	   the	   support	   from	   IL-­‐2.	  
Note	   that	   nTreg	   s(ll	   can	   be	   raised	   from	   other	  
subop(mal	   signaling	   strength	   but	   only	   with	   less	  
probability.	  The	  model	  of	  TCR	  signaling	  strength	  may	  
explain	  the	  low	  composi(on	  ra(o	  (10-­‐20%)	  of	  Tregs	  
to	  the	  total	  T	  cells.	  The	  upper	  and	  lower	  ﬁgures	  are	  
derived	  from	  Josefowicz,	  et	  al.,	  Annu.	  Rev.	  Immunol.	  
2012,	  30:531–64	  and	  Schwartz,	  Nat.	  Rev.	   Immunol.	  
2005,	  6(4):327-­‐330	  respec(vely.	  	  !!!
1.3.2.0.	  Peripheral	  Tolerance	  !
Despite	  of	  central	  tolerance	  induc(on,	  autoreac(ve	  lymphocytes	  are	  s(ll	  found	  in	  the	  
periphery	   and	  have	   to	  be	   controlled	  by	  mechanisms	  of	  peripheral	   tolerance.	  Here,	  
the	  respec(ve	  cell	  popula(ons	  [25,	  128,	  129]	  and	  soluble	  factors	  will	  be	  discussed.	  	  !
1.3.2.1.	  Tolerogenic	  Cells:	  Adap/ve	  Immunity	  Compartment	  !
Among	  the	  adap(ve	  immune	  cells,	  regulatory	  T	  cells	  (Tregs)	  [130,	  131],	  regulatory	  B	  
cells	   (Breg)	   [132,	   133],	   and	   NKT	   cells	   [134,	   135]	   are	   responsible	   for	   regula(ng	  
immune	   responses.	  Taking	  Tregs	  as	  example,	   they	   can	  be	  classiﬁed	  by	   their	  origins	  
into	  the	  already	  men(oned	  nTregs	  [131]	  and	  the	   inducible	  regulatory	  T	  cells	   (iTreg)	  
[130].	    
 
nTreg	   cells	   can	  produce	   Immunoregulatory	   cytokines	   such	   as	   IL-­‐10	   [136]	   and	   TGFβ 
[137]	  to	  suppress	  immune	  responses	  [25,	  121].	  High	  expression	  of	  CD25	  [121,	  131],	  
the	  high	  aﬃnity	  receptor	  of	  IL-­‐2,	  enables	  nTreg	  to	  deprive	  the	  pro-­‐survival	  IL-­‐2	  in	  the	  
environment	   and	   to	   compete	   out	   eﬀector	   T	   cells	   from	   survival	   and	   produc(ve	  
immune	  responses	  [138].	  nTreg	  can	  also	  	  indirectly	  regulate	  ac(vi(es	  of	  other	  T	  cells	  
by	   inducing	   tolerogenic	  dendri(c	  cells	  via	  downregula(ng	  co-­‐s(mulatory	  molecules	  
on	  dendri(c	  cells	  [25,	  139].	  	  !
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iTregs	   include	   various	   types	   of	   regulatory	   T	   cells	   induced	   in	   the	   periphery	   under	  
diverse	  condi(ons	  [130].	  For	  example,	  IL-­‐10	  can	  induce	  T	  regulatory	  type	  1	  (Tr1)	  cells	  
[140,	  141].	  CD103+	  dendri(c	  cells	   in	  the	  gut-­‐associated	  lymphoid	  (ssues	  (GALT)	  can	  
induce	  regulatory	  T	  cells	  by	  presen(ng	  an(gens	  along	  with	  produc(on	  of	  TGFβ and	  
ren(noid	   acid	   [142-­‐144].	   Immature	   dendri(c	   cells	   [145,	   146]	   and	  mTOR-­‐mediated	  
metabolic	   condi(oning	   [147,	   148]	   also	   drive	   dis(nct	   iTreg	   popula(ons	   in	   diﬀerent	  
milieus.	   iTreg	   can	   be	   induced	   to	   restrain	   ongoing	   immune	   responses	   in	   infec(ons,	  
autoimmune	  diseases,	  or	   tumor/transplant	   rejec(on	   [25,	   130].	   iTreg	   cells	  may	  also	  
be	   induced	   in	  the	  peripheral	  (ssues	  such	  as	   in	  mucosal	  system	  [149].	  By	   long-­‐term	  
and	   low-­‐dose	   exposure	   to	   common	   an(gens	   such	   as	   food	   an(gens	   or	   commensal	  
ﬂora,	  iTreg	  can	  be	  induced	  and	  conduct	  peripheral	  tolerance	  in	  speciﬁc	  sites	  [150].	  !
1.3.2.2.	  Tolerogenic	  Cells:	  Innate	  Immunity	  Compartment	  !
Immature	  dendri(c	  cells	   (iDCs)	  express	  only	   low	   levels	  of	  co-­‐s(mulatory	  molecules,	  
such	  as	  CD80	  and	  CD86,	  and	  are	  barely	   capable	   to	  produce	  cytokines	   such	  as	   IL-­‐6,	  
IL-­‐12,	   or	   TNFα.	   Instead,	   they	   produce	   soluble	   immunosuppressive	   factors,	   such	   as	  
IL-­‐10,	  TGFβ and	  indoleamine	  2,3-­‐dioxygenase	  [108,	  146,	  151-­‐153].	  These	  proper(es	  
favour	   the	   diﬀeren(a(on	   of	   iTreg.	   In	   addi(on,	   dendri(c	   cells	   can	   induce	   clonal	  
dele(on	  of	  autoreac(ve	  T	  cells.	  !
Macrophages	   can	   diﬀeren(ate	   into	   classically	   ac(vated	   proinﬂammatory	   M1	   or	  
alterna(vely	   ac(vated	   immunosuppressive	   M2	   macropages	   depending	   on	   the	  
environmental	   condi(ons	   [154,	   155].	   M2	   macrophages	   can	   be	   iden(ﬁed	   by	   high	  
expression	  of	   the	  mannose	   receptor	  CD206	   [156].	  They	  are	  associated	  with	  wound	  
healing	   and	   are	   capable	   to	   suppress	   immune	   responses	   by	   producing	   polyamines	  
[154,	  157]	  and	  high	   levels	  of	   IL-­‐10	  but	   reduced	   levels	  of	   the	  proinﬂammatory	   IL-­‐12	  
[154].	   Tryptophan	   metabolites	   produced	   by	   macrophages	   are	   also	   reported	   to	  
suppress	  T	  cells	  [158].	  Inside	  of	  solid	  tumors,	  tumor	  associated	  macrophages	  (TAMs),	  
in	  par(cular	  M2	  macrophages,	  are	  o{en	  recruited	  and	  correlated	  with	  tumor	  growth	  
and	  poor	  prognosis	  [128,	  155].	  	  !
Furthermore,	  myeloid-­‐derived	  suppressor	  cells	  (MDSCs),	  covering	  a	  broad	  spectrum	  
of	  immature	  myeloid	  cells,	  can	  produce	  radical	  oxygen	  species	  (ROS)	  or	  nitric	  oxygen	  
(NO)	  to	  inhibit	  T	  cell	  ac(vi(es	  directly.	  Moreover,	  they	  can	  recruit	  nTregs	  and	  induce	  
iTregs	  inside	  of	  the	  inﬂammatory	  sites	  or	  tumors	  [25,	  128].	  !
1.3.2.3.	  Tolerogenic	  Cells:	  Peripheral	  Tissues	  
 
Other	   than	   the	   professional	   immune	   cells,	   peripheral	   (ssue	   cells,	   such	   as	  
hepatocytes	   [159-­‐162],	   hepa(c	   stellate	   cells	   [163-­‐165],	   and	   liver	   sinusoidal	  
endothelium	  cells	  (LSECs)	  [166-­‐168]	  in	  the	  liver	  are	  also	  capable	  to	  induce	  peripheral	  
T	   cell	   tolerance	   (Fig.	  1.8).	   In	   the	   case	  of	  hepatocytes,	   they	   can	   tolerate	  CD8+	  T	   cell	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responses	  by	  down-­‐regula(ng	  the	  expression	  of	  TCR	  on	  the	  surface	  of	  autoreac(ve	  
CD8+	   T	   cells	   [159].	   They	   also	   provide	   insuﬃcient	   co-­‐s(mulatory	   signals	   thereby	  
causing	  ac(va(on	   induced	  cell	  death	   (AICD)	   [169-­‐171].	  Moreover,	   they	  can	  express	  
the	  ligand	  of	  programmed	  death	  1	  receptor	  (PD-­‐1L)	  to	  impair	  the	  cytotoxic	  ac(vi(es	  
of	  CD8+	  T	   cells	   [172].	  Hepa(c	   stellate	   cells	   also	  express	  PD-­‐1L	   [163]	  as	  well	   as	  TNF	  
receptor	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  [173]	  to	  induce	  the	  apoptosis	  of	  T	  cells.	  In	  
addi(on,	   they	   promote	   the	   IL-­‐2-­‐dependent	   Treg	   expansion	   [164],	   by	   which	   along	  
with	  induc(on	  of	  T	  cell	  apoptosis	  the	  hepa(c	  stellate	  cells	  may	  help	  pancrea(c	  islet	  
allogra{s	  to	  survive	  [129,	  165].	  Besides	  hepatocytes	  and	  hepa(c	  stellate	  cells,	  LSECs	  
are	  also	  potent	   inducers	  of	  peripheral	  tolerance	  in	  the	   liver	  by	   inducing	  CD4+Foxp3-­‐	  
Treg	  [168],	  tolerizing	  CD8+	  T	  cells	  with	  PD-­‐1	  signaling	  [174],	  and	   leading	  to	  FasL-­‐Fas	  
mediated	   apoptosis	   of	   T	   cells	   [167,	   175].	   The	   capaci(es	   of	   hepa(c	   cells	   to	   induce	  
tolerance	   are	   important	   since	   the	   liver	   is	   a	   major	   site	   for	   the	   body	   to	   encounter	  
foreign	  an(gens,	  including	  food	  an(gens.	  In	  humans,	  about	  1.5	  liter	  of	  blood	  passes	  
through	  the	  liver	  every	  minute	  and	  the	  whole	  volume	  of	  blood	  circulates	  through	  the	  
liver	  for	  about	  360	  (mes	  per	  day	  [104].	  	  !!
  	  
Figure	  1.8	  Peripheral	  tolerance	  induced	  by	  /ssue	  cells	  of	  neonates	  or	  adults	  in	  homeostasis.	  Hepa(c	  
cells	   including	   hepatocytes	   and	   LSECs	   are	   capable	   to	   induce	   peripheral	   tolerance	   of	   T	   cells	   in	   both	  
neonates	   and	   adults	   since	   T	   cells	   are	   capabel	   to	   reach	   them	   throughout	   the	   life	   (me.	   However,	  
kera(nocytes	  are	  only	  tolerogenic	  in	  neonates	  because	  the	  accessibility	  of	  skin	  for	  circula(ng	  T	  cells	  is	  
limited.	  The	  ﬁgure	  is	  derived	  from	  Arnold,	  et	  al.,	  TRENDS	  in	  Immunology	  2005,	  26(8):406-­‐411	  !
The	  accessibility	  of	  naive	   lymphocytes	  to	  (ssues	   is	   limited	   in	  adults	   [176]	  (Fig.	  1.8).	  
However,	   in	   neonates,	   naive	   T	   cells	   are	   able	   to	   travel	   into	   (ssues	   and	   encounter	  
an(gens,	  for	  example	  in	  the	  skin	  [177]	  (Fig.	  1.8).	  Our	  group	  showed	  that	  mice,	  which	  
expressed	   an	   an(gen	   on	   kera(nocytes	   in	   hair	   follicles,	   were	   tolerant	   to	   skin	   and	  
tumor	   transplants	   expressing	   this	   an(gen	   [177].	   Tolerance	  was	   induced	   during	   the	  
neonatal	   life,	   when	   the	   skin	   is	   accessible	   to	   naive	   T	   cells,	   and	  was	  maintained	   by	  
long-­‐lived	  CD8+	  regulatory	  T	  cells	  [178,	  179].	  These	  CD8+	  regulatory	  T	  cell	  prevented	  
ac(va(on	   of	   respec(ve	   an(gen-­‐speciﬁc	   naïve	   CD8+	   T	   cells	   which	   were	   newly	  
exported	  from	  the	  thymus	  during	  adulthood.	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1.3.2.4.	  Tolerogenic	  Cells:	  Mesenchymal	  Stem	  Cells	  (MSCs)	  !
Mesenchymal	   stem	   cells	   (MSCs)	   are	   (ssue-­‐resident	   stem	   cells	   which	   exhibit	  
mul(potency	  giving	  rise	  to	  various	  cell	  lineages	  [180,	  181]	  (Fig.	  1.9).	  	  !
  	  
Figure	  1.9	  MSCs	  can	  give	  rse	  to	  mul/ple	  lineages	  of	  /ssue	  cells.	  The	  ﬁgure	  is	  derived	  from	  Singer	  and	  
Caplan,	  Annu.	  Rev.	  Pathol.	  Mech.	  Dis.	  2011,	  6:457–78	  !
MSCs	   are	   derived	   from	   adult	   (ssues	   and	   taken	   as	   promising	   subs(tu(on	   for	  
embryonic	   stem	   cells	   for	   regenera(ve	   medicine.	   However,	   despite	   of	   their	   well-­‐
known	  roles	  in	  (ssue	  repairing	  and	  renewing,	  accumula(ng	  data	  suggest	  that	  MSCs	  
are	   involved	   in	   limi(ng	   undesirable	   immune	   responses,	   such	   as	   hypersensi(vity,	  
autoimmune	  disease,	  or	  alloreac(vity	  against	  transplants	  [180,	  182,	  183].	  It	  has	  been	  
reported	  that	  MSCs	  can	  suppress	  human	  gra{-­‐versus-­‐host	  disease	  (GvHD)	  [184,	  185]	  
and	   experimental	   autoimmune	   encephalomyeli(s	   (EAE)	   [186,	   187],	   which	   is	   the	  
murine	   model	   for	   human	   mul(ple	   sclerosis	   (MS).	   Also	   in	   the	   contact-­‐dependent	  
hypersensi(vity	  disease,	   systemically	   infused	  MSCs	   can	   suﬃciently	   ameliorate	   local	  
immune	   responses	   [188].	  A	   long	   list	  of	   clinical	   trials	  has	  been	   launched	   to	   test	   the	  
possible	   applica(ons	   of	   MSCs	   to	   regulate	   immunological	   diseases	   [180,	   183,	   189]	  
(Table	  1.1).	  !
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Table.	  1.1.	  Examples	  for	  clinical	  trials	  of	  MSC-­‐mediated	  treatments	  on	  inﬂammatory	  diseases.	  The	  
table	  is	  derived	  from	  Le	  Blanc	  and	  Mougiakakos,	  Nat.	  Rev.	  Immunol.	  2012,	  12:383-­‐396	  !
Besides	   these	   promising	   clinical	   applica(ons	   for	   the	   immunoregulatory	   capaci(es,	  
MSCs	   have	   been	   reported	   to	   support	   the	   tumor	   growth	   [190]	   by	   promo(ng	   the	  
forma(on	  of	  tumor	  stroma	  [191],	   inducing	  angiogenesis[192,	  193],	  and	  maintaining	  
cancer	  stem	  cells	  [194]	  (Fig.	  1.10).	  MSCs	  may	  also	  promote	  the	  metastasis	  of	  tumors	  
by	  producing	  chemokines,	  such	  as	  CCL5	  in	  the	  case	  of	  breast	  cancer	  [195].	  MSCs	  help	  
tumors	  to	  escape	  an(-­‐tumor	  immunity	  by	  inhibi(ng	  T	  cells	  prolifera(on	  [196,	  197]	  or	  
by	   inducing	   regulatory	   T	   cells	   [198].	   TGFβ is	   one	   of	   the	   central	   mediators	   for	   the	  
protumoral	  vicious	  cycle	  (Fig	  1.10).	  
  	  
Figure	  1.10	  MSCs	  are	  part	  of	  the	  Vicious	  Triangle	  to	  inhibit	  an/-­‐tumor	  immunity	  and	  promote	  tumor	  
growth.	   TGFβ produc(on	   by	   MSCs	   and	   tumor	   cells	   promotes	   tumor	   growth	   by	   enhancing	   the	  
forma(on	  of	  tumor	  stem	  cells	   (CSCs)	  and	   induc(on	  of	  regulatory	  T	  cells	   (Treg).	  The	  ﬁgure	   is	  derived	  
from	  Ilmer,	  et	  al.,	  FASEB	  J.	  2014,	  28:1-­‐14	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MSCs	   are	   sensi(ve	   to	   immunological	   s(muli.	   They	   can	   express	   pa/ern	   recogni(on	  
receptors,	   such	  as	  Toll-­‐like	   receptors	   (TLRs)	  and	  NOD-­‐like	   receptors	   (NLRs)	   [183].	   In	  
addi(on,	   they	   also	   express	   complement	   receptor	   C3aR	   and	   C5aR	   [183].	   They	   are	  
sensi(ve	  to	  cytokine	  s(mula(ons	  by	   IL-­‐1β and	   IFNγ [183].	  The	  respec(ve	  receptors	  
enable	   MSCs	   to	   respond	   to	   inﬂamma(on	   and	   ini(ate	   their	   immunoregulatory	  
func(ons	   (Fig.	   1.11)	   by	   produc(on	   of	   immunosupressive	   TGFβ [183]	   (Fig.	   1.10),	  
prostaglandin	  E2	  (PGE2)	  and	  kynurenine	  (KYN).	  These	  soluble	  factors	  can	  repolarize	  
M1	   proinﬂammatory	   macrophages	   into	   immunosupressive	  M2	  macrophages	   [183]	  
and	  also	  can	  directly	  modulate	  T	  cell	  func(on	  [199,	  200].	  	  !
	  !!!!!!!!!!!!
Figure	   4.2	   MSC	   regulates	  
d i ﬀ e r e n / a / o n	   o f	  
macrophages.	   The	   ﬁgure	   is	  
derived	   from	   Katarina	   Le	  
B l a n c	   a n d	   D i m i t r i o s	  
Mougiakakos,	   Nat.	   Rev.	  
Immunol.	  2012,	  12:383-­‐396	  !!
In	  addi(on	  to	  these	  soluble	  factors,	  cell-­‐cell	  contact-­‐mediated	  mechanisms	  are	  also	  
contribu(ng	  to	  MSC-­‐mediated	  immune	  regula(on	  [18,	  196,	  201].	  MSCs	  are	  capable	  
to	  express	  MHC	  molecules	  and	  act	  as	  an(gen	  presen(ng	  cells	  to	  T	  cells	  [17,	  18,	  182,	  
202-­‐204].	  MHC	  class	   I	  expression	   is	  up-­‐regulated	   in	   IFNγ-­‐s(mulated	  MSCs	  [205].	  By	  
contrast,	  expression	  of	  MHC	  class	  II	  molecules	  is	  o{en	  negligible	  [206-­‐208]	  and	  only	  
found	  in	  a	  narrow	  window	  of	  IFNγ s(mula(on	  [202].	  Low	  expression	  of	  MHC	  class	  II	  
decreases	   the	   allogenicity	   and	   consequen(al	   allogeneic	   rejec(on	   of	   MSCs	   during	  
transplanta(on	  [206-­‐208].	  	  !
MSCs	  may	   induce	   regulatory	   CD4+	   or	   CD8+	  T	   cells	   by	   direct	   cell-­‐cell	   contact	   [209].	  
They	  inhibit	  CD8+	  T	  cells	  in	  mixed	  lymphocytes	  responses	  and	  in	  rejec(on	  of	  allogenic	  
tumors	   [210].	   MSCs	   can	   also	   induce	   unresponsiveness	   of	   T	   cells	   by	   aﬀec(ng	   the	  
matura(on	   of	   an(gen	   presen(ng	   cells	   [211].	   MSCs	   favour	   the	   diﬀeren(a(on	   of	   T	  
cells	   from	   Th17	   phenotypes	   to	   Tregs	   [183].	   MSCs	   may	   inhibit	   the	   de	   novo	   Th17	  
diﬀeren(a(on	  [212,	  213]	  directly	  or	  reprogram	  the	  exis(ng	  Th17	  cells	  [212].	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Figure	  1.11	  Mechanisms	  of	  MSC-­‐mediated	  immune	  regula/ons.	  The	  ﬁgure	  is	  derived	  from	  Singer	  and	  
Caplan,	  Annu.	  Rev.	  Pathol.	  Mech.	  Dis.	  2011,	  6:457–78	  !
Taken	  together,	  cells	   from	  both	   innate	  and	  adap(ve	   immune	  compartments	  as	  well	  
as	  non-­‐hematopoie(c	  cells	  can	  contribute	  to	  immunological	  tolerance.	  !
1.4.0.0.	  Dickkopf-­‐3	  (DKK3)	  and	  Immunoregula/on	  !
Dickkopf-­‐3	   (DKK3)	   belongs	   to	   the	   Dickkopf	   protein	   family	   (DKKs)	   [214-­‐216],	   which	  
contains	   only	   4	   evolu(onary	   conserved	  members	   (DKK1-­‐4)	   and	   1	   distantly	   related	  
member,	   Soggy	   (Dickkopf-­‐like	   1,	   DKKL-­‐1)	   [214,	   215]	   (Fig.	   1.12).	   DKK1/2/4	   possess	  
around	   46%	   to	   50%	   of	   homologous	   sequences	   between	   each	   other	   while	   DKK3	  
shares	   only	   37%	   to	   40%	   with	   all	   three	   others	   [215].	   Besides	   less	   homology	   in	  




Figure	  1.12	  Structures	  of	  DKKs.	  The	  ﬁgure	  is	  
derived	  from	  Veeck	  and	  Dahl,	  Biochimica	  et	  
Biophysica	  Acta	  2012,	  1825:18–28.
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DKK1,	  DKK2,	  and	  DKK4	  are	   found	  to	  be	  antagonists	  of	   the	  canonical	  Wnt/β-­‐catenin	  
signaling	   pathway	   (Fig.	   1.14)	   by	   compe(ng	   with	   Wnt	   ligands	   for	   the	   Lrp5/6	   co-­‐
receptors	  [214,	  217].	  However,	  DKK3	  has	  been	  reported	  to	  have	  no	  binding	  capacity	  
for	  the	  Lrp-­‐5/6	  co-­‐receptor	  [214].	  Only	  in	  certain	  cell	  lines,	  over-­‐expressed	  DKK3	  has	  
been	  reported	  to	  reduce	  the	  cytoplasmic	  level	  of	  β-­‐catenin	  and	  therefore	  may	  aﬀect	  
the	   canonical	  Wnt/β-­‐catenin	  pathway	  diﬀerently	   from	  other	  DKKs	   [218]	   (Fig.	   1.13).	  
Moreover,	   intrinsically	   expressed	   DKK3	   has	   been	   shown	   to	   promote,	   instead	   of	  
inhibit,	   the	  Wnt3a-­‐mediated	   canonical	  Wnt/β-­‐catenin	  pathway	  by	  binding	  onto	   co-­‐
receptors	  Kremen	   (Krm)1	  and	  Krm2	   [219].	   Intriguingly,	   this	  has	  not	  been	   found	   for	  
extrinsic	   DKK3	   in	   condi(oned	  medium	   [219].	   Addi(onally,	   DKK3	  may	   regulate	  Wnt	  
signaling	   pathway	   through	   the	   non-­‐canonical	   Wnt/planar	   cell	   polarity	   (Wnt/PCP)	  
pathway	   [214,	   215,	   220]	   because	   over-­‐expression	   of	   DKK3	   induces	   downstream	   c-­‐
Jun-­‐NH2-­‐Kinase	   (JNK)	   ac(vity	   (Fig.	   1.13).	   So	   far,	   no	   clear	   picture	   has	   emerged	  
whether	  and	  how	  DKK3	  inﬂuences	  Wnt	  signaling.	  !
	  
Figure	  1.13	  DKKs	  regulate	  the	  Wnt	  signaling	  pathway.	  
DKK1/2/4	  can	  compete	  with	  Wnt	  ligands	  for	  co-­‐receptors	  
Lrp5/6	  or	  Kremen	  and	  inhibit	  Wnt	  signaling	  through	  the	  
canonical	  Wnt/β-­‐catenin	  pathway.	  However,	  DKK3	  cannot	  
bind	  as	  other	  DKK	  members	  and	  fails	  to	  inhibit	  Wnt	  
signaling	  in	  various	  situa(ons.	  Only	  in	  certain	  cell	  lines	  
DKK3	  can	  reduce	  cytoplasmic	  β-­‐catenin	  and	  aﬀect	  the	  
canonical	  Wnt/β-­‐catenin	  pathway.	  It	  is	  also	  controversial	  
whether	  DKK3	  can	  inhibit	  non-­‐canonical	  Wnt/PCP	  
pathway.	  The	  ﬁgure	  is	  from	  Veeck	  and	  Dahl,	  Biochimica	  et	  
Biophysica	  Acta	  2012,	  1825:18–28.	  !!!
The	   distribu(on	   of	   Wnt	   ligands	   and	   temporal/spa(al	   diﬀerences	   of	   Wnt	   signaling	  
ac(vi(es	   decide	   developmental	   events,	   such	   as	   antero–posterior	   axial	   pa/erning,	  
limb	  development,	  and	  eye	  forma(on	  [214].	  Dysregulated	  Wnt	  signaling	  may	  disrupt	  
the	   developmental	   plans	   [221,	   222].	   Aberant	  Wnt	   signaling	   is	   reported	   in	   various	  
cancers	  [215].	  In	  addi(on,	  Wnt	  signaling	  is	  also	  essen(al	  in	  immunological	  responses	  
[223].	  Since	  DKK	  family	  members	  regulate	  Wnt	  signaling,	  it	  is	  not	  surprising	  that	  DKK	  
proteins	  are	  also	  involved	  in	  developmental	  processes	  [214,	  222].	  Indeed,	  the	  name	  
dickkopf	  of	  the	  DKK	  family	   is	  based	  on	  abnormal	  head	  forma(on	   in	  embryos	   in	  the	  
absence	  of	  DKK1	  during	  development	  [216].	  	  !!
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F igure	   1 .14	   Canonica l	   Wnt	  
signaling	   pathway.	   DKKs	   can	   bind	  
onto	   co-­‐receptor	   LPR5/6	   and	  
Kremen,	   inducing	   internaliza(on	   of	  
co-­‐receptors	   and	   impair	   the	   Wnt	  
signaling.	   However,	   when	   Wnt	  
ligands	   can	   compete	   out	   DKKs	   for	  
the	  binding	  of	  co-­‐receptors	  and	  the	  
receptor,	   Frizzled,	   cytoplasmic	   β-­‐
catenin	  will	  be	  translocated	  into	  the	  
nucleus	   and	   ini(ate	   downstream	  
events.	   The	   ﬁgure	   is	   from	   Frank	  
Staal,	  et	  al,	  Nat.	  Rev.	  Immunol.2008,12:581-­‐593	  !
DKK3	   has	   been	   described	   as	   a	   tumor	   suppressor	   in	   various	   types	   of	   tumors	   [215,	  
224].	  Down-­‐regula(on	  of	  DKK3	  has	  been	  found	  in	  solid	  tumors	  of	  lung,	  colon,	  kidney,	  
prostate,	  and	  breast	  as	  well	  as	  in	  hematopoie(c	  malignancies.	  As	  a	  result,	  DKK3	  has	  
been	   iden(ﬁed	   as	   REIC	   (Reduced	   Expression	   in	   Immortalized	   Cells)	   when	   it	   was	  
discovered	   in	   transcriptome	   screening	   among	   primary	   tumors	   [225].	  
Hypermethyla(on	   of	   the	   DKK3	   promoter	   silences	   its	   expression	   in	   tumors	   [215].	  
Demethyla(on	   drugs	   can	   reverse	   the	   suppression	   of	   DKK3	   expression	   in	   various	  
tumors	   and	   may	   be	   relevant	   to	   the	   beneﬁcial	   outcomes	   observed	   for	   these	  
demethyla(on	  drugs	  in	  tumor	  pa(ents	  [215,	  226].	  	  !
Since	  DKK3	   is	  a	   tumor	  suppressor,	  eﬀorts	   to	  up-­‐regulate	  DKK3	  expression	   in	  cancer	  
pa(ents	   have	   been	   considered	   for	   novel	   treatment	   strategies	   [215].	   However,	   the	  
observa(on	   that	   pa(ents	   with	   dele(on	   at	   the	   DKK3	   locus	   had	   lower	   lymph	   node	  
metastasis	   and	  be/er	  prognosis	   in	   head	   and	  neck	   squamous	   cell	   carcinomas	  point	  
towards	   a	   tumor-­‐promo(ng	   func(on	   of	   DKK3	   [227].	   Thus,	   systemic	   or	   on-­‐site	   up-­‐
regula(on	  of	  DKK3	  may	  abort	  an(-­‐tumor	  responses.	  	  	  	  	  	  	  	  !
Indeed,	  our	  group	  has	  shown	  that	  DKK3	   is	  essen(al	   for	  CD8+	  T	  cell	   tolerance	  [228].	  
Overall,	  the	  exact	  roles	  of	  DKK3	  in	  tumor	  development	  and	  in	  the	  respec(ve	  immune	  
responses	  call	  for	  further	  inves(ga(on.	  	  	  !!!!!!!!
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1.5.0.0.	  Autophagy	  !
Proteasome	  and	  lysosome	  are	  two	  major	  machineries	  to	  destroy	  and	  recycle	  cellular	  
components	   [229].	  While	   the	   proteasomes	   are	   responsible	   for	   short-­‐lived	   proteins	  
labeled	  by	  ubiquityla(on	  [230]	  or	  sumoyla(on	  [231],	   lysosomes	  deal	  with	  damaged	  
organelles	   and	   long-­‐lived	   proteins	   [229].	   Autophagy	   is	   deﬁned	   as	   the	   process	   by	  
which	  the	  cells	  deliver	  damaged	  organelles	  or	  cellular	  proteins	  into	  the	  lysosomes	  for	  
degrada(on	   [229].	   The	  degraded	   components	   can	   therefore	   be	   reused	   as	   anabolic	  
elements	   for	   other	   purposes.	   From	   single-­‐cell	   yeasts	   to	   human,	   autophagy	   is	  
conserved	  through	  evolu(on	  as	  a	  crucial	  mechanism	  to	  maintain	  the	  homeostasis	  of	  
biological	   blocks	   and	   energy	   inside	   of	   cells.	   With	   autophagy	   cells	   can	   struggle	   to	  
survive	   during	   starva(on.	   Addi(onal	   signals	   such	   as	   endoplasmic	   re(culum	   (ER)	  
stress,	  oxida(ve	  stress,	  and	  immune	  ac(va(on	  can	  also	  s(mulate	  autophagy	  [232].	  	  	  !
Autophagy	   can	   be	   categorized	   into	   three	   major	   pathways:	   macroautophagy,	  
microautophagy,	  and	  chaperon-­‐mediated	  autophagy	  (CMA)	  [229]	  (Fig.	  1.15).	  Macro-­‐	  
and	  microautophagy	  can	  pack	  their	  cargos	   in	  both	  selec(ve	  and	  non-­‐selec(ve	  ways	  
[233,	   234],	  while	   CMA	   performs	   selec(ve	   processes	   [233].	   CMA	   deals	  with	  mainly	  
cytosolic	   unfolded	   proteins	   containing	   degenerated	   sequences	   of	   signal	   pep(des	  
[229].	   The	   signal	   pep(des	   can	   be	   recognized	   by	   the	   cytosolic	   HSC-­‐70-­‐centered	  
chaperone	   system	   and	   then	   docked	   onto	   the	   lysosomal	   membrane	   [235].	   On	   the	  
lysosomal	   membrane,	   the	   lysosome-­‐associated	   membrane	   protein	   (LAMP)-­‐2A	   is	  
mul(merized	  to	  form	  transloca(ng	  channels	  [236,	  237]	  and	  mediate	  the	  traﬃcking	  of	  
CMA	  cargos.	   Lysosomal	  HSC-­‐70	  chaperones	  and	   the	  C-­‐terminal	   cytosolic	  domain	  of	  
LAMP-­‐2A	  are	  also	  essen(al	   for	   the	   traﬃcking	   [238].	  Microautophagy	   is	   ini(ated	  by	  
inward	   protrusions	   of	   the	   lysosomal	   membranes	   [229].	   Soluble	   proteins	   can	   be	  
included	  inside	  of	  the	  pocket	  and	  delivered	  into	  the	  lysosome	  when	  the	  protrusions	  
ﬁnally	  round	  up	  and	  are	  isolated	  from	  the	  membrane.	  By	  contrast,	  macroautophagy	  
requires	   a	   cup-­‐shaped	   isolated	   double-­‐membrane	   system,	   of	   which	   the	   origin	   is	  
controversial,	   to	  pack	   the	   target	  cargo	   in	   the	  cytoplasm	   independently	  and	  then	  to	  
fuse	   with	   the	   des(ned	   lysosome	   [229,	   232,	   239].	   Protein	   products	   of	   the	   yeast	  
autophagy-­‐related	   genes	   (ATG)	   [232,	   240]	   and	   their	   corresponding	   homologues	   in	  
higher	   eukaryotes	   are	   required	   to	   ini(ate	   and	   process	  macroautophagy	   [229,	   232,	  
239].	  The	  isola(on	  of	  the	  double-­‐membrane	  system	  is	  ini(ated	  by	  Atg6	  with	  signaling	  
inputs	   from	   PI3K	   signaling	   [233,	   239,	   241,	   242]	   and	   is	   inhibited	   by	   ac(ve	   mTOR	  
signaling	   [233,	   239,	   241-­‐243].	   The	   isolated	  double-­‐membranes	   start	   as	   cup-­‐shaped	  
omegasomes	   [232]	   and	   elongate	   to	   surround	   cargos.	   Two	   protein	   systems	   are	  
involved	  in	  further	  forma(on	  of	  autophagosomes.	  The	  core	  of	  the	  ﬁrst	  system	  is	  the	  
Atg8	  protein	  (named	  LC3	  in	  human).	  Atg8	  proteins	  are	  cleaved	  by	  Atg4	  to	  expose	  the	  
C-­‐terminal	   glycine	   residues	   (G120).	   Cleaved	   Atg8	   proteins	   are	   ac(vated	   by	   E1-­‐like	  
ac(va(ng	  Atg7	  and	  then	  ligated	  onto	  the	  phospha(dylethanolamine	  (PE)	  residues	  on	  
both	  outer	  and	   inner	  elonga(ng	  membranes	  by	  E2-­‐like	  conjuga(ng	  Atg3.	  The	  other	  
protein	   system	   process	   Atg12	   proteins.	   Atg12	   proteins	   are	   conjugated	   with	   Atg5	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through	   the	   help	   from	   E1-­‐like	   Atg7	   and	   E2-­‐like	   Atg10.	   The	   conjugated	   Atg12-­‐Atg5	  
forms	   complexes	   with	   Atg16L	   a{erwards	   and	   stays	   onto	   the	   outer	   elonga(ng	  
membrane.	   It	   is	  believed	   that	  Atg12-­‐Atg5-­‐Atg16L	   complexes	  act	  as	  E3-­‐like	   ligase	   to	  
facilitate	  the	  liga(on	  of	  Atg8	  onto	  PE	  residues.	  All	  accessory	  proteins	  except	  for	  Atg8	  
proteins	   a/ached	   onto	   the	   inner	   membrane	   leave	   the	   autophagosomes	   upon	  
comple(on.	   The	   completed	   autophagosomes	   then	   fuse	   with	   lysosomes	   to	   form	  
autolysosomes	  and	   the	  cargos	  are	  degraded	   [229,	  232].	  Both	  macroautophagy	  and	  
chaperone-­‐mediated	   autophagy	   are	   observed	   in	   higher	   eukaryotes	   and	   related	   to	  
immune	   responses,	  while	  microautophagy	   is	   only	   documented	   in	   yeasts	   and	  other	  
lower	  eukaryotes	  [229].	  	  !
  	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mTOR	  signaling	  suppresses	  autophagy	  (Fig.	  1.16).	  Amino	  acids,	  glucose,	  metabolites,	  
growth	   factors,	   hormones,	   cytokines,	   and	   Wnt	   signaling	   can	   modulate	   mTOR	  
ac(vi(es	   [243].	   Therefore,	   mTOR	   is	   a	   central	   node	   for	   cells	   to	   respond	   to	  
environmental	  stress.	  For	  example,	  during	  nutri(onal	  depriva(on,	  low	  concentra(on	  
of	   amino	   acids	   and	   glucose	   in	   the	   environment	   or	   an	   increased	   AMP:ATP	   ra(o	  
inac(vate	  mTOR	  ac(vi(es	   (Fig.	   1.16).	   Inac(vated	  mTOR	   stops	   biosynthesis	   and	   cell	  
cycle,	  however,	  trigger	  autophagic	  processes	  instead	  to	  reserve	  metabolic	  blocks	  for	  
cell	   survival	   [242,	   243].	   Wnt	   signaling	   can	   ac(vate	   mTOR	   by	   inhibi(ng	   the	   mTOR	  
inhibitor	  GSK3β (Fig.	   1.16),	   providing	   another	   control	   of	  mTOR	  ac(vi(es	   [244]	   and	  
possible	  regula(on	  of	  autophagy.	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Figure	  1.15	  Summary	  of	  autophagy.	  There	  are	  three	  types	  of	  autophagy,	   including	  macroautophagy,	  
microautophagy,	   and	   chaperon-­‐mediated	   autophagy.	   The	   ﬁgure	   is	   derived	   from	  Münz,	   Annu.	   Rev.	  
Immunol.	  2009,	  27:423–49
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Figure	  1.16	  Summary	  of	  the	  regula/on	  of	  mTOR	  signaling.	  Wnt	  signaling	  can	  ac(vate	  mTOR	  ac(vi(es	  
by	  inhibi(ng	  mTOR	  inhibitor	  GSK3β.	  mTOR	  ac(vi(es	  suppress	  autophagy.	  Therefore,	  Wnt	  signaling	  can	  
be	  a	  nega(ve	  regulator	  of	  autophagic	  ac(vi(es.	  The	  ﬁgure	  is	  derived	  from	  Thomson,	  et	  al.,	  Nat.	  Rev.	  
Immunol.	  2009,	  9:324-­‐337	  !
Autophagy	   has	   been	   correlated	   with	   broad	   ranges	   of	   diseases,	   including	   various	  
cancers	   [233,	   241]	   and	   neurodegenera(ve	   diseases	   like	   Alzheimer’s	   disease	   [233,	  
241].	   It	   is	   also	   implicated	   in	   aging	   and	   longevity	   [233].	   In	   immune	   responses,	  
autophagy	   contributes	   to	   eliminate	   intracellular	   pathogens	   [233,	   245].	   It	   is	   also	  
involved	   in	   both	   MHC	   class	   I	   [246]	   and	   MHC	   class	   II	   [247,	   248]	   presenta(on,	  
providing	   help	   to	   enhance	   both	   innate	   and	   adap(ve	   immunity	   [229].	   Both	  macro-­‐	  
and	  chaperone-­‐mediated	  autophagy	  (CMA)	  contribute	  to	  the	   input	  of	  an(gens	   into	  
the	   MHC	   class	   II-­‐containing	   compartments	   (MIICs).	   Autophagosome	   from	  
macroautophagy	   can	   fuse	   with	  MIICs	   while	   CMA	   directly	   import	   unfolded	   protein	  
into	   MIICs	   [229].	   On	   the	   other	   hand,	   immunological	   signaling	   by	   cytokines,	   co-­‐
s(mulatory	   molecules,	   and	   TLRs	   can	   regulate	   autophagy	   [229].	   The	   reciprocal	  
regula(on	  between	  autophagy	  and	  the	  immune	  system	  raises	  the	  issue	  how	  a	  basic	  
cellular	  metabolic	  event	  can	  be	   translated	   into	   immune	   responses.	  Autophagy	  may	  
also	  be	  the	  link	  between	  nutri(onal	  status	  and	  eﬃciency	  of	  immunity.	  	  !
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1.6.0.0.	  Aim	  of	  the	  study	  	  !
A/enua(ng	   T	   cell	   responses	   is	   a	   key	   therapeu(c	   goal	   in	   transplant	   rejec(on	   and	  
autoimmune	   diseases,	   while	   an	   enhanced	   T	   cell	   reac(vity	   is	   a	   pre-­‐requisite	   for	  
rejec(on	  of	  solid	  tumors.	  Understanding	  the	  molecular	  mechanisms	  regula(ng	  T	  cell	  
reac(vity	   is,	   therefore,	   required	   for	   a	   successful	   reprogramming	   of	   immune	  
responses	  in	  such	  medical	  condi(ons.	  T	  cell	  responses	  can	  be	  regulated	  by	  mul(ple	  
factors	   including	   intrinsic	   and	   extrinsic	   modulators.	   The	   aim	   of	   this	   study	   is	   to	  
inves(gate	  the	  role	  of	  Nck	  adaptor	  proteins,	  as	  T	  cell	  intrinsic	  factors,	  and	  of	  Dkk3,	  as	  
an	  extrinsic	  modulator,	  in	  the	  control	  of	  T	  cell	  responses.	  	  !
In	   the	   ﬁrst	   part	   of	   the	   thesis,	  we	  will	   assess	   the	   contribu(on	   of	   the	  Nck	   adaptor	  
proteins	   to	   in	   vivo	   T	   cell	   responses	   to	   foreign	   an(gens.	   It	   will	   be	   inves(gated	  
whether	   loss	   of	   Nck	   func(on	   could	   cause	   any	   altera(ons	   in	   CD4	   helper	   T	   cell	  
ac(vity,	   using	  an(body	  produc(on	  by	  B	   cells	   as	   read-­‐out	   system.	   In	   addi(on,	   EAE	  
will	   be	   employed	   to	   study	   the	   role	   of	   the	   Nck	   adaptors	   in	   a	   T	   cell-­‐mediated	  
autoimmune	  disease.	  !
The	  second	  part	  of	  the	  thesis	  will	  focus	  on	  the	  ques(on	  whether	  and	  how	  DKK3	  can	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2.	  Materials	  and	  Methods	  
!
Mice	  !
Nck.T-­‐/-­‐	  mice	  were	  bred	  as	  described	  before	  [249,	  250]	  (Fig.	  2.1).	  In	  short,	  Nck1	  single	  
knock-­‐out	   mice	   were	   crossed	   with	   Nck2ﬂx/ﬂx	   mice,	   in	   which	   exon1	   of	   Nck2	   was	  
ﬂanked	  by	  loxP	  sites.	  The	  oﬀsprings	  were	  further	  crossed	  with	  Lck-­‐Cre	  deleter	  mice	  in	  
which	  the	  Cre	  recombinase	  was	  under	  the	  control	  of	  T	  cell	  speciﬁc	  Lck	  promoter.	  This	  
T	  cell-­‐speciﬁc	  Nck	  knock-­‐out	  mice	  were	  then	  maintained	  by	  sibling	  ma(ng.	  Absence	  
of	  Nck	  in	  T	  cells	  was	  conﬁrmed	  on	  protein	  level	  (Fig.	  2.2)	  and	  regularly	  controlled	  by	  
PCR.	  Lck-­‐Cre	  deleter	  mice	  were	  used	  as	  controls	  and	  noted	  as	  Nck.T+/+.	  !
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Figure	   2.1	   Summary	   of	   Nck.T-­‐/-­‐	   murine	   model.	   The	   ﬁrst	   exon	   of	   Nck2	   was	   ﬂanked	   by	   loxP	   sites	  
(Nck2ﬂx).	   The	  Nck2ﬂx	  mice	  were	   then	  crossed	  with	  Nck1	  knock-­‐out	   (Nck1-­‐/-­‐)	  mice	  and	  Lck-­‐Cre	  mice,	  
which	  expressed	  the	  deleter	  gene	  cre	  under	   the	  control	  of	  T	  cell-­‐speciﬁc	  promotor	  Lck.	  Descendant	  
Nck.T-­‐/-­‐	  mice	  were	  monitored	  by	  checking	  the	  expression	  of	  Nck1	  and	  Nck2	  genes	  in	  the	  mice	  through	  




Figure	   2.2	   Ansence	   of	   Nck	   expression	   in	   T	   cells	   of	  
Nck.T-­‐/-­‐	  murine	  model.	  The	  expression	  of	  Nck	  proteins	  
in	   splenic	   T	   cells	  was	   speciﬁcally	   abrogated	   in	  Nck.T-­‐/-­‐	  
mice.	  	  	  !!
C57BL/6	   (B6)	  or	  RAGE-­‐EGFP+/+	  x	  B6	   (EGFP+/-­‐)	  mice	  were	  used	  as	  control	   in	  diﬀerent	  
experiments.	   DKK3	   knock-­‐out	   (DKK3-­‐/-­‐)	   mice	   were	   mice	   with	   systemic	   dele(on	   of	  
DKK3	   expression	   [251].	   RAGE-­‐EGFP+/+	   mice	   were	   crossed	   with	   DKK3-­‐/-­‐	   mice	   to	  
generate	  EGFP-­‐expressing	  mice	  with	  DKK3	  systemic	  dele(on	  (EGFP+/-­‐xDKK3-­‐/-­‐).	  Rag2-­‐/-­‐	  
mice	  were	  with	  systemic	  dele(on	  of	  Rag2	  gene	  as	  described	  before	  [75].	  Mice	  were	  
bred	  and	  housed	  in	  central	  animal	  laboratory	  in	  German	  Cancer	  research	  Center.	  !!!
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Immuniza/on	  and	  Sampling	  	  !
For	   subcutaneous	   primary	   immuniza(on,	   TNP23-­‐	   or	   TNP26-­‐BSA	   (#T-­‐5050,	   Biosearch	  
Technology)	   was	   diluted	   in	   100μl	   DPBS	   and	   mixed	   with	   100μl	   complete	   Freund’s	  
adjuvant.	  Spleen	  and	  blood	  were	  collected	  10	  days	  a{er	  primary	  immuniza(on	  or	  7	  
days	  from	  secondary	  immuniza(on.	  	  !
Mesenchymal	  stem	  cells	  (MSCs)	  isola/on	  !
Isola(on	   of	  MSCs	  was	   based	   on	   the	   protocol	   described	   before	   [252,	   253]	   and	   the	  
manufacturer’s	   guides	   from	   STEMCELL	   Technologies	   by	   which	   the	   MesenCult™ 
selec(on	  medium	   system	  was	  produced.	   In	   short,	   the	   femur	   and	  (bia	   bones	  were	  
isolated	  from	  two	  mice	  scariﬁed	  by	  CO2.	  Furs	  and	  muscles	  were	  removed	  by	  scalpels.	  
Openings	  were	  trimmed	  at	  two	  ends	  of	  the	  bones	  to	  allow	  the	  bone	  marrows	  being	  
washed	   out	   by	   isola(on	   buﬀer	   (1x	   PBS	  with	   2%FBS	   and	   1mM	   EDTA).	  Washed	   out	  
bone	  marrow	  was	   suspended	   in	   isola(ng	  buﬀer	   and	   kept	  on	   ice.	   Bones	  were	   then	  
cracked	  down	  then	  by	  scalpels	  into	  small	  fragments	  without	  scratching	  and	  damaging	  
the	  bone	  membranes.	  Fragments	  of	  bones	  were	  soaked	  in	  diges(ng	  medium	  (1x	  PBS	  
with	   20%	   FBS	   and	   0.25%	   collagenase	   type	   I)	   in	   room	   temperature	   for	   5	   minutes.	  
Soaked	  bone	  fragments	  were	  further	  cracked	  to	  ﬁne	  pieces.	  The	  diges(ng	  buﬀer	  was	  
then	  ﬁlled	  up	  to	  10ml	  and	  the	  containing	  tubes	  were	  shook	  in	  37°C	  for	  45	  minutes.	  
Treated	   bone	   pieces	   were	   suspended	   by	   directly	   adding	   isola(on	   buﬀer	   to	   ﬁnal	  
volume	  of	  30ml	  and	  then	  ﬁltered	  through	  70μm	  cell	  strainers.	  The	  cell	  strainers	  were	  
washed	  by	  addi(onal	  10ml	  isola(on	  buﬀer.	  Cells	  from	  bone	  and	  bone	  marrow	  were	  
centrifuged	  and	  the	  respec(ve	  cell	  pellets	  were	  suspended	  in	  MesenCult™ selec(on	  
medium.	   Cells	   were	   cultured	   in	   the	   selec(on	   medium	   for	   at	   least	   3	   weeks.	   A{er	  
checking	   for	   expression	   of	   MSCs	   surface	   markers,	   the	   selec(on	   medium	   was	  
gradually	  replaced	  by	  complete	  DMEM.	  When	  the	  diﬀeren(a(ng	  capaci(es	  of	  these	  
cells	  were	   conﬁrmed,	   the	  MSCs	  were	   cultured	  only	   in	   complete	  DMEM	   for	   further	  
experiments.	  	  !
Mesenchymal	  stem	  cells	  (MSCs)	  diﬀeren/a/on	  assays	  !
The	  diﬀeren(a(ng	  medium	  for	  adipogenesis	  was	  prepared	  by	  MesenCult™ selec(on	  
medium	   containing	   5μg/ml	   insulin	   (#I6634,	   Sigma),	   50μM	   indomethacin	   (#I7378,	  
Sigma),	   1μM	   dexamaethasone	   (#D4902,	   Sigma),	   and	   0.5μM	   IBMX	   (#I7018,	   Sigma).	  
The	  medium	  for	  osteogenesis	  was	  MesenCult™ selec(on	  medium	  containing	  20mM	  
β-­‐glycerol	  phosphate	  (#G9891,	  Sigma),	  1nM	  dexamaethasone	  (#D4902,	  Sigma),	  and	  
0.5μM	  ascorbate	  2-­‐phosphate	  (#A8960,	  Sigma).	  2x105	  MSCs	  were	  seeded	  in	  6-­‐wells	  
microplates	  one	  day	  before	  inducing	  the	  diﬀeren(a(on.	  On	  the	  day	  of	  diﬀeren(a(on,	  
culture	   medium	   was	   replaced	   with	   diﬀeren(a(ng	   medium.	   The	   diﬀeren(a(ng	  
medium	   was	   changed	   every	   3	   days	   for	   3	   weeks.	   3	   weeks	   later,	   the	   medium	   was	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removed	   and	   the	   cells	   were	   washed	   with	   1x	   PBS	   twice	   and	   then	   ﬁxed	   with	   10%	  
formalin	   in	  room	  temperature	  for	  20	  minutes.	  A{er	  the	  ﬁxa(on,	  cells	  were	  washed	  
with	  1x	  PBS	  and	  processed	   for	   staining.	   For	   staining	  of	   adipocytes,	   0.5%	  Oil	   Red	  O	  
(#O0625,	  Sigma)	  was	  dissolved	  in	  methanol.	  For	  staining	  of	  osteogenesis,	  2%	  Alizarin	  
Red	   S	   (#S5533,	   Sigma)	   was	   dissolved	   in	   dis(lled	  water	   in	   pH	   4.1.	   Fixed	   cells	   were	  
stained	  by	  indicated	  solu(on	  in	  room	  temperature	  for	  20	  minutes	  and	  then	  washed	  
twice	   with	   1x	   PBS	   before	   ﬁlled	   up	   with	   2mL	   1x	   PBS	   and	   observed	   by	   op(cal	  
microscope	  in	  40x	  magniﬁcence.	  !
Culture	  and	  Re-­‐s/mula/on	  of	  Splenic	  Cells	  !
Single	   cells	   from	   spleens	   were	   suspended	   and	   cultured	   in	   complete	   RPMI	   1640	  
medium.	   For	   re-­‐s(mula(on,	   an(-­‐CD3	   an(bodies	   (LEAF™ puriﬁed,	   clone	   145-­‐2C11,	  
#100314	   BioLegend)	   were	   diluted	   in	   500μl	   PBS	   in	   5μg/ml	   and	   coated	   on	   24-­‐wells	  
microplates	  in	  37°C	  for	  24	  hours.	  Coa(ng	  solu(on	  was	  removed	  right	  before	  adding	  
500μl	   single	   cells	   suspensions.	   48	   hours	   later	   cells	   were	   harvested	   for	   further	  
analysis.	  For	  the	  intracellular	  staining	  of	  cytokines,	  4	  hours	  before	  the	  harvest,	  500μl	  
fresh	   culture	   medium	   containing	   PMA	   and	   ionomycin	   along	   with	   monensin	  
(GolgiStop™,	  #554724	  BD)	  was	  added	  into	  the	  culture.	  	  !
Culture	  and	  IFNγ s/mula/on	  of	  MSCs	  !
Established	  MSCs	   were	   cultured	   in	   complete	   DMEM	   containing	   10%	   FBS,	   2mM	   L-­‐
Glutamine,	  and	  1%	  HEPES.	  RMA-­‐mOVA	  cells	  were	   cultured	   in	   complete	  RPMI	  1640	  
containing	  10%	  FBS,	  2mM	  L-­‐Glutamine,	  and	  1%	  HEPES.	  For	  IFNγ s(mula(on,	  mouse	  
recombinant	   IFNγ (#300-­‐02,	   PeproTech)	   was	   prepared	   into	   the	   concentra(on	   of	  
20ng/ml	   in	   complete	  DMEM.	  One	  day	  before	   the	   s(mula(on,	   1x106	  WT	  or	  DKK3-­‐/-­‐	  
MSCs	  were	  seeded	  in	  10cm	  petri	  dishes	  (or	  1x105	  cells	  in	  6-­‐wells	  microplates).	  On	  the	  
day	  of	  s(mula(on,	  culture	  medium	  was	  replaced	  with	  s(mula(ng	  medium	  and	  the	  
cells	  were	   cultured	   for	   further	   48	   hours.	   Before	   every	   experiment,	   the	  MSCs	  were	  
checked	   by	   their	   surface	   markers	   for	   quality	   control.	   RMA-­‐mOVA	   cells	   were	  
controlled	   by	   ﬂow	   cytometry	   for	   the	   surface	   expression	   of	  membrane-­‐bound	  OVA	  
protein	  and	  MHC	  class	  I.	  !
Flow	  Cytometry	  	  	  !
To	  stain	  surface	  markers,	  harvested	  cells	  were	  washed	  twice	  with	  staining	  buﬀer	  (3%	  
FBS	  and	  0.1%	  sodium	  azide	  in	  DPBS)	  and	  stained	  with	  an(body	  combina(ons	  diluted	  
in	  staining	  buﬀer	  in	  the	  dark	  on	  ice	  for	  30	  minutes.	  Stained	  cells	  were	  washed	  twice	  
before	  analysis	  on	  the	  BD	  FACSCanto™	  II	  ﬂow	  cytometry.	  For	  intracellular	  staining	  of	  
cytokines	  or	  transcrip(onal	   factors,	  surface	  markers	  were	  stained	  ﬁrst.	  The	  ﬁxa(on,	  
permeabiliza(on,	   and	   cytokine	   staining	   were	   carried	   out	   with	   the	   buﬀer	   sets	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(#560409,	   BD	   and	   88-­‐8824-­‐00,	   eBioscience)	   and	   manufacturer’s	   instruc(ons.	   The	  
same	   buﬀer	   set	   was	   applied	   for	   the	   staining	   of	   intracellular	   DKK3.	   For	   staining	   of	  
transcrip(onal	   factors,	   an	   alterna(ve	   buﬀer	   set	   from	  eBioscience	   (#00-­‐5523-­‐00)	   or	  
BD™ (#560409)	  was	  used	  instead.	  For	  staining	  of	  apopto(c	  cells,	  apoptosis	  detec(on	  
kit	  (#559793,	  BD)	  was	  used.	  For	  staining	  of	  phosphorylated	  Akt,	  BDTM	  Phosﬂow	  Perm	  
Buﬀer	  III	  (#558050,	  BD)	  was	  used	  and	  the	  manufacturer’s	  instruc(ons	  were	  followed.	  	  	  !
ELISA	  	  	  !
For	  the	  quan(ﬁca(on	  and	  aﬃnity	  assay	  of	  serum	  an(bodies,	  TNP26-­‐BSA,	  TNP16-­‐KLH,	  
or	   TNP5-­‐KLH	   (#T-­‐5050,	   #T-­‐5060	   Biosearch	   Technology)	   molecules	   were	   diluted	   in	  
coa(ng	   buﬀer	   (50mM	   sodium	   carbonate,	   pH9.5)	   and	   then	   coated	   on	   the	   96-­‐wells	  
ELISA	  plates	   in	  4°C	  overnight.	  For	  TNP26-­‐BSA	   the	  coa(ng	  concentra(on	  was	  1μg/ml	  
and	  for	  TNP16-­‐KLH	  or	  TNP5-­‐KLH	  was	  10μg/ml.	  Coa(ng	  buﬀer	  was	  discarded	  and	  the	  
wells	  were	  washed	   3	   (mes	   by	  wash	   buﬀer	   (1x	   TBS	  with	   0.1%	   Tween-­‐20).	   Gela(n-­‐
containing	   blocking	   buﬀer	   was	   used	   to	   block	   the	   wells	   in	   4°C	   overnight.	   Samples,	  
standards,	   or	   HRP-­‐conjugated	   secondary	   an(bodies	   recognizing	   various	   an(body	  
isotypes	  were	  diluted	  in	  wash	  buﬀer	  and	  then	  incubated	  in	  room	  temperature	  for	  1	  
hour.	   Serial	   dilu(ons	  were	  made	   for	   samples	   and	   standards.	   Secondary	   an(bodies	  
were	  diluted	  in	  1:1000.	  Signals	  were	  developed	  by	  100μl	  OPD	  solu(on	  (400μg/ml	  in	  
0.1M	  K2PO4,	  pH6.0)	  containing	  0.03%	  peroxide	  and	  then	  stopped	  by	  adding	  50μl	  1M	  
sulfuric	   acid	   solu(ons.	   The	  op(cal	   density	   at	  wavelength	  of	   495	  nM	   (O.D.495)	  was	  
measured	   by	   automa(c	   reader	   (Victor™ 1420	   Mul(label	   Counter,	   Perkin	   Elmer).	  
An(body	  concentra(ons	  were	  calculated	  by	  O.D.495	  values	  gained	   from	  TNP26-­‐BSA	  
binding	  and	  standard	  curves.	  Aﬃnity	  units	  were	  calculated	  by	  dividing	   the	  O.D.495	  
values	  gained	   from	  TNP16-­‐KLH	  binding	  with	  corresponding	  an(body	  concentra(ons.	  
Reduc(on	  ra(o	  was	  calculated	  by	  dividing	  the	  O.D.495	  values	  gained	  from	  TNP5-­‐KLH	  
binding	   with	   values	   from	   TNP16-­‐KLH	   binding	   in	   the	   same	   serum	   dilu(on	   [26].	   For	  
quan(ﬁca(on	   of	   cytokine	   concentra(ons	   in	   the	   serum,	   Ready-­‐SET-­‐Go!®	   kits	   for	  
mouse	   IL-­‐4	   or	   IL-­‐10	   (#88-­‐7044,	   #88-­‐7104,	   eBioscience)	   were	   used.	   The	   protocols	  
were	  according	  to	  the	  manufacturer’s	  instruc(ons.	  !
Western	  blogng	  !
MSCs	  were	  lysed	  directly	  on	  the	  10cm	  petri	  dishes	  a{er	  being	  washed	  by	  1x	  PBS	  for	  
two	   (mes.	   Lysis	   buﬀer	   (#78501,	   Thermo	   Scien(ﬁc)	   contained	   protease	   and	  
phosphatase	   inhibitors	   cocktail	   (#11873580001	   and	   #04906837001,	   Roche)	   was	  
prepared	  according	  to	  the	  manufacturer’s	  instruc(on.	  Cell	  debris	  was	  removed	  by	  10	  
minutes	  of	  13000r.p.m.	   centrifuga(on.	  Supernatants	   containing	  proteins	  of	   interest	  
were	  analyzed	  by	  Western	  bloong	  [254].	  Samples	  were	  denatured	  by	  cooking	  with	  
DTT	  for	  10	  minutes	  in	  96°C.	  Western	  bloong	  was	  carried	  out	  by	  mini	  gel	  system	  from	  
BioRad	   for	   the	   SDS-­‐PAGE.	   Acrylamide	   gels	   were	   prepared	   for	   10%	   and	   15%	   of	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acrylamide	   concentra(on.	   Proteins	   were	   transferred	   by	   Trans-­‐Blot® SD	   Semi-­‐Dry	  
Transfer	   Cell	   and	   detected	   by	   speciﬁc	   primary	   an(bodies	   and	   HRP-­‐conjugated	  
an(bodies.	   The	   results	   were	   visualized	   by	   HRP	   substrates	   (#WBKLS0100,	   Merck	  
Millipore)	  and	  op(cal	  ﬁlms	  according	  to	  the	  manufacturer’s	  guides.	  !
An/bodies	  	  	  !
For	   analysis	   by	   ﬂow	   cytometry:	   an(-­‐mouse	   CD3ε PerCP-­‐eFluor®710	   (clone	   17A2,	  
#46-­‐0032-­‐82	   eBioscience);	   an(-­‐mouse	   CD4	   Paciﬁc	   Blue™ (clone	   RM4-­‐5,	   #100531	  
BioLegend);	   an(-­‐mouse	   CD8α APC-­‐Cy7	   (clone	   53-­‐6.7,	   #100714	   Biolegend);	   an(-­‐
mouse	   CD11b	   PE-­‐Cy7	   (clone	   M1/70,	   #101216	   Biolegend);	   an(-­‐mouse	   CD11c	  
AlexaFluor®647	   (clone	   N418,	   #117312	   Biolegend);	   an(-­‐mouse	   CD29	   bio(nylated	  
(clone	   HMβ1-­‐1,	   #102203	   Biolegend);	   an(-­‐mouse/human	   CD44	   PE-­‐Cy7(clone	   IM7,	  
#103030	  Biolegend);	  an(-­‐mouse	  CD69	  FITC	  (clone	  H1.2F3,	  #553236	  BD);	  an(-­‐mouse	  
CD105	   bio(nylated	   (clone	  MJ7/18,	   #120404	   Biolegend);	   an(-­‐mouse	   CD185(CXCR5)	  
PerCp-­‐eFluor®710	   (clone	   SPRCL5,	   #46-­‐7185	   eBioscience);	   an(-­‐mouse	   CD206(MMR)	  
Brilliant	   Violet	   421™ (clone	   C068C2,	   #141717,	   Biolegend);	   an(-­‐human/mouse/rat	  
CD278	  Alexa	  Fluor®647	  (clone	  C398.4A,	  #313516	  BioLegend);	  an(-­‐mouse	  CD279	  PE-­‐
Cy7	   (clone	  29F.1A12,	  #135215	  BioLegend);	  an(-­‐human/mouse	  GL-­‐7	  PE	   (clone	  GL-­‐7,	  
#12-­‐5902	  eBioscience);	  an(-­‐mouse	  NK1.1	  PE	  (clone	  PK136,	  #108708	  Biolegend);	  an(-­‐
mouse	   F4/80	   AlexaFluor® 647	   (clone	   BM8,	   #123122	   Biolegend);	   an(-­‐mouse	   IL-­‐4	  
Alexa	   Fluor®488	   (clone	   11B11,	   #504111	   BioLegend);	   an(-­‐mouse	   IL-­‐10	   Alexa	  
Fluor®647	   (clone	   JES5-­‐16E3,	   #505014	   BioLegend);	   an(-­‐mouse	   IL-­‐21	   PE	   (clone	  
mhalx21,	  #12-­‐7213	  eBioscience);	  an(-­‐pAkt(pS473)	  PE	   (clone	  M89-­‐61,	  #560378	  BD);	  
an(-­‐human/mouse	   Bcl-­‐6	   puriﬁed	   (clone	   603406,	   #MAB5046	   R&D	   Systems);	   an(-­‐
human/mouse	  GATA-­‐3	  eFluor®660	   (clone	  TWAJ,	  #50-­‐9966-­‐41	  eBioscience);	  Annexin	  
V	  PE	  (#51-­‐65875X	  BD);	  7-­‐AAD	  (#51-­‐68981E	  BD).	  	  !
For	   ELISA:	   goat-­‐an(-­‐mouse	   IgM,	   IgG1,	   IgG2a,	   IgG2b	   HRP-­‐conjugated	   (#1021-­‐05,	  
#1070-­‐05,	   #1080-­‐05,	   #1090-­‐05	   Southern	   Biotech);	   AﬃniPure	   goat-­‐an(-­‐mouse	   IgG
+IgM(H+L)	   (#115-­‐005-­‐068	  Jackson	   ImmunoResearch);	  puriﬁed	  mouse	   IgM	  (#550963	  
BD),	  IgG1	  (#553485	  BD),	  IgG2a	  (home-­‐made),	  IgG2b	  (home-­‐made).	  !
For	   Western	   bloong:	   Autophagy	   An(body	   Sampler	   Kit	   (#4445	   Cell	   Signaling	  
Technology®),	   mTOR	   Pathway	   An(body	   Sampler	   Kit	   (#9964	   Cell	   Signaling	  
Technology®),	   mTOR	   Regula(on	   An(body	   Sampler	   Kit	   (#9864	   Cell	   Signaling	  
Technology®),	   Wnt	   Signaling	   An(body	   Sampler	   Kit	   (#2915	   Cell	   Signaling	  
Technology®),	   Wnt/β-­‐catenin	   Ac(vated	   Targets	   An(body	   Sampler	   Kit	   (#8655	   Cell	  
Signaling	   Technology®),	   LC3A(D50G8)	   XP®Rabbit	   mAb	   (#4599	   Cell	   Signaling	  
Technology®),	  LC3B(D11)	  XP® Rabbit	  mAb	  (#3868	  Cell	  Signaling	  Technology®),	  MCP-­‐1	  
An(body	   (Mouse	   Speciﬁc)	   (#2029	   Cell	   Signaling	   Technology®),	   CCL-­‐3	   an(body	  
(#GTX29927	   GeneTex),	   RANTES	   Ani(body	   (Rodent	   Speciﬁc)	   (#2989	   Cell	   Signaling	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Technology®),	   CXCL-­‐8	   an(body	   (#GTX62979	   GeneTex),	   CXCL-­‐10	   an(body	   (#ab8098	  
abcam®),	   CXCL-­‐12	   (#NBP1-­‐45849Novus	   Biologicals),	   an(-­‐β-­‐ac(n	   an(body	   (#A5441	  
Sigma),	   An(-­‐mouse	   IgG	   HRP-­‐linked	   An(body	   (#7076	   Cell	   Signaling	   Technology®),	  
An(-­‐rabbit	  IgG	  HRP-­‐linked	  An(body	  (#7074	  Cell	  Signaling	  Technology®).	  !
Histology	  	  !
Mice	  were	   immunized	  subcutaneously	  with	  TNP23-­‐BSA	  mixed	  by	  complete	  Freund’s	  
adjuvant.	  The	  spleens	  were	  recovered	  a{er	  10	  days.	  Frozen	  sec(ons	  were	  made	  for	  
H&E	  staining	  and	  further	  light	  microscopy	  imaging.	  	  !
Experimental	  Autoimmune	  Encephalomyeli/s	  (EAE)[255]	  	  !
Mice	   were	   immunized	   by	   20μg	   MOG35-­‐55	   pep(des	   mixed	   with	   complete	   Freund’s	  
adjuvant	  (CFA)	  subcutaneously	   in	  the	  tail	  bases.	  1μg	  pertussis	  toxin	  (#P2980	  Sigma-­‐
Aldrich)	   in	  500μL	  DPBS	  was	   injected	  simultaneously	   into	  the	  peritoneal	  cavity	   (i.p.).	  
Addi(onal	  pertussis	  toxin	  was	  injected	  i.p.	  a{er	  2	  days.	  Disease	  scores	  were	  recorded	  
as	   described	   before	   [256].	   Mice	   were	   sacriﬁced	   on	   day	   17	   a{er	   EAE	   induc(on.	  
Inﬁltrated	   lymphocytes	  were	  extracted	  from	  brains	  and	  spinal	  cords	  by	  scissors	  and	  
forceps.	   Isolated	  (ssues	  were	   cut	   into	   small	   pieces	   and	   then	  digested	  by	   complete	  
RPMI	   culture	   medium	   containing	   collagenase	   IV	   in	   37°C	   for	   10	   minutes.	   So{ened	  
(ssues	  were	  pressed	  through	  metal	  sieves	  and	  the	  extract	  suspension	  was	  separated	  
by	  Percoll	   (GE	  Healthcare	  Life	  Sciences)	  gradients.	  For	  analyzing	  Th17	  cells,	   isolated	  
cells	  were	  re-­‐s(mulated	  with	  PMA	  plus	   ionomycin	  along	  with	  monensin,	  which	  was	  
added	  4	  hours	  before	  harves(ng.	  FACS	  analysis	  was	  performed	  a{er	  6	  hours	  of	   re-­‐
s(mula(on	  or	  right	  a{er	  the	  separa(on.	  !
Tumor	  growth	  and	  isola/on	  !
4x105	   cells	   of	   RMA-­‐mOVA	  mixed	  with	   equal	   numbers	  of	  WT	  or	  DKK3-­‐/-­‐	  MSCs	  were	  
washed	   three	   (mes	   with	   1xPBS	   and	   then	   suspended	   in	   200μl	   1xPBS.	   Mice	   were	  
shaved	  at	  their	  right	  ﬂanks.	  Subcutaneous	  injec(on	  was	  performed	  to	  inoculate	  the	  
cells.	  Tumor	  size	  was	  measured	  in	  mm	  and	  calculated	  by	  the	  following	  equa(on:	  0.5 
×  (width)2  ×  (length)	   for	   approximate	   volume	   [257].	   The	   tumor	   growth	   was	   then	  
followed	   for	   about	   3	   weeks.	   For	   analysis	   of	   tumor-­‐inﬁltra(ng	   cells,	   survival	   and	  
stemness	   of	   MSCs,	   tumors	   were	   isolated	   a{er	   14-­‐17	   days	   of	   inocula(on.	   Tumor-­‐
bearing	  mice	  were	   sacriﬁced	  by	  CO2	  on	   the	  day	  of	   tumor	   isola(on.	  Tumor	  nodules	  
were	  taken	  out	  by	  scissors	  and	  forceps.	  Isolated	  nodules	  were	  cut	  into	  smaller	  pieces	  
and	   then	   digested	   by	   diges(ng	   buﬀer	   in	   room	   temperature	   for	   3	   hours.	   Digested	  
(ssues	  were	  ﬁltered	  through	  40μm	  cell	  strainer	  with	  one	  round	  of	  addi(onal	  wash	  by	  
complete	  RPMI	  1640	  medium.	  Collected	  cells	  were	  then	  ready	  for	  FACS	  staining.	  !!
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For	  the	  ﬁrst	  part	  of	  study,	  unpaired	  t-­‐test	  was	  applied	  throughout	  the	  studies	  except	  
for	   the	   analysis	   on	   an(body	   aﬃnity	  matura(on,	   for	  which	   the	   2-­‐ways	   ANOVA	  was	  
applied.	   For	   the	   second	   part,	   unpaired	   t-­‐test	   was	   applied	   throughout	   the	   studies	  
except	  for	  the	  analysis	  on	  tumor	  growth,	  for	  which	  2-­‐ways	  ANOVA	  was	  applied.  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3.	  Results	  !
3.1	  Nck	  Adaptor	  Proteins	  Modulate	  Diﬀereneaeon	  and	  
Eﬀector	  Funceons	  of	  T	  Cells	  
!
3.1.1	  Nck	  dele/on	  results	  in	  impaired	  germinal	  center	  forma/on	  and	  reduc/on	  of	  
follicular	  helper	  T	  cells.	  	  !
To	  study	  the	  role	  of	  Nck	  adaptors	  in	  helper	  T	  cell	  func(on,	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice	  
were	   immunized	   with	   keyhole	   limped	   hemocyanin	   (KLH)	   in	   Complete	   Freund’s	  
Adjuvant	  (CFA)	  and	  germinal	  center	  (GC)	  forma(on	  was	  inves(gated	  in	  the	  respec(ve	  
spleens.	   The	  GC	  architecture	  was	  disrupted	   in	  Nck.T-­‐/-­‐	  mice	   (Fig.3.1	  A).	   In	   addi(on,	  
the	  cellularity	  of	  GC	  B	  cells	   [258]	  with	  the	  phenotype	  [259,	  260]	  B220+GL7+CD95dim	  
was	  decreased	   in	  Nck.T-­‐/-­‐	  mice	   in	  comparison	   to	  Nck.T+/+	  mice	   (Fig.3.1	  B).	  Based	  on	  
these	   ini(al	   ﬁndings	   we	   performed	   a	   detailed	   analysis	   of	   the	   splenic	   T`	   cell	  
compartment	   in	   both	   types	   of	  mice	   a{er	   immuniza(on	  with	   the	   T	   cell-­‐dependent	  
an(gen	   TNP26-­‐BSA.	   Splenic	   CD4+CXCR5+	   T`	   cells	   [261]	   (Fig.3.1	   C)	   as	   well	   as	   GC-­‐
associated	  T`	  cells	   (GC-­‐T`)	   [69]	  expressing	   the	  germinal	  center	  marker	  GL-­‐7	   [262,	  
263]	   (Fig.3.1	   D)	   were	   reduced	   in	   Nck.T-­‐/-­‐	   mice.	   Furthermore,	   T`	   cells	   which	  
expressed	  the	  ac(va(on	  marker	  CD69	  or	  the	  co-­‐s(mulatory	  proteins	  ICOS	  and	  PD-­‐1	  
[258]	   were	   also	   reduced	   (Fig.3.1	   D).	   Similar	   altera(ons	   were	   observed	   a{er	  
secondary	  immuniza(on	  (Fig.	  3.2	  A-­‐B).	  Taken	  together,	  loss	  of	  Nck	  func(on	  resulted	  
in	  impaired	  GC	  forma(on	  and	  in	  a	  reduc(on	  of	  GC-­‐associated	  B	  and	  T`	  cells.	  	  	  	  !
3.1.2	  Nck	  adaptors	  are	  required	  for	  eﬃcient	  cytokine	  produc/on	  by	  CD4+	  helper	  T	  
cells.	  !
To	   determine	   the	   capacity	   of	   CD4+	   helper	   T	   cells	   deﬁcient	   for	   Nck	   adaptors	   to	  
produce	  cytokines,	  we	  immunized	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice	  with	  TNP26-­‐BSA.	  Splenic	  
T	   cells	  were	   isolated	   10	   days	   later	   and	   re-­‐s(mulated	  with	  α-­‐CD3	   an(bodies	   for	   48	  
hours.	  Protein	  levels	  of	  IL-­‐4	  and	  IL-­‐10,	  both	  of	  which	  can	  be	  produced	  by	  T`	  cells	  and	  
support	   germinal	   center	   forma(on	   [261,	   264],	   were	   strongly	   reduced	   in	   the	  
supernatant	   of	   T	   cells	   isolated	   from	  Nck.T-­‐/-­‐	  mice	   (Fig.3.3	  A).	  When	   single	   T`	   cells	  
were	   further	   assessed	   by	   intracellular	   staining,	   IL-­‐10	   produc(on	   was	   signiﬁcantly	  
reduced	   in	   T`	   cells	   from	   Nck.T-­‐/-­‐	   mice	   while	   IL-­‐4	   or	   IL-­‐21	   [261]	   produc(on	   was	  
slightly	  reduced	  without	  reaching	  sta(s(cal	  signiﬁcance	  (Fig.3.3	  B).	  However,	  strong	  
reduc(on	  of	  all	  three	  cytokines	  was	  observed	  in	  PD-­‐1+	  T`	  cells	  (Fig.3.3	  B).	  Thus,	  Nck	  
adapters	  are	  required	  for	  eﬃcient	  cytokine	  produc(on	  by	  T`	  cells.	  !
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Figure	  3.1	  Loss	  of	  Nck	  in	  T	  cells	  leads	  to	  impaired	  germinal	  center	  (GC)	  forma/on	  and	  reduc/on	  of	  
GC-­‐associated	  B	  cells	  and	  follicular	  helper	  T	  (TX)	  cells.	  (A)	  In	  contrast	  to	  Nck.T+/+	  mice,	  Nck.T-­‐/-­‐	  mice	  
showed	  impaired	  GC	  forma(on	  9-­‐10	  days	  a{er	  subcutaneous	  immuniza(on	  of	  100μg	  KLH/CFA.	  Three	  
independent	  experiments	  were	  carried	  out	  and	  representa(ve	  H&E	  staining	  on	  frozen	  sec(ons	  were	  
presented.	  3-­‐4	  mice	  were	  used	   in	  each	  experiment.	   (B)	  Nck.T-­‐/-­‐	  (●,	  N=12)	  and	  Nck.T+/+	   (○,	  N=9)	  mice	  
were	  immunized	  with	  100µg	  KLH/CFA	  and	  splenic	  cells	  were	  isolated	  on	  day	  10	  a{er	  immuniza(on.	  GC	  
associated	   B220+GL-­‐7+CD95dim	   B	   cells	   were	   signiﬁcantly	   decreased	   in	   Nck.T-­‐/-­‐	   mice	   (p<0.0001).	   (C)	  
Nck.T-­‐/-­‐	   (●,	  N=6)	  and	  Nck.T+/+	   (○,	  N=6)	  mice	  were	   immunized	  with	  100µg	  TNP26-­‐BSA/IFA	   i.p..	  10	  days	  
later	  the	  splenic	  T	  cells	  were	  analyzed.	  CD4+CXCR5+	  T`	  cells	  were	  signiﬁcantly	  reduced	  in	  Nck.T-­‐/-­‐	  mice	  
in	   comparison	   with	   Nck.T+/+	   (p<0.0001).	   	   (D)	   Further	   analysis	   of	   these	   Nck.T-­‐/-­‐	   mice	   showed	   also	  
signiﬁcant	   reduc(on	   of	   the	   following	   T`	   cell	   popula(ons:	   CD69+	   cells	   (p=0.0006),	   GL-­‐7+	   (GC-­‐
associated)	   cells	   (p=0.0111),	   ICOS+	   cells	   (p=0.0188),	   PD-­‐1+	   cells	   (p<0.0001),	   and	   ICOS+PD-­‐1+	   cells	  
(p=0.0004).	  Unpaired	  t	  test	  was	  carried	  out	  for	  analysis.	  !!
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Figure	   3.2	   Altered	   composi/ons	   of	   splenic	   TX	   cells	   in	   Nck.T-­‐/-­‐	   mice	   during	   secondary	   immune	  
responses.	  Nck.T-­‐/-­‐	   (●,	  N=8)	  and	  Nck.T+/+	  (○,	  N=10)	  mice	  were	  immunized	  with	  100μg	  TNP26-­‐BSA/CFA	  
s.c.	  and	  then	  boosted	  with	  TNP26-­‐BSA/IFA	  10	  days	  later.	  Splenic	  cells	  were	  analyzed	  on	  day	  7	  a{er	  the	  
secondary	   immuniza(on.	   (A)	   The	   percentage	   of	   CD4+CXCR5+	   follicular	   helper	   T	   (T`)	   cells	   did	   not	  
change	  signiﬁcantly	  between	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice	   (p=0.3288).	   (B)	  However,	   the	  GL-­‐7+	   (GC-­‐T`),	  
PD-­‐1+,	   or	   ICOS+PD-­‐1+	   T`	   cells	   were	   reduced	   signiﬁcantly	   in	   Nck.T-­‐/-­‐	   mice	   (p=0.0437,	   p=0.0083,	  
p<0.0001),	  while	   the	   ICOS+	  T`	  remained	  comparable	   (p=0.4366).	  Unpaired	  t	   test	  were	  used	   for	   the	  
analysis.	  !
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Figure	  3.3	  Loss	  of	  Nck	  reduces	  the	  produc/on	  of	  Th2/TX	  cytokines.	  Nck.T-­‐/-­‐	  (●,	  N=6)	  and	  Nck.T+/+	  (○,	  
N=6)	  mice	  were	  immunized	  with	  100µg	  TNP26-­‐BSA/IFA.	  Splenic	  T	  cells	  were	  isolated	  10	  days	  later	  and	  
re-­‐s(mulated	  with	  5µg/mL	  plate-­‐bound	  α-­‐CD3	  an(bodies	  for	  48	  hours.	   (A)	  Cytokines	   in	  supernatant	  
were	  analyzed	  by	  ELISA.	  IL-­‐4	  and	  IL-­‐10	  were	  signiﬁcantly	  reduced	  in	  the	  supernatant	  of	  T	  cells	  isolated	  
from	  Nck.T-­‐/-­‐	   (both	  p<0.0001).	   (B)	   For	   intracellular	   staining	   of	   cytokines,	   50ng/ml	   PMA	  and	  1μg/mL	  
Ionomycin	  along	  with	  monensin	  were	  added	  to	  the	  culture	  medium	  4	  hours	  before	  cell	  harves(ng	  and	  
an(body	  staining.	   IL-­‐10	  producing	  CD4+CXCR5+	  T`	  cells	  were	  signiﬁcantly	  decreased	   in	  Nck.T-­‐/-­‐	  mice	  
(p=0.0096),	  while	  IL-­‐4	  and	  IL-­‐21	  producers	  were	  decreased	  by	  average	  but	  without	  reaching	  sta(s(cal	  
signiﬁcance	  (p=0.1096,	  p=0.0922).	  PD-­‐1+	  T`	  cells	  producing	  IL-­‐4,	   IL-­‐10,	  or	   IL-­‐21	  were	  all	  signiﬁcantly	  
reduced	  in	  Nck.T-­‐/-­‐	  mice	  (p=0.0248,	  p=0.0066,	  p=0.0086).	  When	  speciﬁcally	  inves(ga(ng	  the	  cytokine	  
producing	  popula(ons	  in	  PD-­‐1+	  T`	  cells	  from	  Nck.T-­‐/-­‐	  mice,	  the	  mean	  ﬂuorescence	  intensi(es	  (MFIs)	  
of	  IL-­‐10	  and	  IL-­‐21	  were	  both	  signiﬁcantly	  reduced	  (p=0.0107,	  p=0.0453).	  The	  MFI	  of	  IL-­‐4	  reduced	  but	  
reached	   no	   signiﬁcance	   (p=0.1602).	   When	   analyzing	   the	   total	   T`	   cells	   in	   the	   same	   way,	   similar	  
reduc(on	  was	  found	  for	  three	  respec(ve	  cytokines	  but	  only	  reached	  signiﬁcance	  in	  the	  case	  of	  IL-­‐10	  
(p=0.0084).	  Unpaired	  t	  test	  was	  applied.	  !
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3.1.3	  Nck	  is	  not	  essen/al	  for	  the	  expression	  of	  Th2/TX	  transcrip/onal	  factors.	  !
To	  inves(gate	  whether	  the	  observed	  decrease	  in	  T`	  cellularity	  and	  the	  reduc(on	  in	  
cytokine	   produc(on	   might	   be	   a/ributed	   to	   impaired	   T	   cell	   diﬀeren(a(on	   we	  
determined	  the	  expression	  of	  the	  transcrip(on	  factors	  GATA-­‐3	  [265]	  and	  Bcl-­‐6	  [258,	  
261,	  266].	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice	  were	   immunized	  with	  TNP26-­‐BSA	  and	  splenic	  T	  
cells	   were	   isolated	   10	   days	   later.	   Expression	   of	   both	   transcrip(on	   factors	   was	  
assessed	   in	   total	   T`	   and	   GC-­‐T`	   popula(ons	   a{er	   re-­‐s(mula(on	   with	   α-­‐CD3	  
an(bodies	   in	   vitro.	   Neither	   the	   percentage	   of	   expressing	   cells	   nor	   the	   expression	  
intensity	  was	   found	   to	  be	  diﬀerent	   in	   the	  studied	  cell	  popula(ons	  of	  both	   types	  of	  
mice	   for	   Bcl-­‐6	   (Fig.3.4	   A)	   and	   GATA-­‐3	   (Fig.3.4	   B).	   Therefore,	   Nck	   adaptors	   do	   not	  
inﬂuence	  expression	  of	  transcrip(on	  factors	  promo(ng	  Th2/T`	  cell	  diﬀeren(a(on.	  	  !
! 	  !
Figure	  3.4	  Nck	   is	  not	  essen/al	   for	  the	  expression	  of	  Th2/TX	  transcrip/onal	   factors.	   (A)	  Nck.T-­‐/-­‐	   (●,	  
N=6)	  and	  Nck.T+/+	  (○,	  N=6)	  mice	  were	  immunized	  with	  100μg	  TNP26-­‐BSA/IFA	  i.p.	  and	  splenic	  cells	  were	  
isolated	   10	   days	   later.	   Expression	   of	   Bcl-­‐6	   and	   GATA-­‐3	   was	   assessed	   by	   ﬂow	   cytometry	   a{er	   re-­‐
s(mula(on	  with	  5μg/ml	  plate-­‐bound	  α-­‐CD3	  an(bodies	  for	  48	  hours.	  Similar	  percentages	  of	  Bcl-­‐6	  and	  
GATA-­‐3	   posi(ve	   popula(ons	  were	   detected	   among	   T`	   cells	   (p=0.8113,	   p=0.4717)	   and	   (B)	  GL7+	   T`	  
(GC-­‐T`)	  cells	  (p=0.1891,	  p=0.6304).	  Mean	  ﬂuorescence	  intensi(es	  were	  comparable	  in	  T`	  or	  GC-­‐T`	  
cells	  (p=0.3432,	  p=0.3411,	  p=0.4970,	  p=0.7529).	  Unpaired	  t	  test	  was	  applied.	  !
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3.1.4	  Nck	  deﬁcient	  T	  cells	  are	  more	  suscep/ble	  to	  apoptosis.	  	  !
Although	   Nck	   deﬁcient	   T`	   cells	   express	   the	   respec(ve	   transcrip(on	   factors	   for	  
successful	  diﬀeren(a(on,	  it	  is	  possible	  that	  their	  complete	  diﬀeren(a(on	  or	  survival	  
is	   impaired.	  Therefore,	  we	   inves(gated	  apopto(c	  cell	  death	  of	  CD4+	  T	  cells	   isolated	  
from	  TNP26-­‐BSA	   immunized	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice	  a{er	  re-­‐s(mula(on	  with	  an(-­‐
CD3	   an(bodies	   in	   vitro.	   Cell	   staining	   with	   7-­‐AAD	   and	   ﬂuorochrome-­‐conjugated	  
Annexin	   V	   did	   not	   show	   a	   signiﬁcant	   diﬀerence	   in	   apoptosis	   of	   total	   CD4+	   T	   cells	  
isolated	   from	   both	   types	   of	   mice.	   (Fig.3.5	   A).	   However,	   more	   than	   60%	   of	   Nck	  
deﬁcient	  GL-­‐7+	  GC-­‐T	  cells	  entered	  the	  late	  phase	  of	  apoptosis	  while	  wild-­‐type	  T	  cells	  
mostly	  remained	  alive	  or	  entered	  only	  the	  early	  phase	  of	  apoptosis	  within	  the	  tested	  
(me	  frame	  (Fig.3.5	  A).	  Since	  Nck	  adaptors	  inﬂuence	  Akt	  signaling	  [267]	  and	  since	  Akt	  
signaling	   takes	   part	   in	   an(-­‐apopto(c	   pathways	   [268,	   269]	   we	   studied	   Akt	  
phosphoryla(on	   (pAkt)	   in	   the	   ac(vated	   Nck-­‐deﬁcient	   and	   -­‐suﬃcient	   CD4+	   T	   cells.	  
pAkt	   levels	  were	   significantly	   decreased	   in	   total	   CD4+	   T	   cells	   and	   in	   T`	   cells	   from	  
Nck.T-­‐/-­‐	  mice	  (Fig.3.5	  B).	  Taking	  together,	  loss	  of	  Nck	  leads	  to	  enhanced	  apoptosis	  of	  
T`	   cells,	   which	   is	   associated	   with	   decreased	   an(-­‐apopto(c	   signaling	   by	   Akt	  
phosphoryla(on.	  	  !
  	  
Figure	  3.5	  Nck	  deﬁcient	   T	   cells	   are	  more	   suscep/ble	   to	   apoptosis.	   Ten	  days	   a{er	   immuniza(on	  of	  
100μg	  TNP26-­‐BSA/IFA	   i.p.	  splenic	  cells	  were	   isolated	  from	  Nck.T-­‐/-­‐	   (●,	  N=6)	  or	  Nck.T+/+	   (○,	  N=6)	  mice	  
and	  re-­‐s(mulated	  with	  5μg/ml	  plate-­‐bound	  α-­‐CD3	  an(body.	  (A)	  Re-­‐s(mulated	  cells	  were	  stained	  with	  
7-­‐AAD	  and	  PE-­‐conjugated	  Annexin	  V.	  Among	  total	  CD4+	  T	  cells,	  cells	  in	  late	  stage	  apoptosis	  (Annexin	  V
+7-­‐AAD+)	  were	  increased	  but	  without	  reaching	  signiﬁcance	  (p=0.0942).	  Among	  GL-­‐7+CD4+	  T	  cells,	  cells	  
in	   late	   stage	  of	   apoptosis	   increased	   signiﬁcantly	   in	  Nck.T-­‐/-­‐	  mice	   (p=0.0001).	   (B)	   Phosphorylated	  Akt	  
(pAkt)	  was	  detected	  by	  ﬂow	   cytometry.	   pAkt	   levels	   (MFI)	   dropped	   signiﬁcantly	   in	   total	   CD4+	   T	   cells	  
(p=0.0026)	  as	  well	  as	  in	  total	  CD4+CXCR5+	  T`	  cells	  (p=0.0024)	  from	  Nck.T-­‐/-­‐	  mice.	  Unpaired	  t	  test	  was	  
carried	  out.	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3.1.5	  Nck.T-­‐/-­‐	  mice	  show	  reduced	  an/body	  produc/on	  and	  insuﬃcient	  aﬃnity	  
matura/on.	  !
Finally,	  we	  extended	  our	  studies	  on	  the	  role	  of	  Nck	  adaptors	  in	  helper	  T	  cell	  func(on	  
by	  measuring	  the	  produc(on	  and	  quality	  of	  an(bodies	   in	  Nck.T-­‐/-­‐	  and	  Nck.T+/+	  mice.	  
The	  basal	  levels	  of	  natural	  IgM,	  IgG1,	  IgG2a,	  and	  IgG2b	  were	  signiﬁcantly	  decreased	  
in	   the	   serum	   of	   Nck.T-­‐/-­‐	   mice	   (Fig.3.6	   A).	   This	   phenomenon	   was	   consistent	   with	  
reported	  T	  cell-­‐dependency	  of	  natural	  an(body	  produc(on	  [270].	  Similarly,	  primary	  
an(body	   responses	   against	   TNP26-­‐BSA	   were	   also	   impaired	   in	   all	   four	   measured	  
isotypes	   in	   Nck.T-­‐/-­‐	   mice	   (Fig.3.6	   B).	   Moreover,	   when	   Nck.T-­‐/-­‐	   mice	   experienced	  
secondary	  and	  ter(ary	  immuniza(on,	  the	  produc(on	  of	  IgG2a	  remained	  signiﬁcantly	  
lower	  while	  IgG1	  reduced	  in	  average	  without	  reaching	  signiﬁcance	  (Fig.3.6	  C).	  Thus,	  
Nck	  abla(on	   in	  T	  cells	   leads	   to	  a	   reduc(on	   in	  an(body	  produc(on	  of	  both	  primary	  
and	  secondary	  responses.	  !
We	  now	  asked	  whether	  Nck	  expression	  in	  T	  cells	  has	  also	  an	  impact	  on	  the	  quality	  of	  
the	  produced	  an(bodies	  as	  measured	  by	  aﬃnity	  matura(on.	  As	  an	  assay	  for	  aﬃnity	  
matura(on	  we	  ﬁrstly	  determined	  hapten	  binding	  per	  mass	  unit	  of	  an(bodies	   in	  the	  
serum	   to	   the	   2	   lower	   hapten	   conjugates	   on	   one	   carrier,	   TNP5-­‐KLH	   and	   TNP16-­‐KLH,	  
a{er	   secondary	   immuniza(on	  with	   TNP26-­‐BSA.	  We	   then	   calculated	   the	   ra(o	  of	   the	  
obtained	  signal	  strength	  of	  TNP5-­‐binding	  to	  TNP16-­‐binding[26].	  All	  isotypes	  except	  for	  
IgG1	  showed	  signiﬁcantly	  lower	  strength	  ra(o	  in	  sera	  from	  Nck.T-­‐/-­‐	  mice	  compared	  to	  
sera	  from	  Nck.T+/+	  mice	  (Fig.	  3.6D).	  This	   indicated	  that	  Nck.T-­‐/-­‐	  an(body	  popula(ons	  
contained	  less	  high-­‐aﬃnity	  an(bodies	  than	  controls,	  because	  they	  could	  not	  bind	  as	  
strong	   as	   control	   an(bodies	   when	   the	   number	   of	   haptens	   on	   the	   carrier	   was	  
decreased.	  Hence,	  we	  propose	  that	  aﬃnity	  matura(on	  is	  impaired	  in	  Nck.T-­‐/-­‐	  mice.	  !
  	  !
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Figure	  3.6	  Nck.T-­‐/-­‐	  mice	  show	  reduced	  an/body	  produc/on	  and	  insuﬃcient	  aﬃnity	  matura/on.	   (A)	  
Basal	  immunoglobulin	  levels	  in	  the	  serum	  of	  6	  to	  8	  weeks-­‐old	  Nck.T-­‐/-­‐	  (●,	  N=12)	  and	  Nck.T+/+	  (○,	  N=11)	  
mice	   were	   assessed	   by	   ELISA.	   The	   serum	   levels	   of	   IgM	   (p<0.0001),	   IgG1	   (p<0.0001),	   and	   IgG2a	  
(p=0.001)	  were	  signiﬁcantly	  reduced	  in	  Nck.T-­‐/-­‐	  mice,	  when	  compared	  to	  the	  Nck.T+/+	  mice.	  By	  contrast,	  
the	  levels	  of	  IgG2b	  were	  comparable	  in	  both	  types	  of	  mice	  (p=0.0696).	  (B)	  Nck.T-­‐/-­‐	  (●,	  N=18)	  and	  Nck.T
+/+	   (○,	   N=13)	  mice	  were	   immunized	  with	   200μg	   TNP26-­‐BSA/CFA	   s.c.	   in	   4	   diﬀerent	   sites	   of	   the	   belly.	  
An(gen	   speciﬁc	   an(bodies	  were	   analyzed	   in	   the	   serum	  on	  day	   7,	   14,	   and	   21.	   Signiﬁcantly	   reduced	  
levels	  of	  IgM	  (p=0.0163),	  IgG1	  (p=0.0007),	  IgG2a	  (p=0.0002),	  and	  IgG2b	  (p=0.0008)	  were	  observed	  on	  
day	  14.	  (C)	  Nck.T-­‐/-­‐	  (●,	  N=15)	  and	  Nck.T+/+	  (○,	  N=13)	  mice	  were	  immunized	  with	  100mg	  TNP23-­‐BSA/CFA	  
s.c.	   on	   day	   0	   and	   boosted	   twice	   with	   100mg	   TNP23-­‐BSA/IFA	   s.c.	   42	   and	   84	   days	   a{er	   the	   primary	  
s(mula(on.	   Serum	  was	   collected	   on	   day	   7	   a{er	   the	   secondary	   boos(ng.	   The	   levels	   of	   TNP-­‐speciﬁc	  
IgG1	   and	   IgG2a	  were	   assessed	   by	   ELISA.	   The	   levels	   of	   IgG1	  were	   comparable	   between	  Nck.T-­‐/-­‐	   and	  
Nck.T+/+	  mice	  (p=0.0708)	  ,	  whereas	  the	  levels	  of	  IgG2a	  were	  signiﬁcantly	  decreased	  (p=0.0015)	  in	  the	  
absence	  of	  Nck.	  (D)	  Nck.T-­‐/-­‐	  (●,	  N=8)	  and	  Nck.T+/+	  (○,	  N=10)	  mice	  were	  immunized	  with	  100μg	  TNP26-­‐
BSA/CFA	  s.c.	  in	  the	  tail	  base	  and	  boosted	  with	  TNP26-­‐BSA/IFA	  i.p.	  10	  days	  later.	  Sera	  were	  collected	  on	  
day	   7	   a{er	   the	   secondary	   immuniza(on.	   The	   levels	   of	   an(gen-­‐speciﬁc	   IgM,	   IgG1,	   IgG2a	   and	   IgG2b	  
were	  assessed	  by	  ELISA.	  10μg	  of	  TNP5-­‐KLH	  or	  TNP16-­‐KLH	  were	  coated	  on	  ELISA	  plates.	  Sera	  were	  4-­‐fold	  
diluted	  from	  1/100	  serially.	  Binding	  signal	  (O.D.	  values)	  of	  every	  serum	  dilu(on	  was	  acquired	  by	  ELISA.	  
Aﬃnity	  Index	  (AI)	  was	  calculated	  by	  dividing	  the	  O.D.	  values	  with	  corresponding	  serum	  concentra(ons	  
of	   an(body	   isotypes.	   AIs	   from	   TNP5-­‐KLH	   detec(on	   were	   then	   divided	   by	   corresponding	   AIs	   from	  
TNP16-­‐KLH	   detec(on.	   All	   isotypes	   showed	   signiﬁcantly	   stronger	   decrease	   in	   ra(o	   of	   AIs	   (p<0.0001,	  
p=0.0104,	  p<0.0001)	  except	  for	  IgG1(p=0.2525).	  Unpaired	  t	  test	  was	  applied	  for	  analyzing	  (A)	  and	  (B).	  
2-­‐ways	  ANOVA	  was	  carried	  out	  for	  analyzing	  (C)	  and	  (D).	  	  
!!!!!!
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3.1.6	  EAE	  disease	  is	  ameliorated	  in	  Nck.T-­‐/-­‐	  mice.	  !
To	   verify	  whether	   the	   aberra(on	  of	   immunity	   a{er	   loss	  of	  Nck	   is	   only	   limited	   to	   T	  
cell-­‐dependent	   humoral	   responses,	   we	   extended	   our	   studies	   to	   experimental	  
autoimmune	  encephalomyeli(s(EAE)	  [255]	  as	  an	  autoimmune	  model.	  	  !
!
Figure	   3.7	  AGenuated	   EAE	   disease	   and	   T	   cells	  with	   altered	   chemotaxis	   proﬁles	  were	   observed	   in	  
Nck.T-­‐/-­‐	  mice.	   (A)	   EAE	  was	   induced	   on	  Nck.T-­‐/-­‐	   (●,	   N=11)	   or	  Nck.T+/+	   (○,	   N=10)	  mice.	   Disease	   scores	  
were	   recorded	   since	   day	   9	   a{er	   the	   induc(on.	   Scoring	   criteria	   were	   according	   to	   descrip(ons	   in	  
published	  protocol	  [256].	  Nck.T-­‐/-­‐	  mice	  were	  observed	  for	  signiﬁcantly	  a/enuated	  and	  delayed	  disease.	  
The	  remission	  of	  disease	  also	  progressed	  faster	  in	  Nck.T-­‐/-­‐	  mice	  (p<0.0001).	  2-­‐way	  ANOVA	  was	  carried	  
out.	  (B)	  On	  day	  14	  a{er	  induc(on	  of	  EAE,	  Nck.T-­‐/-­‐	  (●,	  N=24)	  or	  Nck.T+/+	  (○,	  N=24)	  mice	  were	  sacriﬁced	  
and	  the	  CNS	  inﬁltrated	  cells	  were	  isolated.	  Isolated	  cells	  were	  s(mulated	  by	  500ng/ml	  PMA	  and	  1μg/
ml	   Ionomycin	  for	  4	  hours	  before	   intracellular	  staining.	  On	  day	  14,	  the	  disease	  was	  close	  to	  the	  peak	  
but	   signiﬁcantly	   ameliorated	   in	   Nck.T-­‐/-­‐	   mice	   (p<0.0001).	   However,	   CD4+IL-­‐17+	   Th17	   cells	   were	  
comparable	  (p=0.6267).	  Unpaired	  t	  test	  was	  applied.	  (C)	  For	  transcrip(onal	  factors	  RORγ-­‐t	  and	  T-­‐bet,	  
comparable	  expression	   levels	  were	  observed	  among	  CD4+	  T	   cells	   (p=0.2495	  and	  p=0.8417).	   (D)	  CNS	  
inﬁltrated	   cells	   were	   isolated	   from	   Nck.T-­‐/-­‐	   (●,	   N=7)	   or	   Nck.T+/+	   (○,	   N=6)	  mice	   on	   day	   10	   a{er	   EAE	  
induc(on.	  CCR6-­‐posi(ve	  CD4+	  T	  cells	  were	  signiﬁcantly	  reduced	  in	  Nck.T-­‐/-­‐	  mice	  (p=0.0061).	  Unpaired	  t	  
test	  was	  used.	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The	   EAE	  was	   induced	   by	   immuniza(on	  with	   the	  murine	  MOG35-­‐55	   pep(des	   in	   CFA.	  
A/enuated	  EAE	  disease	  was	  observed	  in	  Nck.T-­‐/-­‐	  mice	  (Fig.	  3.7A).	  The	  disease	  scores	  
were	   lower,	   the	  dynamics	  were	  delayed,	  and	   the	   recovery	   from	  disease	  was	   faster.	  
Although	  Th17	  cells	  were	  characterized	  as	  the	  signature	  popula(on	  for	  EAE	  induc(on	  
[271,	  272],	   intriguingly,	  the	  size	  of	  Th17	  popula(on	  was	  not	  changed	  signiﬁcantly	  in	  
the	  CNS	  samples	   from	  Nck.T-­‐/-­‐	  mice	  (Fig.	  3.7B),	   indica(ng	  that	  the	  diﬀeren(a(on	  of	  
Th17	  might	  not	  cause	  the	  a/enuated	  disease.	  This	  assump(on	  was	  supported	  by	  the	  
observa(on	  that	  no	  signiﬁcant	  change	  in	  the	  expression	  of	  the	  transcrip(onal	  factors	  
RORγt	  or	   T-­‐bet	   could	  be	  detected	   (Fig.	   3.7C).	  As	   a	   chemotaxis	  marker	   for	   the	   ‘ﬁrst	  
wave’ of	  Th17	  cells	  migra(ng	  into	  the	  CNS,	  CCR6(CD196)	  expression	  [273]	  on	  CD4+	  T	  
cells	   was	   assessed.	   Numbers	   of	   CCR6-­‐posi(ve	   CD4	   T	   cells	   were	   signiﬁcantly	  
decreased	  in	  Nck.T-­‐/-­‐	  mice	  (Fig.	  3.7D),	  indica(ng	  that	  less	  disease	  ini(a(ng	  Th17	  cells	  
were	   able	   to	   ﬁnd	   their	   ways	   into	   CNS.	   On	   the	   other	   hand,	   an	   increase	   in	   Th1	  
chemokine	   receptor	   CXCR3(CD183)	   expression	   [274]	   was	   found	   among	   CNS-­‐
inﬁltra(ng	  CD4+	  T	  cells	   in	  Nck.T-­‐/-­‐	  mice	  (Fig.	  3.7D),	  which	  further	  supported	  the	  idea	  
for	  an	  altered	  chemotaxis	  behavior	  of	  Nck.T-­‐/-­‐	  T	  cells.	  	  !
By	   summary,	   we	   found	   that	   Nck	   adaptor	   proteins	   are	   essen(al	   for	   successful	   TCR	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3.2	  Dickkopf-­‐3	  contributes	  to	  the	  immune-­‐suppressive	  
aceons	  of	  mesenchymal	  stem	  cells.	  !
There	  have	  been	  accumula(ng	  data	  demonstra(ng	  the	  immunosuppressive	  capacity	  
of	  mesenchymal	  stem	  cells	  (MSCs)	  [180,	  183]	  mediated	  by	  cell-­‐cell	  contact	  as	  well	  as	  
soluble	   factors,	   such	   as	   transforming	   growth	   factor	   beta	   (TGFβ)	   and	   indoleamine-­‐
dioxygenase	   (IDO)	   [180,	   183,	   275].	   However,	   these	   factors	   did	   not	   count	   for	   the	  
en(re	   suppressive	   ac(vity	   of	   MSCs.	   Therefore,	   we	   asked	   whether	   the	   newly	  
iden(ﬁed	  immunoregulatory	  Dickkopf-­‐3	  (DKK3)	  protein	  [228]	  may	  also	  play	  a	  role	  in	  
MSCs-­‐mediated	   immunosuppression.	   Indeed,	   there	   was	   already	   preliminary	  
evidence	  in	  our	  group	  that	  MSCs	  express	  DKK3	  (Dr.	  Amel	  Tounsi,	  unpublished	  data).	  	  	  !
3.2.1	  Mesenchymal	  stem	  cells	  express	  Dickkopf-­‐3	  !
Bone	  marrow-­‐derived	  MSCs	  were	  isolated	  from	  the	  femur	  and	  (bia	  of	  wild-­‐type	  (WT)	  
B6	  mice	  or	   the	  DKK3-­‐/-­‐	  mice	   according	   to	   the	  protocols	   described	   in	  Materials	   and	  
Methods.	  Both	  WT	  and	  DKK3-­‐/-­‐	  MSCs	  were	   capable	   to	  diﬀeren(ate	   into	  adipocytes	  
and	  osteocytes	   [276,	   277]	   (Fig.	   3.8A).	   In	   addi(on,	   the	   expression	  of	  MSCs	  markers	  
[276,	   277]	   such	   as	   CD29,	   CD34,	   CD44,	   and	   CD105	  were	  maintained	   in	   both	  MSCs	  
while	   neither	   of	   them	   expressed	   myeloid	   or	   lymphoid	   markers	   (Fig.	   3.8B).	   To	   be	  
noted,	  during	  the	  FACS	  analysis,	  MSCs	  exhibited	  high	  background	  autoﬂuorescence.	  
This	  phenomenon	  counted	   for	   the	  dim	  signals	  of	  myeloid	  and	   lymphoid	  markers	   in	  
WT	  MSCs.	  (Fig.	  3.8B)	  Thus,	  the	  isolated	  WT	  and	  DKK3-­‐/-­‐	  MSCs	  were	  both	  potent	  MSCs	  
by	  phenotype	  and	  func(on.	  In	  the	  following	  studies	  we	  kept	  monitoring	  the	  quality	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  	  !
Figure	   3.8	   DKK3-­‐/-­‐	   MSCs	   and	   WT	   MSCs	   were	   potent	   MSCs.	   The	   induc(on	   of	   adipogenesis	   and	  
osteogenesis	  was	  done	  as	  described	  before.	  In	  short,	  MSCs	  were	  cultured	  in	  condi(oned	  MesenCult™ 
selec(on	  medium	  for	  3	  weeks.	  MSCs	  were	  stained	  by	  Oil	  Red	  O	  for	  adipogenesis	  and	  Alizarin	  Red	  S	  for	  
osteogenesis.	  (A)	  Both	  WT	  and	  DKK3-­‐/-­‐	  MSCs	  were	  able	  to	  diﬀeren(ate.	  Images	  were	  taken	  under	  100x	  
magniﬁcence	   by	   light	  microscope.	   Representa(ve	   images	   from	   both	   types	   of	  MSCs	   are	   shown.	   (B)	  
MSCs	   were	   cultured	   in	   complete	   DMEM	   when	   they	   were	   stabilized	   a{er	   4	   weeks	   of	   selec(on	   by	  
MesenCult® selec(on	  medium.	  Surface	  staining	  was	  performed	  for	  FACS	  analysis.	  Both	  WT	  and	  DKK3-­‐/-­‐	  
MSCs	  expressed	  MSC	  markers	  CD29,	  CD34,	  CD44,	  and	  CD105	  while	  both	  were	  nega(ve	  for	  myeloid,	  
endothelium,	  or	  lymphoid	  markers	  CD11b,	  CD11c,	  CD31,	  or	  CD45R.	  The	  light	  grey	  shadow	  represents	  
for	   the	   staining	   control,	   while	   the	   solid	   line	   and	   dark	   shadow	   indicate	   WT	   and	   DKK3-­‐/-­‐	   MSCs	  
respec(vely.	  !
By	  using	  the	  MSCs	  isolated	  in	  our	  study,	  we	  could	  conﬁrm	  that	  MSCs	  express	  high	  
levels	  of	  DKK3	  (Fig.	  3.9).	  !
 !!!!
Figure	  3.9	  MSCs	  expressed	  DKK3	  proteins.	  Bone-­‐derived	  
MSCs	  were	  isolated	  from	  the	  femur	  and	  (bia	  of	  wild-­‐type	  
(WT)	   B6	   mice	   or	   the	   DKK3-­‐/-­‐	   mice	   according	   to	   the	  
protocols	   and	   principles	   described	   before.	   Intracellular	  
staining	   for	  ﬂow	  cytometry	  was	  performed	   to	  detect	   the	  
DKK3	  exprssion	  within	  the	  MSCs.	  The	  DKK3	  was	  expressed	  
within	   WT	   MSCs	   while	   it	   was	   not	   detectable	   in	   DKK3-­‐/-­‐	  
MSCs.	   The	   grey	   shadow	   represents	   the	   isotype	   control	  
staining.	  The	  solid	  line	  and	  dashed	  lines	  stand	  for	  WT	  and	  
DKK3-­‐/-­‐	  MSCs	  respec(vely.	  	  !
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3.2.2	  DKK3-­‐/-­‐	  MSCs	  do	  not	  have	  immunosuppressive	  capacity	  in	  vivo.	  !
We	   next	   asked	   whether	   loss	   of	   DKK3	   would	   compromise	   the	   immunosuppressive	  
capacity	  of	  MSCs.	  We	  chose	  growth	  of	  RMA-­‐mOVA	  tumor	  cells	  as	  our	  model	  for	  two	  
reasons.	   First,	   tumor	   rejec(on	   in	   this	  model	  was	  highly	  dependent	  on	  CD8+	  T	   cells	  
and	   it	   was	   shown	   before	   that	   DKK3	   could	   abrogate	   CD8+	   T	   cells	   responses	   [228].	  
Second,	  MSCs	   can	   support	   tumor	   growth	   by	   reducing	   CD8+	   T	   cells	   and	   promo(ng	  
regulatory	  T	  cells	  [198].	  Hence,	  loss	  of	  DKK3	  may	  disable	  MSCs	  to	  inhibit	  CD8+	  T	  cell	  
responses.	  By	   inocula(ng	  mice	  with	  MSCs	  together	  with	  tumor	  cells	  expressing	  the	  
membrane-­‐bound	  ovalbumin	  (mOVA)	  an(gen,	  we	  observed	  tumor	  growth	  in	  contrast	  
to	  tumor	  rejec(on	  by	  mice	  which	  had	  not	  received	  any	  MSCs	  or	  DKK3-­‐defec(ve	  MSCs	  
(Fig.	   3.10A).	   To	   facilitate	   the	   iden(ﬁca(on	   of	   tumor-­‐inﬁltra(ng	   host	   cells	   we	  
conﬁrmed	  these	  results	  in	  C57BL/6	  (B6)	  mice	  carrying	  EGFP	  (EGFP+/-­‐)	  as	  a	  transgene	  
[278]	   (Fig.	   3.10B).	  Moreover,	   the	   capacity	   of	  WT	  MSCs	   to	   sustain	   tumor	   growth	   in	  
DKK3-­‐/-­‐	   mice	   (Fig.	   3.10C)	   indicated	   that	   it	   was	   the	   MSC-­‐derived	   but	   not	  
environmental	   DKK3	   which	  mediated	   the	   immunosuppressive	   func(on	   of	  MSCs	   in	  
tumors.	   Tumor	   growth	   was	   similar	   when	   tumor	   cells	   with	   DKK3-­‐suﬃcient	   or	   -­‐
deﬁcient	   MSCs	   were	   injected	   into	   the	   Rag2-­‐/-­‐	   mice	   lacking	   any	   lymphocytes	   (Fig.	  
3.10D).	   Taken	   together,	   DKK3	   does	   not	   inﬂuence	   tumor	   growth	   directly	   but	   was	  
essen(al	  for	  MSCs	  to	  promote	  tumor	  growth	  by	  modula(ng	  lymphocyte	  reac(vity.	  !
  	  !
Figure	  3.10	  MSC-­‐derived	  DKK3	  enabled	  MSCs	  to	  promote	  tumor	  growth	  by	  modula/ng	  lymphocyte	  
ac/vity.	   4x105	   RMA-­‐mOVA	   cells	   were	   inoculated	   subcutaneously	   alone	   or	   together	   with	   equal	  
numbers	  of	  WT	  or	  DKK3-­‐/-­‐	  MSCs.	  The	  tumor	  volume	  was	  observed	  on	  indicted	  days.	  In	  (A)	  B6,	  (B)	  EGFP
+/-­‐	  B6,	  or	  (C)	  DKK3-­‐/-­‐	  mice,	  DKK3-­‐/-­‐	  MSCs	  failed	  to	  support	  the	  tumor	  growth.	  In	  (D)	  Rag2-­‐/-­‐	  mice,	  which	  
lacked	  of	  lymphocytes,	  the	  tumors	  were	  not	  rejected	  even	  with	  DKK3-­‐/-­‐	  MSCs.	  For	  every	  experimental	  
group	  6	  mice	  were	  used.	  	  !
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3.2.3	  Loss	  of	  DKK3	  does	  not	  aﬀect	  viability	  and	  stemness	  of	  MSCs	  in	  tumors.	  !
Since	   it	   was	   possible	   that	   the	   decreased	   immune-­‐suppressive	   capacity	   by	   DKK3-­‐/-­‐	  
MSCs	   was	   simply	   due	   to	   poorer	   survival	   or	   loss	   of	   MSC	   characteris(cs,	   we	  
inves(gated	   whether	   there	   was	   any	   diﬀerence	   on	   viability	   or	   MSC	   phenotypes	  
between	  WT	  and	  DKK3-­‐/-­‐	  MSCs	  within	  the	  tumors.	  !
	  
Figure	  3.11	  Loss	  of	  DKK3	  did	  not	  compromise	  the	  survival	  and	  stemness	  of	  MSCs.	  MSCs	  derived	  from	  
EGFP+/-­‐	   B6	   or	   EGFP+/-­‐xDKK3-­‐/-­‐	  mice	  were	   subcutaneously	   inoculated	   together	  with	   RMA-­‐mOVA	   cells	  
into	  B6	  mice.	  On	  day	  14	   the	   tumors	  were	   isolated	  and	  homogenized	   for	   single	  cell	   suspension.	  The	  
EGFP+	  cells	  were	   iden(ﬁed	  as	   inoculated	  MSCs	  or	   their	  descendant	  cells.	   (A)	  The	   intratumoral	  EGFP
+MSCs	  were	   comparable	   in	  percentage	  between	  WT	  and	  DKK3-­‐/-­‐	  MSCs.	  When	   further	   analyzing	   the	  
EGFP+MSCs	  surface	  markers	  (B)	  no	  diﬀerence	  was	  found	  in	  CD29+CD44+	  or	  CD44+CD105+	  cells.	  !
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Both	  the	  percentage	  of	  MSCs	  within	  the	  tumors	  (Fig.	  3.11A)	  and	  the	  MSC	  markers	  
(Fig.	  3.11B)	  were	  not	  diﬀerent	  between	  WT	  and	  DKK3-­‐/-­‐	  MSCs.	  This	  indicated	  that	  loss	  
of	  DKK3	  did	  not	  aﬀect	  the	  survival	  or	  stemness	  of	  MSCs.	  Thus,	  the	  DKK3-­‐/-­‐	  MSCs	  were	  
persistent	  within	  tumors	  but	  failed	  to	  carry	  out	  any	  immunosuppressive	  func(on.	  !
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Figure	  3.12	  DKK3-­‐/-­‐	  MSCs	   failed	  to	  reduce	  the	   inﬁltra/on	  of	  CD8+	  T	  cells.	  MSCs	  derived	   from	  B6	  or	  
DKK3-­‐/-­‐	  mice	  were	  subcutaneously	  inoculated	  together	  with	  RMA-­‐mOVA	  cells	  into	  EGFP+/-­‐	  B6	  mice.	  14	  
days	  later	  the	  tumors	  were	  isolate	  and	  analyzed	  by	  FACS.	  The	  EGFP+	  cells	  were	  iden(ﬁed	  as	  inﬁltrated	  
cells.	   If	   not	   speciﬁcally	   men(oned,	   the	   comparisons	   were	   done	   between	   WT	   and	   DKK3-­‐/-­‐	   MSC-­‐
inoculated	  tumors.	   (A)	  When	   looking	   into	  the	  composi(ons,	   the	  NK1.1+	  NK	  cells	  or	  NK1.1+CD3+	  NKT	  
cells	  were	  reduced	  in	  DKK3-­‐/-­‐	  MSC-­‐inoculated	  tumors	  but	  without	  reaching	  signiﬁcance.	  Among	  NK1.1-­‐
CD3+	   T	   cells,	   CD8+	   cells	  were	   decreased	  while	   CD4+	   cells	  were	   increased	   in	   DKK3-­‐/-­‐	  MSC-­‐inoculated	  
tumors.	  (B)	  In	  the	  case	  of	  CD11b+F4/80hiCD206hi	  M2	  type	  	  macrophages,	  less	  recruitment	  was	  found	  in	  
DKK3-­‐/-­‐	  MSC-­‐inoculated	   tumors	   though	  without	   reaching	   sta(s(cal	   signiﬁcance.	  Unpaired	   t	   test	  was	  
carried	  out	  for	  analysis.	  !
Next,	   we	   analyzed	   tumor-­‐inﬁltra(ng	   immune	   cells.	   The	   percentage	   of	   inﬁltra(ng	  
CD8+	   T	   cells	   was	   signiﬁcantly	   increased	   in	   DKK3-­‐/-­‐	   MSC-­‐inoculated	   tumors	   in	  
comparison	  to	  WT	  MSC-­‐inoculated	  tumors	  (Fig.	  3.12A)	  and	  reached	  the	  level	  of	  CD8+	  
T	  cells	  in	  tumors	  without	  MSC	  inocula(on	  (Fig.	  3.12A).	  This	  indicated	  that	  MSCs	  could	  
reduce	  CD8+	  T	  cells	  inﬁltra(on	  into	  tumors	  and	  DKK3	  was	  essen(al	  for	  it.	  By	  contrast,	  
the	  percentage	  of	   inﬁltra(ng	  CD4+	  T	  cells	  was	  signiﬁcantly	  decreased	   in	   the	  DKK3-­‐/-­‐	  
MSC-­‐inoculated	  tumors	  while	  the	  percentages	  of	  NK	  or	  NKT	  cells	  were	  decreased	  but	  
without	  reaching	  signiﬁcance	  (Fig.	  3.12A).	  We	  also	  observed	  reduced	  numbers	  of	  M2	  
macrophages	  in	  the	  DKK3-­‐/-­‐	  MSC-­‐inoculated	  tumors	  in	  comparison	  with	  the	  WT	  MSC-­‐
inoculated	   tumors	   (Fig.	   3.12B)	  but	  without	   reaching	   signiﬁcance.	   The	   inﬁltra(on	  of	  
M2	  macrophages	  called	  for	  further	  veriﬁca(on.	  !
Overall,	  WT	  MSCs	   could	   reduce	   the	   inﬁltra(on	  of	   CD8+	   T	   cells	   and	   slightly	   but	   not	  
signiﬁcantly	  enhance	  the	  recruitment	  of	  M2	  macrophages.	  These	  could	  contribute	  to	  
suppress	  the	  an(-­‐tumor	  immunity	  and	  ﬁ/ed	  to	  our	  observa(ons	  of	  sustained	  tumor	  
growth	   in	  WT	  MSC-­‐inoculated	  tumors.	  DKK3	  was	  essen(al	   for	   these	  MSC-­‐mediated	  
immunoregula(on.	  !
3.2.5	  DKK3-­‐/-­‐	  MSCs	  produce	  less	  chemokines,	  such	  as	  CCL2,	  CXCL8,	  and	  CXCL10. 
 
Since	  the	  pa/ern	  of	  tumor-­‐inﬁltra(ng	  cells	  changed	  depending	  on	  the	  types	  of	  MSCs	  
inoculated,	   we	   asked	   for	   the	   underlying	   mechanisms.	  MSCs	   are	   capable	   to	   secret	  
various	   chemokines	   to	   regulate	   migra(on	   of	   immune	   cells	   [183].	   Therefore	   we	  
measured	  the	  expression	  proﬁles	  of	  chemokines	  in	  both	  WT	  and	  DKK3-­‐/-­‐	  MSCs.	  	  !
Figure	  3.13	  DKK3-­‐/-­‐	  MSCs	  showed	  diﬀered	  chemokine	  proﬁles.	  
WT	  and	  DKK3-­‐/-­‐	  MSCs	  were	  lysed	  by	  lysis	  buﬀer	  in	  res(ng	  status	  
or	   a{er	   s(mulated	   with	   20ng/ml	   IFNγ in	   complete	   DMEM.	  
Western	   bloong	   was	   performed.	   Diminished	   expression	   of	  
CCL2,	   CXCL8,	   and	   CXCL10	   were	   found	   in	   DKK3-­‐/-­‐	   MSCs,	   no	  
ma/er	   in	   res(ng	   status	   or	   a{er	   IFNγ-­‐s(mula(on.	  
Representa(ve	   results	   wre	   shown	   for	   5	   independent	  
experiments.	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In	  both	  res(ng	  and	  IFNγ-­‐s(mulated	  status,	  DKK3-­‐/-­‐	  MSCs	  expressed	  merely	  no	  CCL2,	  
CXCL8,	  or	  CXCL10.	  However,	  WT	  MSCs	  were	  competent	  to	  produce	  such	  chemokines	  
(Fig.	  3.13).	  Our	   results	   showing	  aberrant	  chemotaxis	   capacity	  of	  MSCs	  deﬁcient	   for	  
DKK3	  might	  explain	  the	  observed	  abnormali(es	  in	  macrophage	  inﬁltra(on.	  CCL2	  was	  
reported	   to	   be	   a	   chemoa/ractant	   to	   leukocytes,	   such	   as	   monocytes	   and	   M2	  
macrphages	  [279].	  !
3.2.6	  DKK3-­‐/-­‐	  MSCs	  fail	  to	  elicit	  MHC	  class	  I	  expression	  upon	  IFNγ-­‐s/mula/on,	  while	  
constantly	  expressing	  higher,	  but	  s/ll	  minimal,	  level	  of	  MHC	  class	  II.	  !
Besides	   the	   produc(on	  of	   chemokines	   for	   recruitment,	   cell-­‐cell	   contact	   dependent	  
mechanisms	  between	  MSCs	   and	   immune	   cells	  might	   regulate	   immune	   ac(vi(es	   of	  
the	  recruited	  immune	  cells.	  Expression	  of	  MHC	  class	  I	  was	  shown	  as	  a	  mechanism	  for	  
IFNγ-­‐ac(vated	  MSCs	  to	  prevent	  NK	  cell-­‐mediated	  cytolysis	  [205].	  On	  the	  other	  hand,	  
MSCs	  can	  express	  MHC	  class	  II	  and	  present	  an(gens	  under	  certain	  condi(ons,	  such	  as	  
s(mula(on	  by	  low	  concentra(on	  of	  IFNγ [202,	  203].	  Therefore,	  we	  tested	  MHC	  class	  I	  
and	  class	  II	  expression	  in	  both	  DKK3-­‐suﬃcient	  and	  -­‐deﬁcient	  MSCs.	  	  !!
  	  !!
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Figure	   3.14	   DKK3-­‐/-­‐	   MSCs	   failed	   to	   elicit	   MHC	   class	   I	   expression	   arer	   IFNγ-­‐s/mula/on,	   while	  
expressing	  higher	  MHC	  class	   II	  molecules.	  MSCs	  were	  s(mulated	  with	  20ng/ml	   IFNγ for	  48hrs.	  The	  
surface	  expression	  of	  MHC	  class	  I	  or	  II	  was	  analyzed	  by	  FACS.	  (A)	  In	  the	  res(ng	  status,	  the	  expression	  
of	   MHC	   class	   I	   by	   either	   WT	   or	   DKK3-­‐/-­‐	   MSCs	   was	   low.	   A{er	   IFNγ-­‐s(mula(on,	   only	   WT	   MSCs	  
drama(cally	  elicited	  the	  expression	  of	  MHC	  class	  I	  while	  DKK3-­‐/-­‐	  MSCs	  were	  impaired.	  (B)	  In	  the	  case	  
of	  MHC	  class	  II,	  IFNγ-­‐s(mula(on	  did	  not	  induce	  up-­‐regula(on	  in	  either	  WT	  or	  DKK3-­‐/-­‐	  MSCs.	  However,	  
in	   both	   res(ng	   and	   IFNγ-­‐s(mulated	   status,	   DKK3-­‐/-­‐	   MSCs	   expressed	   higher	   levels	   of	   MHC	   class	   II.	  
Unpaired	  student	  t	  test	  was	  applied	  for	  analysis. 
!
DKK3-­‐/-­‐	  MSCs	  were	   strongly	   impaired	   in	   their	   expression	  of	  MHC	   class	   I	   a{er	   IFNγ-­‐
s(mula(on	   (Fig.	   3.14A).	   However,	   they	   expressed	   higher	   levels	   of	   MHC	   class	   II	   in	  
either	   res(ng	  or	   IFNγ-­‐s(mulated	   status	   (Fig.	   3.14B).	   These	   results	   suggest	   that	   the	  
DKK3-­‐/-­‐	  MSCs	  may	   be	   less	   capable	   to	   suppress	  NK	   cell	   ac(vi(es	   and	  may	   be	  more	  
capable	  to	  present	  an(gens	  to	  CD4+	  T	  cells.	  	  !
3.2.7	  Intensiﬁed	  autophagy	  is	  found	  in	  DKK3-­‐/-­‐	  MSCs	  !
Next	   we	   asked	   what	   might	   be	   the	   mechanisms	   beneath	   the	   altered	   surface	  
expression	  of	  MHC	  molecules	  by	  DKK3-­‐/-­‐	  MSCs.	  As	  discussed	  earlier,	  autophagy	  could	  
contribute	  to	  the	  an(gen	  inﬂux	  into	  MIIC	  and	  therefore	  could	  enhance	  the	  MHC	  class	  
II	  expression.	  Since	  we	  have	  found	  cons(tu(vely	  higher	  expression	  of	  MHC	  class	  II	  in	  
DKK3-­‐/-­‐	  MSCs,	  we	  hypothesized	  that	  autophagy	  might	  be	  increased	  in	  these	  cells.	  !
	  !!
Figure	   3.15	   DKK3-­‐/-­‐	   MSCs	   showed	   intensiﬁed	  
autophagic	  ac/vi/es.	  WT	  or	  DKK3-­‐/-­‐	  MSCs	  were	  cultured	  
with	  or	  without	  20ng/ml	  IFNγ for	  48hrs.	  MSCs	  were	  then	  
washed	  and	  lysed	  by	  lysis	  buﬀer.	  Proteins	  were	  analyzed	  
by	  Western	   bloong.	   In	   the	   lysates	   from	   DKK3-­‐/-­‐	   MSCs,	  
either	   uns(mulated	   or	   s(mulated	   with	   IFNγ,	   stronger	  
LC3B-­‐II	  signals	  were	  detected.	  Beclin-­‐1	  was	  reduced	  only	  
in	  DKK3-­‐/-­‐	  MSCs	  a{er	  IFNγ s(mula(on.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  !
Beclin-­‐1,	  which	   ini(ates	  the	  forma(on	  of	  autophagosomes,	  remained	  unchanged	   in	  
untreated	   DKK3-­‐/-­‐	   MSCs	   and	   was	   decreased	   a{er	   IFNγ-­‐s(mula(on	   (Fig.	   3.15).	  
However,	   we	   iden(ﬁed	   enhanced	   autophagic	   ac(vi(es	   by	   observing	   intensiﬁed	  
expression	  of	  LC3B-­‐II	  (Fig.	  3.15).	  LC3	  proteins	  are	  cleaved	  by	  proteases	  like	  Atg4	  from	  
LC3-­‐I	   to	   become	   LC3-­‐II.	   Cleaved	   LC3	   proteins	   are	   then	   incorporated	   into	   the	  
autophagosome.	   Hence,	   intensiﬁed	   signals	   of	   cleaved	   LC3	   proteins	   indicate	   ac(ve	  
autophagy.	   Therefore	   higher	   cleavage	   and	   consump(on	   rates	   of	   LC3	   in	   DKK3-­‐
deﬁcient	  MSCs	  point	  to	  an	  inhibi(on	  of	  autophagy	  by	  DKK3.	  	  !
Thus,	  DKK3-­‐/-­‐	  MSCs	  exhibited	  stronger	  autophagic	  ac(vi(es,	  which	  were	  compa(ble	  
with	  be/er	  expression	  of	  MHC	  class	  II	  in	  DKK3-­‐/-­‐	  MSCs.	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3.2.8	  Diminished	  mTOR	  signaling	  in	  DKK3-­‐/-­‐	  MSCs	  !
Since	  mTOR	  was	   reported	   to	   inhibit	   autophagy	   [243,	   280,	   281],	  we	  asked	  whether	  
DKK3	  could	  modulate	  mTOR	  signaling.	  In	  DKK3-­‐/-­‐	  MSCs,	  decreased	  phosphoryla(on	  of	  
mTOR	   proteins	   at	   both	   serine	   2448(S2448)	   and	   serine	   2481(S2481)	   sites	   indicated	  
diminished	  mTOR	  ac(va(on	  (Fig.	  3.16).	  Moreover,	   the	  phosphoryla(on	  of	  Raptor,	  a	  
member	   of	   the	  mTORC1,	  was	   also	   reduced,	   further	   suppor(ng	   the	   observa(on	   of	  
weakened	  mTOR	  ac(vi(es	   (Fig.	  3.16).	  These	   results	  are	  compa(ble	  with	   intensiﬁed	  
autophagy	  and	  MHC	  class	  II	  expression	  we	  found	  in	  DKK3-­‐/-­‐	  MSCs.	  !!
	  !!
Figure	   3.16	   Loss	   of	   DKK3	   caused	   diminished	   mTOR	  
ac/vi/es	   in	  MSCs.	  WT	   or	   DKK3-­‐/-­‐	  MSCs	   were	   cultured	  
with	   or	   without	   20ng/ml	   IFNγ s(mula(on	   for	   48hrs.	  
Cells	  were	  washed	  and	  lysed	  by	  lysis	  buﬀer	  for	  Western	  
bloong.	  The	   signals	  of	  phosphorylated	  mTOR,	  p-­‐mTOR	  
S2448	   and	   p-­‐mTOR	   S2481,	   were	   diminished	   in	   DKK3-­‐/-­‐	  
MSCs	  with	   or	  without	   IFNγ s(mula(on.	   Phsphorylated	  
Raptor,	   p-­‐Raptor	   S792,	   was	   also	   decreased	   in	   DKK3-­‐/-­‐	  
MSCs	  in	  both	  condi(ons.	  The	  expression	  of	  total	  mTOR	  
or	  Raptor	  was	  not	  signiﬁcantly	  changed.	  Representa(ve	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4.	  Discussions	  !
The	   immune	   system	   defends	   organisms	   against	   harmful	   environmental	   insults.	  
Thereby,	  it	  is	  essen(al	  to	  have	  a	  (ght	  balance	  between	  the	  strength	  of	  the	  immune	  
response	  to	  eliminate	  the	  respec(ve	  pathogen	  and	  the	  protec(on	  of	  the	  respec(ve	  
organ	   against	   excessive	   inﬂamma(on	   and	   subsequent	   (ssue	   damage.	   A	   detailed	  
knowledge	   of	   the	   processes	   contribu(ng	   to	   this	   balance	   is	   required	   for	   the	  
development	  of	  novel	  therapeu(c	  strategies	  for	  the	  treatment	  of	  diseases,	  in	  which	  
the	  immune	  system	  is	  involved.	  	  !
In	  this	  study	  we	  inves(gated	  the	  role	  of	  proteins,	  which	  contribute	  to	  regulate	  T	  cell	  
responses:	  the	  T	  cell	  intrinsic	  Nck	  adapter	  proteins	  and	  the	  extrinsic	  modulator	  DKK3.	  !
4.1	  Nck	  Adaptor	  Proteins	  Modulate	  Diﬀereneaeon	  and	  
Eﬀector	  Funceons	  of	  T	  Cells	  !
4.1.1	  T	  cell-­‐dependent	  an/body	  responses	  were	  reduced	  in	  Nck.T-­‐/-­‐	  mice	  !
Here	  we	   provide	   evidence	   that	  Nck	   proteins	   are	   essen(al	   for	   survival	   and	   eﬀector	  
func(ons	  of	  T`	  cells.	  Loss	  of	  Nck	  proteins	  lead	  to	  impaired	  GC	  forma(on	  along	  with	  
reduced	  cellularity	  of	  splenic	  T`	  cells	  and	  GC-­‐T`	  cells.	  Produc(on	  of	  key	  Th2	  and	  T`	  
cytokines,	  such	  as	  IL-­‐4,	  IL-­‐10,	  and	  IL-­‐21	  [261,	  282],	  was	  also	  diminished.	  These	  signs	  
of	   dysfunc(on	   were	   associated	   with	   decreased	   levels	   of	   Akt	   phosphorylation	   and	  
intensiﬁed	  apoptosis	  of	  T`	  cells.	  Consequently,	  T	  cell-­‐dependent	  an(body	  responses	  
were	  reduced	  in	  regard	  to	  quan(ty	  as	  well	  as	  quality	  by	  aﬃnity	  matura(on.	  !
In	   our	   Nck.T-­‐/-­‐	   model	   Nck1	   is	   deleted	   among	   all	   soma(c	   cells,	   including	   B	   cells.	  
Although	  Nck2	  remains	  intact	  and	  the	  two	  Nck	  homologues	  are	  highly	  conserved	  in	  
sequence	  and	  most	   likely	   func(onal	   redundant	   [283,	  284],	  one	  may	  s(ll	  argue	  that	  
the	   loss	  of	  Nck1	   in	  B	  cells	  may	  contribute	  to	  the	  observed	  dysfunc(ons	   in	  an(body	  
produc(on.	  Dele(on	  of	  Nck1	  in	  all	  soma(c	  cells	  or	  both	  Nck	  homologues	  speciﬁcally	  
in	  B	   cells	  has	  been	   studied	   in	  detail	   [267]	  and	   the	  pa/erns	  of	  an(body	  produc(on	  
were	  dis(nct	  from	  our	  results	  in	  the	  Nck.T-­‐/-­‐	  system.	  For	  example,	  soma(c	  dele(on	  of	  
Nck1	  or	  B	  cell-­‐speciﬁc	  dele(on	  of	  Nck	  proteins	  lead	  to	  increased	  basal	  levels	  of	  IgG1	  
and	   IgG2a	   in	   the	   serum.	   By	   contrast,	   both	   isotypes	   are	   diminished	   in	   our	   Nck.T-­‐/-­‐	  
mice.	  Therefore,	  the	  defec(ve	  an(body	  responses	  we	  observed	  can	  be	  a/ributed	  to	  
the	  role	  of	  Nck	  proteins	  in	  T	  helper	  cell	  func(ons.	  	  !
During	   humoral	   immune	   responses	   GCs	   are	   formed	   in	   secondary	   lymphoid	   organs	  
and	  provide	  microenvironments	  for	  diﬀeren(a(on	  and	  ac(va(on	  of	  B	  cells	  [285].	  GCs	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were	   normally	   generated	   in	   mice	   with	   Nck-­‐deﬁcient	   B	   cells	   [267].	   In	   contrast,	   we	  
found	  impaired	  GC	  forma(on	  in	  Nck.T-­‐/-­‐	  mice.	  Follicular	  helper	  T	  (T`)	  cells,	  which	  are	  
characterized	   by	   high	   expression	   of	   CXCR5	   and	   ICOS,	   contribute	   to	   GC	   forma(on	  
[261,	   285].	   Un-­‐physiological	   excess	   of	   GC-­‐T`	   associated	   with	   increased	   cytokine	  
secre(on	   could	   lead	   to	   increased	   an(body	   produc(on	   with	   possible	   autoimmune	  
pathology	   [286].	   The	   func(on	  of	  GC-­‐T`	  has	  been	   reported	   to	  be	   regulated	  by	   the	  
strength	   of	   TCR	   binding	   to	   pep(de-­‐MHC	   complexes	   [287].	   Our	   ﬁndings	   show	   that	  
also	  T	   cell-­‐intrinsic	  modula(on	  of	   TCR	   signal	   strength	  by	  Nck	  proteins	   can	   regulate	  
the	  func(on	  of	  GC-­‐T`	  and	  thereby	  the	  forma(on	  of	  GC.	  	  !
Reduced	  numbers	  of	  GC-­‐T`	  cells	  and	  enhanced	  apoptosis	  of	  these	  cells	  suggest	  that	  
defects	   in	   T`	   cell	   survival	   limit	   produc(ve	   T	   cell-­‐dependent	   an(body	   responses	   in	  
Nck.T-­‐/-­‐	  mice.	  In	  addi(on,	  Nck	  proteins	  may	  also	  be	  involved	  in	  regula(on	  of	  T	  helper	  
cell	   diﬀeren(a(on.	   Expression	   of	   transcrip(on	   factors	   promo(ng	   Th2/T`	   cell	  
diﬀeren(a(on,	  such	  as	  Bcl-­‐6	  and	  GATA-­‐3,	  was	  comparable	  in	  in	  vitro	  s(mulated	  total	  
T`	  and	  GC-­‐T`	  popula(ons	  of	  wild-­‐type	  and	  Nck.T-­‐/-­‐	  mice.	  However,	   T`	  cells	   from	  
Nck.T-­‐/-­‐	   mice	   produced	   less	   amounts	   of	   IL-­‐10,	   IL-­‐4	   and	   IL-­‐21	   per	   cell	   than	   the	  
respec(ve	  cells	  from	  wild-­‐type	  mice	  (Fig.	  3.3B).	  This	  diﬀerence	  was	  most	  pronounced	  
when	  PD-­‐1+	   T`	  cells	  were	   compared.	   Thus,	   these	   cytokine-­‐producing	   cells	  may	  be	  
able	   to	   diﬀeren(ate	   but	   fail	   to	   be	   fully	   equipped	   to	   secrete	   normal	   levels	   of	  
cytokines.	   This	   observa(on	   could	   be	   explained	   by	   decreased	   Akt	   ac(vi(es	   and	  
reported	   impairment	   of	   ERK	  phosphoryla(on	   and	  Ca2+	   ﬂux	   in	  Nck.T-­‐/-­‐	   T	   cells	   [249].	  
Akt	   ac(vity	   is	   reported	   to	   support	   the	  produc(on	  of	   diﬀerent	   cytokines	   by	   T	   cells,	  
including	  IL-­‐4,	  IL-­‐10,	  and	  IL-­‐21	  [288-­‐290].	  However,	  although	  ERK	  signaling	  promotes	  
IL-­‐10	  produc(on	  [291],	   it	  also	  nega(vely	  regulates	  the	  produc(on	  of	  IL-­‐4	  or	  IL-­‐21	  in	  
certain	  situa(ons	  [292-­‐294].	  Therefore,	  the	  reduc(on	  of	   IL-­‐10	  a{er	   loss	  of	  Nck	  may	  
be	  explained	  by	  synergis(c	  eﬀects	  of	  decreased	  Akt	  and	  ERK	  signaling.	  However,	  the	  
observed	  changes	  of	   IL-­‐4	  and	  IL-­‐21	  in	  Nck.T-­‐/-­‐	  T	  cells	  may	  be	  the	  results	  of	  opposite	  
ac(vi(es	  by	  decreased	  Akt	  ac(vi(es	  and	  decreased	  ERK	  signaling.	  This	  may	  help	  to	  
explain	  why	  the	  reduc(on	  of	  IL-­‐4	  and	  IL-­‐21	  is	  not	  universally	  signiﬁcant	  among	  all	  T`	  
but	   speciﬁcally	   pronounced	   in	   PD-­‐1+	   T`.	   The	  detailed	   balance	  between	  decreased	  
Akt	  and	  ERK	  signaling	  a{er	  loss	  of	  Nck	  proteins	  requires	  further	  inves(ga(on.	  	  	  	  !
4.1.2	  EAE	  disease	  was	  aGenuated	  in	  Nck.T-­‐/-­‐	  mice	  !
To	   inves(gate	  whether	   loss	  of	  Nck	   in	  T	  cells	   is	  perturbing	  T	  cell	   func(on	   in	  general,	  
we	  extended	  our	  studies	  to	  the	  autoimmune	  model	  EAE.	  This	  demyelina(ng	  disease	  
is	  associated	  with	  mul(ple	  CNS	  lesions,	  mostly	  pronounced	  in	  the	  brain	  stem	  and	  the	  
spinal	   cord.	   The	   inﬂammatory	   process	   is	   characterized	   by	   the	   disrup(on	   of	   the	  
blood-­‐brain	  barrier	  and	  the	  inﬁltra(on	  of	  various	  cell	  types.	  !
A/enuated	  EAE	  disease	  was	  observed	  in	  Nck.T-­‐/-­‐	  mice	  (Fig.	  3.7A)	  with	  lower	  disease	  
scores,	  delayed	  dynamics	  and	  faster	  recovery.	  The	  size	  of	  disease	  ini(a(ng	  Th17	  cells	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was	   not	   changed	   in	   CNS	   samples	   from	   Nck.T-­‐/-­‐	   in	   comparison	   to	   wild	   type	   mice,	  
sugges(ng	   normal	   T	   cell	   diﬀeren(a(on.	   This	   assump(on	  was	   supported	   by	   similar	  
expression	   levels	   of	   the	   transcrip(on	   factors	   RORγt	   or	   T-­‐bet	   in	   CD4	   T	   cells	   of	   both	  
types	   of	  mice.	   However,	   CCR6+CD4+	   T	   cells	   were	   signiﬁcantly	   decreased	   in	   Nck.T-­‐/-­‐	  
mice	   (Fig.	   3.7C).	   The	   altera(on	   in	   the	   expression	   of	   this	   receptor	   media(ng	  
chemotaxis	   suggests	   an	   impairment	   of	   Th17	   cell	   migra(on	   within	   the	   CNS.	   This	  
ﬁnding	  requires	  further	  inves(ga(on,	  as	  Nck	  proteins	  have	  so	  far	  not	  been	  associated	  
with	  migra(on.	  In	  contrary,	  normal	  migra(on	  of	  Nck-­‐deﬁcient	  B	  cells	  was	  observed	  in	  
secondary	  lymphoid	  organs	  [267].	  !
Together,	   our	   ﬁndings	   and	   previously	   published	  data	   point	   to	   an	   important	   role	   of	  
Nck	  proteins	   in	  ﬁne	   tuning	  TCR	   signaling	   strength	  during	  all	   T	   cell	   stages,	   including	  
development	   (Fig.	   4.1),	  maintenance,	   ac(va(on	  and	  eﬀector	   func(on.	  Nck	  adaptor	  
proteins	   contribute	   to	   shaping	   the	   pre-­‐immune	   T	   cell	   repertoire	   during	   thymic	  
selec(on,	  contribute	  to	  the	  size	  and	  sensi(vity	  of	  the	  peripheral	  T	  cell	  repertoire	  and,	  
as	   shown	   here,	   regulate	   helper	   T	   cell	   func(ons	   during	   T	   cell-­‐dependent	   an(body	  
responses	   in	   GC.	   Thus,	   defects	   in	   Nck	   protein	   func(on	   may	   have	   a	   so	   far	   un-­‐
recognized	  role	  in	  human	  diseases	  with	  defec(ve	  T-­‐dependent	  an(body	  responses.	  	  !
	  !!
Figure	   4.1	   Model	   of	   Nck	   adaptor	   tuning	   TCR	  
signaling	  strength	   in	   thymic	  selec/on.	  Nck	  adaptor	  
proteins	   enhance	   the	   signaling	   strength	   of	   TCR	   on	  
developing	  thymocytes	  to	  appropriate	  range.	  Tuning	  
of	   TCR	   signaling	   by	   Nck	   proteins	   are	   also	   essen(al	  
for	   peripheral	   maintenance,	   responsiveness,	   and	  
eﬀector	   func(ons	   of	   mature	   T	   cells.	   The	   ﬁgure	   is	  
based	   on	   the	   ﬁindings	   of	   Roy,	   et	   al.,	   J.	   Immunol.	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4.2	  Dickkopf-­‐3	  can	  limit	  T	  cell-­‐mediated	  ane-­‐tumor	  
responses.	  !
In	  this	  part	  of	  the	  studies	  we	  showed	  that	  DKK3	  is	  produced	  by	  MSCs	  and	  can	  limit	  T	  
cell	   mediated	   an(-­‐tumor	   responses.	   Impaired	   chemokine	   produc(on	   by	   DKK3	  
deﬁcient	  MSCs	   could	  be	   related	   to	   enhanced	   inﬁltra(on	  of	   CD8+	   T	   cells	  within	   the	  
DKK3-­‐/-­‐	   MSC-­‐inoculated	   tumors.	   In	   addi(on,	   loss	   of	   DKK3	   in	   MSCs	   resulted	   in	  
increased	  expression	  of	  MHC	  class	  II	  an(gens,	  which	  was	  associated	  with	  intensiﬁed	  
autophagy	  and	  reduced	  mTOR	  ac(vity.	  	  !
4.2.1	  Dickkopf	  3	  is	  essen/al	  for	  the	  immune-­‐suppressive	  capacity	  of	  mesenchymal	  
stem	  cells.	  !
The	   RMA-­‐mOVA	   transplanta(on	   tumor	   is	   rejected	   by	   C57BL/6	   mice	   a{er	   a	   short	  
growth	  period	  but	  is	  growing	  in	  Rag2-­‐deﬁcient	  mice	  lacking	  lymphocytes.	  Therefore,	  
it	   is	  a	  suitable	  model	  to	  study	  possible	  immune-­‐modulatory	  capaci(es	  of	  MSCs.	  WT	  
MSCs	  inhibited	  an(-­‐tumor	  responses	  whereas	  DKK3-­‐deﬁcient	  MSCs	  did	  not	  aﬀect	  the	  
rejec(on	  process.	  This	   func(onal	  diﬀerence	  between	  WT	  and	  DKK3-­‐/-­‐	  MSC	  was	  not	  
due	  to	  diﬀerent	  in	  vivo	  survival	  of	  the	  two	  types	  of	  cells.	  Therefore,	  we	  conclude	  that	  
DKK3	   can	   contribute	   to	   the	   reported	   immune-­‐suppressive	   capacity	  of	  MSCs,	  which	  
can	  aﬀect	  both	  innate	  and	  adap(ve	  immune	  responses	  [180,	  183]	  by	  cell-­‐cell	  contact	  
or	  soluble	  factors.	  To	  clarify	  mechanisms	  resul(ng	  in	  the	  tolerogenic	  capacity	  of	  Dkk3	  
we	   analyzed	   the	   composi(on	   of	   tumor-­‐inﬁltra(ng	   cells	   using	   eGFP-­‐transgenic	  
recipient	  mice.	  WT	  MSCs	  could	  reduce	  CD8+	  T	  cells	  inﬁltra(on	  into	  tumors,	  whereas	  
the	  percentage	  of	  inﬁltra(ng	  CD8+	  T	  cells	  was	  signiﬁcantly	  increased	  in	  DKK3-­‐/-­‐	  MSC-­‐
inoculated	   tumors	   and	   reached	   the	   level	   of	   CD8+	   T	   cells	   in	   tumors	   without	   MSC	  
inocula(on	  (Fig.	  3.12A).	  	  !
We	   also	   observed	   reduced	   numbers	   of	   M2	   macrophages	   in	   the	   DKK3-­‐/-­‐	   MSC-­‐
inoculated	   tumors	   in	   comparison	  with	   the	  WT	  MSC-­‐inoculated	   tumors	  but	  without	  
reaching	   signiﬁcance.	   MSCs	   are	   known	   to	   modulate	   the	   recruitment	   and	  
diﬀeren(a(on	   of	  macrophages.	   TNFα	   and	   IFNγ	   produced	   by	   pro-­‐inﬂammatory	  M1	  
macrophages	  can	  trigger	  MSCs	  to	  produce	  prostaglandin	  E2	  (PGE2)	  and	  kynurenine	  
(KYN),	   by	   which	   the	   recruited	   M1	   macrophages	   can	   be	   repolarized	   to	   an	  
immunosuppressive	   M2	   type	   [183].	   For	   example,	   in	   a	   sepsis	   model,	   MSCs	   were	  
transferred	  and	  M2	  macrophages	  were	  polarized	  upon	  MSCs	  transfer	  and	  the	   IL-­‐10	  
produced	   by	   M2	   macrophages	   decreased	   further	   inﬁltra(on	   of	   pro-­‐inﬂammatory	  
neutrophils	  and	  (ssue	  damage	  [295].	  As	  macrophages	  belong	  to	  the	  main	  target	  cells	  
of	   MSCs	   to	   exert	   their	   immune-­‐regulatory	   func(on,	   further	   inves(ga(ons	   are	  
required	  to	  clarify	  the	  role	  of	  DKK3	  produced	  by	  MSCs	  in	  macrophage	  recruitment	  to	  
inﬂammatory	  sites.	  !
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4.2.2	  Dickkopf-­‐3	  contributes	  to	  the	  control	  of	  chemokine	  produc/on	  by	  MSCs	  !
We	   next	   inves(gated	   whether	   the	   observed	   diﬀerences	   in	   inﬂammatory	   cell	  
recruitment	   in	   the	   WT	   and	   DKK3-­‐/-­‐	   MSC-­‐inoculated	   tumors	   could	   be	   related	   to	  
diﬀeren(al	  chemokine	  produc(on	  by	  the	  two	  types	  of	  MSCs.	  Impaired	  produc(on	  of	  
CCL2,	  CXCL8,	  and	  CXCL10	  by	  DKK3-­‐/-­‐	  MSCs	  was	  found	  (Fig.	  3.13).	  	  !
CCL2	   is	   associated	  with	   the	   recruitment	  of	  macrophages	  and	  monocytes	   in	   tumors	  
[296,	  297].	   In	  various	  human	  cancers,	  such	  as	  breast	  [298],	  ovarian	  [299],	  and	  non-­‐
small	   cell	   lung	   cancer	   [300]	   as	   well	   as	   glioblastoma	   [301],	   expression	   of	   CCL2	   is	  
posi(vely	   related	  to	   the	   inﬁltra(on	  of	   tumor-­‐associated	  macrophages	   (TAM),	  which	  
are	   mainly	   M2	   type	   and	   suppress	   the	   an(-­‐tumor	   immunity.	   Higher	   expression	   of	  
CCL2	  in	  the	  epithelial	  regions	  of	  various	  tumors	  [302-­‐304]	  indicates	  the	  primary	  sites	  
for	  monocyte	  recruitment	  (Fig.	  4.3).	  In	  murine	  melanoma,	  higher	  expression	  of	  CCL2	  
is	  also	  associated	  with	  enhanced	  recruitment	  of	  monocyte	  and	  macrophages	  [305].	  
Impaired	   CCL2-­‐mediated	   chemotaxis	   of	   monocytes	   and	   macrophages	   by	   siRNAs	  
silencing	   CCR2	   [306]	   or	   an(body	   neutralizing	   CCL2	   [307]	   lead	   to	   delayed	   tumor	  
progression	  and	  impaired	  metastasis.	  All	  these	  ﬁndings	  indicate	  the	  CCL2	  produc(on	  
in	  tumors	  is	   important	  for	   immunosuppression	  and	  tumor	  growth.	  MSCs	  have	  been	  
reported	   to	   recruit	   monocytes	   by	   CCL2	   [279].	   Therefore,	   the	   reduc(on	   of	   CCL2	  
produc(on	   by	   DKK3-­‐/-­‐	  MSCs	  may	   be	   causal	   for	   reduced	   recruitment	   of	  monocytes	  
and	  macrophages	  to	  the	  tumor.	  	  	  	  	  !
  	  !
Figure	  4.3	  CCL2	  mediates	   the	  recruitment	  of	  monocytes	   into	   the	  tumor	   in	   the	  epithelial	   region	  of	  
tumor.	  The	  ﬁgure	  is	  derived	  from	  Lee,	  et	  al.,	  Biochimica	  et	  Biophysica	  Acta	  2013,	  1835:170–179.	  !
CXCL8	   is	   essen(al	   for	   the	   recruitment	   of	   neutrophils	   [297,	   308,	   309].	   Although	   in	  
early	   studies	   both	   CXCL8	   and	   neutrophils	   were	   characterized	   as	   pro-­‐inﬂammatory	  
elements	   in	   the	   immune	   system,	   emerging	  evidences	  have	   shown	   that	  neutrophils	  
can	   produce	   an(-­‐inﬂammatory	   IL-­‐10	   [310]	   and	   can	   diﬀeren(ate	   into	  
immunosuppressive	   ‘N2’ neutrophils	   according	   to	   environmental	   cues,	   like	   TGFβ 
[311,	  312].	  Tumor-­‐associated	  neutrophils	  (TANs)	  are	  composed	  of	  both	  an(-­‐tumoral	  
N1	  and	  pro-­‐tumoral	  N2	  neutrophils	  [313].	  The	  an(-­‐tumoral	  eﬀect	  of	  N1	  neutrophils	  
is	   dependent	   on	   the	   release	   of	   tumorcidal	   molecules,	   such	   as	   ROS	   [314-­‐316]	   and	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HOC1	   [317]	   as	   well	   as	   on	   the	   support	   of	   CD8+	   T	   cell	   ac(vity	   [311,	   313,	   318].	   By	  
contrast,	   pro-­‐tumoral	   N2	   neutrophils	   can	   suppress	   the	   cytotoxicity	   and	   cytokine	  
produc(on	   of	   CD8+	   T	   cells	   [311]	   and	   can	   support	   tumor	   survival	   by	   produc(on	   of	  
matrix	   metalloproteinase-­‐9	   (MMP-­‐9)	   [319,	   320].	   MMP-­‐9	   produced	   by	   TANs	   can	  
support	  angiogenesis	  and	  neovasculariza(on	  [321-­‐323].	  The	  roles	  of	  N2	  neutrophils	  
can	  be	  analogous	  to	  the	  func(on	  of	  M2	  macrophages	  [320],	  which	  are	  found	  to	  be	  
reduced	   in	   rejected	  DKK3-­‐/-­‐	  MSC-­‐inoculated	   tumors	   (Fig.	   3.12).	   Therefore,	   impaired	  
produc(on	   of	   CXCL8	   by	   DKK3-­‐/-­‐	   MSCs	   may	   possibly	   lead	   to	   reduced	  
immunosuppressive	   N2	   neutrophils	   in	   the	   tumor	   mass	   and	   thereby	   may	   fail	   to	  
restrain	   the	   tumor	   rejec(on.	   This	   hypothesis	   need	   to	   be	   inves(gated	   by	  
dis(nguishing	  CD11b+Ly6G+Ly6Cneg.→int.	  N2	  neutrophils	   from	  CD11b+Ly6G+	  N1	  cells	   in	  
tumor	  mass.	  	  !
The	  impaired	  CXCL8	  produc(on	  can	  also	  be	  a	  sign	  of	  reduced	  PGE2	  by	  DKK3-­‐/-­‐	  MSCs	  
or	   by	   other	   stromal	   cells.	   PGE2	   can	   promote	   the	   produc(on	   of	   CXCL8	   by	   Caco2	  
colonic	   epithelial	   cells	   through	   receptor	   EP4-­‐CREB	   (cyclic	  AMP-­‐responsive	   element-­‐
binding	   protein)	   signaling	   [324].	   Hypoxia	   can	   also	   synergize	  with	   PGE2	   to	   promote	  
the	   produc(on	   of	   CXCL8	   [325].	   Since	   hypoxia	   can	   be	   found	   in	   internal	   regions	   of	  
growing	  tumors,	  MSCs	  may	  encounter	  the	  hypoxic	  condi(ons	  along	  with	  PGE2	  from	  
the	  environment	  or	  in	  an	  autocrine	  fashion	  and	  may	  be	  s(mulated	  to	  produce	  CXCL8.	  
Since	   PGE2	   can	  be	   an	   important	   immunosuppressive	  mediator	   for	  MSCs,	   it	  will	   be	  
interes(ng	  to	  determine	  whether	  reduced	  CXCL8	  in	  DKK3-­‐/-­‐	  MSCs	   is	  associated	  with	  
reduced	   PGE2	   in	   these	   cells	   or	   in	   the	   tumor	   mass	   compromising	   immune-­‐
suppression.	  	  !
Furthermore,	  MSCs	  have	  been	  reported	  to	  be	  involved	  in	  promo(ng	  angiogenesis	  of	  
tumors	   by	   producing	   VEGF	   [192].	   In	   addi(on,	   CXCL8	   is	   reported	   to	   promote	  
angiogenesis	  [326,	  327].	  Hence,	   loss	  of	  CXCL8	  produc(on	  in	  DKK3-­‐/-­‐	  MSCs	  may	  limit	  
tumor	  growth	  by	  depriving	  the	  nutri(onal	  supply.	  The	  ques(on	  whether	  an	  increased	  
angiogenesis	   or	   the	   recruitment	   of	   immunosuppressive	   cells	  weights	  more	   for	   the	  
DKK3-­‐competent	  MSC-­‐mediated	  tumor	  growth	  requires	  further	  inves(ga(on.	  	  	  	  	  !
CXCL10	   is	   known	   to	   recruit	   Th1	   T	   cells,	   CD8+	   T	   cells	   as	   well	   as	   NK	   cells	   into	  
inﬂammatory	  sites	  [308,	  328-­‐330]	  and	  is	  considered	  to	  promote	  immune	  responses.	  
Since	  signiﬁcantly	  higher	  numbers	  of	  CD8+	  T	  cells	   inﬁltrated	  DKK3-­‐/-­‐	  MSC-­‐inoculated	  
tumors	  and	  since	  these	  tumors	  were	  rejected,	  higher	  expression	  of	  CXCL10	  in	  DKK3-­‐/-­‐	  
MSCs	  was	  expected.	  However,	  DKK3-­‐/-­‐	  MSCs	  produced	  far	  less	  CXCL10	  in	  comparison	  
to	   WT	   MSCs.	   We	   assume	   that	   other	   mechanisms	   might	   mask	   the	   recruitment	   of	  
those	   an(-­‐tumoral	   immune	   cells,	   because	   the	   expression	   of	   CXCL10	   in	   DKK3-­‐
competent	  MSCs	  did	  not	  cause	  the	  rejec(on	  of	  tumors.	  The	  co-­‐localiza(on	  of	  MSCs	  
and	   target	   cells	  may	   be	   essen(al	   for	   short-­‐distanced	   immunoregulatory	  molecules	  
like	  PGE2	  and	  KYN	  to	  be	  eﬀec(ve.	  PGE2	  produced	  by	  MSCs	  can	  limit	  the	  prolifera(on	  
of	   T	   cells	   by	   down-­‐regula(ng	   the	   produc(on	   of	   IL-­‐2	   [331]	   and	   decreasing	   the	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expression	  of	  IL-­‐2	  receptors	  [332]	  of	  T	  cells	  [199,	  333].	  For	  CD4+	  T	  cells,	  PGE2	  favours	  
Th2	   [334,	   335]	   and	   Th17	   [336]	   diﬀeren(a(on	   rather	   than	   tumor-­‐reac(ve	   Th1	   cells	  
[199].	  Moreover,	  PGE2	  can	  induce	  the	  diﬀeren(a(on	  of	  regulatory	  T	  cells[337-­‐339].	  
The	  cytotoxic	  ac(vity	  of	  CD8+	  T	  cells	  can	  be	  abolished	  by	  PGE2	  in	  the	  ac(va(ng	  [340]	  
as	  well	   as	   in	   the	  eﬀector	   stage	   [341].	   KYN	   [200,	   342]	   can	   inhibit	   Th1	   responses	  by	  
suppor(ng	  Th2	  instead	  [200,	  342,	  343].	  It	  is	  also	  capable	  to	  induce	  the	  diﬀeren(aiotn	  
of	  CD4+Foxp3+	  iTreg	  [344].	  Therefore,	  the	  expression	  of	  CXCL10	  may	  serve	  as	  a	  ‘trap’ 
of	  MSCs	  to	  recruit	  T	  cells	  closely	  and	  then	  unarm	  their	  an(-­‐tumoral	  capaci(es.	  	  !
4.2.3	  Dickkopf	  3	  may	  regulate	  MHC	  class	   II	  expression	  by	  ac/va/on	  of	  mTOR	  and	  
suppression	  of	  autophagy	  !
Besides	   the	   impaired	   chemokine	   produc(on	   by	   DKK3-­‐/-­‐	   MSCs,	   we	   also	   observed	  
altered	  expression	  of	  MHC	  an(gens	   in	  these	  cells.	   It	   remains	  controversial	  whether	  
or	  not	  the	  expression	  levels	  of	  MHC	  molecules	  contribute	  to	  the	  immunosuppressive	  
ac(vity	  of	  MSCs	  [345].	  It	  has	  been	  reported	  that	  autophagy	  could	  contribute	  to	  the	  
an(gen	  inﬂux	  into	  MIIC	  compartments	  and	  therefore	  could	  enhance	  the	  MHC	  class	  II	  
expression	   [247].	   Thus,	   the	   reduced	  mTOR	   signaling	   and	   the	   enhanced	   autophagy	  
which	  we	  observed	  in	  DKK3-­‐/-­‐	  MSCs	  may	  explain	  the	  cons(tu(vely	  higher	  expression	  
of	  MHC	  class	  II	  an(gens	  in	  these	  cells.	  Consequently,	  one	  may	  argue	  that	  the	  DKK3-­‐/-­‐	  
MSCs	  could	  be/er	  present	  an(gen	  to	  CD4+	  T	  cells	  in	  comparison	  to	  DKK3-­‐competent	  
MSCs	   and	   therefore	   support	   the	   an(-­‐tumor	   response.	   It	   requires	   further	  
inves(ga(ons	  to	  clarify,	  whether	  or	  not	  DKK3-­‐/-­‐	  MSCs	  can	  indeed	  induce	  destruc(ve	  
CD4+	  T	  cell	  responses.	  !
As	   discussed	   earlier,	   it	   is	   unclear	   whether	   or	   not	   DKK3	   is	   an	   antagonist	   of	   the	  
canonical	   Wnt/β-­‐catenin	   signaling	   pathway.	   Wnt	   signaling	   has	   been	   reported	   to	  
ac(vate	   mTOR	   signaling	   by	   inhibi(ng	   GSK3β [244].	   Hence,	   Wnt	   signaling	   should	  
suppress	   the	  autophagy.	   Indeed,	   three	   recent	   reports	  conﬁrmed	  that	   the	  canonical	  
Wnt/β-­‐catenin	   pathway	   could	   suppress	   autophagy	   by	   Wnt1	   or	   Wnt5a	   induced	  
signaling	   [346-­‐348].	   Furthermore,	   silencing	   or	   deple(on	   of	   β-­‐catenin	   enhanced	  
autophagy	   [347].	   On	   the	   other	   hand,	   autophagy	   could	  modulate	  Wnt	   signaling	   by	  
degrading	   β-­‐catenin	   [347]	   or Dishevelled	   proteins	   [349,	   350],	   indica(ng	   reciprocal	  
regula(on.	  If	  DKK3	  could	  antagonize	  the	  canonical	  Wnt/β-­‐catenin	  signaling	  pathway,	  
mTOR	  ac(vity	  should	  be	   intensiﬁed	  and	  autophagy	  should	  be	  diminished	   in	  DKK3-­‐/-­‐	  
MSCs.	  However,	  our	  ﬁndings	   (Fig.	  3.15-­‐16)	  do	  not	  support	   this	  hypothesis.	   Instead,	  
we	   assume	   that	   DKK3	   aﬀects	   autophagy	   by	   modula(ng	   JNK	   signaling.	   Previous	  
ﬁndings	   demonstrated	   that	   DKK3	   over-­‐expression	   in	   tumor	   cells	   induced	   JNK	  
phosphoryla(on	   [220]	   and	   that	   JNK	   signaling	   ac(vates	  mTOR	   signaling	   [351,	   352].	  
Therefore,	  we	  like	  to	  propose	  that	  DKK3	  may	  ac(vate	  mTOR	  signaling	  and	  suppress	  
autophagy	  via	  promo(ng	  JNK	  signaling	  (Fig.	  4.3).	  !
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This	   assump(on	   would	   be	   in	   line	   with	   the	   abrogated	   chemokine	   produc(on	   in	  
DKK3-­‐/-­‐	  MSCs.	  JNK	  signaling	  can	  promote	  the	  produc(on	  of	  CCL2	  and	  CXCL8	  in	  various	  
cell	   types	   by	   diﬀerent	   s(muli	   [353-­‐355].	   Inhibi(on	   of	   JNK	   signaling	   reduces	   the	  
produc(on	  of	   both	   chemokines	   [354,	   356,	   357].	  Moreover,	  Wnt5a,	   the	  Wnt	   ligand	  
protein	   that	   ac(vates	   the	   non-­‐canonical	   Wnt/PCP	   pathway	   via	   JNK	   signaling	  
[358-­‐362],	  can	   induce	  the	  produc(on	  of	  both	  CCL2	  and	  CXCL8	   [358,	  363]	   (Fig.	  4.5).	  
Interfering	   with	   Wnt5a	   signaling	   by	   sFRP5	   inhibits	   the	   produc(on	   of	   CCL2	   [364].	  
Hence,	  posi(ve	  modula(on	  of	  the	  non-­‐canonical	  Wnt/PCP	  pathway	  by	  DKK3	  via	  JNK	  
signaling,	   would	   explain	   the	   observed,	   impaired	   produc(on	   of	   CCL2	   and	   CXCL8	   in	  
DKK3-­‐/-­‐	  MSCs.	  !!
  	  !
Figure	  4.5	  Summary	  of	  the	  DKK3	  working	  model	   in	  MSC-­‐mediated	  immunosuppression	  and	  tumor	  
growth.	   In	  MSCs,	   DKK3	  may	   synergize	   or	   agonize	  with	   the	   non-­‐canonical	  Wnt	   signaling	   to	   ac(vate	  
mTOR	  and	  then	  to	  inhibit	  autophagy	  and	  MHC	  II	  expression.	  Also,	  DKK3	  may	  synergize	  or	  agonize	  with	  
the	  non-­‐canonical	  Wnt	  signaling	  to	  enhance	  JNK	  ac(vi(es	  and	  to	  induce	  the	  expression	  of	  chemokines	  
such	  as	  CCL2	  and	  CXCL8.	  These	  DKK3-­‐mediated	  ac(vi(es	  may	  support	  MSCs	  to	  suppress	  an(-­‐tumor	  
immunity	   and	   therefore	   support	   the	   tumor	   growth.	   The	   ﬁgure	   is	  modiﬁed	   from	  Mϋnz,	   Annu.	   Rev.	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4.3	  Outlook	  !
Our	  studies	  contribute	  to	  a	  be/er	  understanding	  of	  mechanisms,	  which	  are	  involved	  
in	   the	   control	   of	   T	   cell	   responses,	   and	   open	   new	   perspec(ves	   for	   further	  
inves(ga(ons.	  	  !
Previous	  studies	  and	  our	  work	  provided	  evidence	  that	  the	  Nck	  adaptor	  proteins	  are	  
essen(al	  for	  thymic	  selec(on,	  peripheral	  maintenance	  and	  eﬀector	  func(on	  [52,	  53].	  
Our	   ﬁnding	   that	   secondary	   T	   cell-­‐dependent	   an(body	   responses	   are	   impaired	   in	  
Nck.T-­‐/-­‐	   mice	   suggests	   defects	   in	   memory	   T	   cell	   forma(on	   in	   the	   absence	   of	   Nck.	  
Muta(ons	  on	  SLP-­‐76,	  which	  is	  the	  central	  adaptor	  in	  proximal	  TCR	  signaling	  [31,	  365]	  
and	  can	  be	  a	  binding	  partner	  of	  Nck	  adaptor	  proteins,	  have	  been	  shown	  to	  dampen	  
the	   TCR	   signaling	   and	   favour	   the	  memory	   forma(on	   in	   T	   cells	   [366].	   Deﬁciency	   of	  
SLP-­‐76	  in	  CD4+	  T	  cells	  led	  to	  poorer	  persistence	  of	  formed	  CD4+	  memory	  T	  cells	  and	  
impaired	   produc(on	   of	   cytokines	   in	   memory	   responses	   [367].	   Intriguingly,	   the	  
persistence	   of	   CD8+	  memory	   T	   cells	   seems	   to	   be	   less	   dependent	   on	   SLP-­‐76	   [368].	  
Therefore,	   it	   will	   be	   interes(ng	   to	   further	   clarify	   the	   contribu(on	   of	   TCR	   signaling	  
strength	   and	   of	   diﬀerent	   signaling	   components,	   such	   as	   Nck	   adaptor	   proteins,	   to	  
memory	  T	  cell	  forma(on	  and	  to	  evaluate	  possible	  consequences	  for	  vaccina(on.	  !
Based	  on	  our	  ﬁndings,	  Nck	  proteins	  may	  serve	  as	  possible	  clinical	   index	   for	  human	  
primary	   immunodeﬁciency	   diseases	   (PIDs)	   [369].	   Among	   common	   variable	  
immunodeﬁciency	  (CVID)	  [370]	  pa(ents,	  around	  90%	  cases	  are	  caused	  by	  unknown	  
factors.	   About	   10	   to	   20%	   of	   pa(ents	   demonstrate	   familial	   inheritent	   pa/erns	   of	  
diseases,	  indica(ng	  an	  involvement	  of	  the	  gene(c	  informa(on.	  The	  basic	  criteria	  for	  
CVID	   include	   reduced	   serum	   concentra(ons	   of	   IgG,	   impaired	   speciﬁc	   an(body	  
responses,	   decreased	   T	   cell	   responses,	   and	   recurrent	   infec(ons	   [371].	   These	  
phenotypes	  of	  CVID	   in	  an(body	  and	  T	  cell	   responses	  may	  recall	  our	  ﬁndings	   in	   the	  
Nck.T-­‐/-­‐	   murine	  model.	   Impaired	   germinal	   center	   forma(on	   is	   also	   reported	   in	   the	  
lymphadenopathy	  of	  pa(ents	  with	  CVID	  [372].	  Hence,	  it	  may	  worth	  to	  study	  whether	  
Nck	  genes	  may	  be	  linked	  to	  the	  pathogenesis	  of	  the	  immunodeﬁciencies.	  !
Based	  on	  our	  studies,	  DKK3	  promotes	  tumor	  growth	  through	  MSCs.	  However,	  DKK3	  is	  
found	  to	  be	  commonly	  reduced	  in	  tumor	  (ssues	  of	  developing	  tumors	  [215],	  which	  
indicates	  adversary	  roles	  of	  DKK3	  for	  tumor	  growth.	  Nowadays,	  increasing	  eﬀorts	  are	  
carried	   on	   to	   develop	   DKK3	   as	   a	   poten(al	   an(-­‐tumoral	   agent	   in	   various	   types	   of	  
human	  cancer	  [373-­‐375].	  Our	  studies	  revealed	  immunosuppressive	  eﬀects	  of	  DKK3	  in	  
the	  tumor	  mass.	  These	  ﬁndings	  may	  counteract	  the	  op(mmis(c	  expecta(on	  for	  the	  
an(tumoral	  capacity	  of	  DKK3.	  Hence,	  we	  propose	  further	  detailed	  studies	  on	  the	  role	  
of	  Dkk3	  in	  tumor	  development	  and	  immune	  responses	  against	  these	  tumors	  before	  
star(ng	  clinical	  trials.	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Furthermore,	  MSCs	  have	  been	  applied	   in	  murine	  autoimmune	  models,	  such	  as	  EAE	  
[376]	   to	   evaluate	   the	   therapeu(c	   poten(al	   for	   corresponding	   human	   autoimmune	  
diseases.	   In	   some	   studies	   MSC-­‐treated	   mice	   show	   ameleorated	   disease	   outcome	  
[377]	  whereas	  such	  a	  reduc(on	  in	  EAE	  was	  not	  observed	  in	  others	  [378],	  sugges(ng	  
that	   the	   heterogenicity	   of	   the	   used	   MSCs	   popula(on	   and	   thereby	   possibly	   its	  
capacity	   to	   produce	   DKK3	   may	   be	   cri(cal	   for	   successful	   treatment.	   Moreover,	  
autopahgy	   was	   found	   to	   inhibit	   the	   immunosuppressive	   func(on	   of	   MSCs	   in	   EAE	  
[379].	  This	   is	  corresponding	  to	  our	  ﬁndings	  that	  the	  enhanced	  autophagy	   in	  DKK3-­‐/-­‐	  
MSCs	   is	   correlated	   with	   the	   loss	   of	   the	   immunosuppressive	   capacity.	   Hence,	   it	   is	  
possible	   that	   DKK3	   can	   play	   an	   important	   role	   in	   the	   MSC-­‐based	   therapy	   of	  
autoimmune	  diseases.	  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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